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Abstract 
The indole nucleus is the core structure of many natural and synthetic molecules. In fact, indole-based 
compounds have been described with different biological activities, ranging from antitumor to 
antimalarials. 
Recent studies made by our research group led to the discovery of one enantiopure tryptophanol-derived 
oxazoloisoindolinone as novel activator of wild-type p53 and reactivator of mutant-type p53. The first 
objective of this thesis was centered on the hit-to-lead optimization of this specific derivative. Several 
alkyl substituents with increasing size and electron withdrawing/donating groups were selected for the 
protection of the indole nitrogen to assemble a library of new analogues for biological screening. A 
study of the activity based on chirality revealed one compound to be more active than the hit compound 
34. Particularly, compound 34d restores the wt-like growth inhibitory effect to mut p53R280K in a 
percentage of 86.8%. Finally, the stability-profile of this chemical family was evaluated using 
compounds 34 and 34e as models. 
The second main goal of this thesis was the investigation of new leads as promising antimalarials, based 
on the recent report that a library of enantiopure indolizinoindolones exhibits in vitro activity against 
erythrocytic and liver-stages of malaria parasite. Structural derivatization of the hit-compounds was 
carried out using an enantioselective two-step route, involving an intramolecular cyclization to 
assemble the final polycyclic indolizinoindolones derivatives. In vitro screening of these tryptophanol-
derived tricyclic compounds permitted the identification of two indolizinoindolone small molecules as 
the most active compounds. 
 
 
Keywords: indole, p53, hit-to-lead optimization, tryptophanol, stability-profile, liver-stage malaria. 
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Resumo 
O núcleo indole possui diferentes atividades biológicas, tais como anti-cancerigenas e anti-maláricas. 
Estudos recentes feitos pelo nosso grupo de investigação conduziram à descoberta de uma 
oxazoloisoindolinona derivada de triptofanol enantiopura que activa a p53 wild-type e a p53 mutant. O 
primeiro objetivo desta tese consistiu na optimização deste composto hit. Em particular, de forma a 
obter-se uma biblioteca de novos compostos para avaliação biológica, foram seleccionados para a 
protecção do azoto do indole vários substituintes alquílicos de diferentes volumes, grupos dadores de 
electrões e grupos eletroatratores. Um estudo da atividade baseado na quiralidade revelou um composto 
mais ativo que o composto hit, que levou a um restabelecimento do efeito inibitório do crescimento wt 
a mut p53R280K numa percentagem de 86.8%. Finalmente, foi realizado um estudo de estabilidade em 
plasma, microsomas e PBS desta família química utilizando como modelos os compostos 34 e 34e. 
O Segundo objetivo desta tese foi o desenvolvimento de novos potenciais anti-maláricos, tendo como 
base uma família de indolizinoindolonas enantiopuras que reportadas recentemente como tendo 
actividade in vitro contra as fases sanguíneas e hepáticas dos parasitas da malária. Os compostos a ser 
testados foram obtidos enantioseletivamente através de dois passos sintéticos, envolvendo uma 
ciclização intramolecular para obtenção dos derivados policiclicos de indolizinoindolonas. In vitro 
screening dos compostos tricíclicos derivados de triptofanol sintetizados permitiu a identificação de 
duas indolizinoindolonas mais ativas. 
 
 
Palavras-chaves: indole, p53, optimização, triptofanol, estudo de estabilidade, fase hepática da 
malária. 
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1.1. The importance of chirality 
“L’Univers est dissymétrique”, Louis Pasteur, ca. 1860 
Perhaps even more than Louis Pasteur imagined, this famous conjecture of him turned out to be true, a 
first brick posed, in the direction of the true knowledge of Nature. At any spatial dimension, from that 
of elementary particles to the macroscopic scale of mammal morphology and perhaps of galaxies [1], 
Nature exhibits a curious asymmetry between the left and the right, which is generally called ‘chiral 
asymmetry’. Nature has a left and a right, and it can tell the difference between them. It is possible that 
human beings are sadly lacking in this respect, since as children we all had to learn which is which. 
Anyway, everybody has no doubt in distinguishing for example the smell of oranges from the smell of 
lemons. The smells of orange and lemon differ in being the left- and right- handed versions of the same 
molecule, limonene. (R)-(+)-limonene 1 smells rounded and orangey; (S)-(-)-limonene 2 is sharp and 
lemony [2] (Figure 1.1). 
 
Figure 1.1. Enantiomeric forms of limonene molecule 1 and 2. 
It is already widely stated and defined from IUPAC, International Union of Pure and Applied 
Chemistry, that an enantiomer is one of a pair of molecular entities, which are mirror images of each 
other and for this reason they are non-superimposable [3]. The condition, which make this affirmation 
verified, consists in the presence in the molecular framework of a structural element which identifies 
the compound in this way. In organic compounds, it is possible to identify this element with a carbon, 
which it is attached to four different types of atoms or groups of atoms [4] and for this reason is defined 
as chiral. Enantiomers are so always present as a couple of two non-superimposable structures and the 
chiral centre, included in the structure, is a quite powerful tool in the way it is found responsible for the 
ability of the enantiomers to rotate the plan-polarized light (+/-) by equal amounts but in opposite 
directions. Moreover, it is important to remark that enantiomers are identical until they are placed in a 
chiral environment. So, in practise, we take out the lead from Nature: all life is chiral and all living 
systems are chiral environments. Nature has chosen to make all its living structures starting from chiral 
4 
 
molecules, where fundamental examples are amino acids and sugars. Not a casual example, in the 
contest of this thesis, it is that every amino acid in our body has the S and not the R configuration. From 
another hand, one striking aspect of biological systems is the stereoselectivity associated with many 
processes [5]. Thus, most chemical substances formed and broken down in metabolic processes are 
optically active, and usually one particular enantiomer is formed in these processes. Consequently, it 
has been found in many occasions that the physiological activity of a particular compound resides 
almost exclusively in one of its optically active forms. The scientific and the practical importance of 
processes for the preparation of specific optical isomers is therefore quite evident [6]. To resolve this 
important issue one immediate way to obtain enantiomerically pure compounds is to isolate natural 
products from the chiral pool of Nature and, if necessary, to derivatize them. Yet, another possibility is 
a racemic synthesis and the subsequent separation of the enantiomers (resolution of racemates). 
However, half of this process’s result would be undesired side product. As more and more 
enantiomerically pure active agents are required nowaday, enantioselective synthesis is a widely 
approached research subject. The selective synthesis of enantiomers is called asymmetric synthesis and 
it emploies chiral agents, which it permits to introduce a chiral centre in a prochiral molecule [7]. 
1.2. Enantioselective Synthesis 
1.2.1. Separation of enantiomers: resolution of racemates 
The resolution of racemates consists in the separation of an equimolar mixture of enantiomers, that 
constitute the racemate. This is carried out by physical or chemical methods [8]. Usually, the separation 
takes place after a preceding conversion of the enantiomers into diastereoisomers, because, as it is 
known, pair of enantiomers have identical chemical and physical properties and cannot be separated 
directly. Certainly, the methods of resolution of racemates can also be applied to non-equimolar 
mixtures of enantiomers that are usually obtained by asymmetric synthesis, since asymmetric synthesis 
can never have a stereoselectivity of 100 % [5]. Several are the methods through which the resolution 
of racemates can occur. Manual separation of enantiomers starts when, in the crystallization process of 
enantiomers, a racemic mixture has the enantiomers crystallizing separately and forms two 
macroscopically different kinds of crystals. These crystals have the peculiarity to have a mirror-image 
relationship and they can be separated manually with a pair of tweezers. Resolution of racemates after 
conversion into diastereomers move by formation of a salt with a chiral acid or base. In this way, the 
enantiomers can be converted into diastereomers, which can then be separated as a result of their 
different physical and chemical properties. Subsequently, the acid or base is released and the pure 
enantiomers are recovered. Covalent derivatization of enantiomers with chiral reagents also yields 
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diastereomers. In this case, the diastereomers are separated by common separation techniques, as they 
possess different physical and chemical properties. Afterwards, separated derivatives are returned to the 
initial chiral reagent and the desired pure enantiomers, respectively. In addition, the separation of 
enantiomers can be carried out by chromatographic methods, such as high-pressure liquid 
chromatography (HPLC), and thin-layer chromatography (TLC) in association with a chiral stationary 
phase, which retards one enantiomer relatively more than the other one by stereoselectively constructing 
of diversely stable, chiral complexes. Biochemical resolution of racemates is one more tool used in the 
field: most enzymes convert their substrate in an enantioselective way. Therefore, microorganisms can 
be used to metabolize only one of the enantiomers of a racemate. If the microorganism is wisely chosen, 
the desired enantiomer is the only thing that remains and can then be separated from the mixture by 
common separation techniques [9]. At last, kinetic resolution of enantiomers moves from another 
starting input [10]. In the reaction with chiral reaction partners or chiral catalysts, enantiomers display 
different reaction rates. If the difference is large enough, the enantiomers can be separated 
stereoselectively converting only one of the enantiomers, while the desired enantiomer remains not 
mutated. Since this is based on different reaction rates, the separation technique is called kinetic 
resolution. An example given in Scheme 1.1 of kinetic resolution, performed in the first year of master 
course, is the biochemical resolution of racemic mixture of alcohol 3 by stereoselective enzymatic 
conversion of one enantiomer, compound 5, with the use of Lipase CALB, a hydrolase from the yeast 
species C. antartica [11]. 
 
Scheme 1.1. Enzymatic kinetic resolution of racemate 3 [11]. 
1.2.2. Synthesis of enantiomerically pure compounds: Asymmetric synthesis 
Asymmetric synthesis is a reaction or reaction sequence in which one configuration of one or more new 
stereogenic elements is selectively formed [12]. In an asymmetric synthesis, an achiral molecule is 
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enantioselectively converted into a chiral molecule or a chiral molecule is diastereoselectively 
converted into a new chiral molecule that contains at least one more chirality element. In summary: in 
an asymmetric synthesis, the enantiomers (or diastereomers) of a chiral product are formed in different 
yields. In effect, a synthesis can be stereoselective if it displays a diastereomeric transition state, because 
the transition states for the formation of the different stereoisomeric products then usually contain 
different energies. As a result, the activation energies differ from each other. Consequently, the 
stereoisomer whose formation requires the lower activation energy is preferably formed. The 
stereoselectivity increases with growing energy difference of the transition states. An unconditional 
prerequisite for a diastereomeric transition state is the presence of at least one chiral reactant. This may 
be either the substrate, a reagent, or a catalyst. In a rationalization of the methods of asymmetric 
synthesis elaborated it is important to take in account the fact that these methods can be controlled either 
by reagent or controlled by substrate. In first case, of asymmetric synthesis, if an achiral molecule 
(substrate) should be stereoselectively converted into a chiral molecule by reaction with an achiral 
reagent, one of the reactants must previously made chiral [13]. This is achieved by covalently attaching 
a chiral molecule to a substrate that can be removed and intactly recovered after the asymmetric 
synthesis. Such a chiral molecule is called chiral auxiliary. The stereoselectivity of the asymmetric 
synthesis is then controlled by the stereochemistry of the chiral auxiliary [14]. Certainly, to successfully 
achieve a diastereomeric transition state, a chiral reagent that will not be recovered after the synthesis 
can also be applied. The stereochemistry of the chiral auxiliary, or the chiral reagent, respectively, 
controls the stereoselectivity of the asymmetric synthesis. In contrast to a chiral catalyst, the chiral 
auxiliary, as well as the chiral reagent, must be applied in appropriate amounts, according to the 
stoichiometry of the reaction. Therefore, that kind of asymmetric synthesis is a stoichiometric, reagent-
controlled method. In second case, if the substrate is chiral, the reagent does not necessarily have to be 
chiral for an asymmetric synthesis [15]. In this case, the stereoselectivity is controlled by the 
stereochemistry of the substrate. The substrate is obviously applied in stoichiometric amounts. 
Therefore, the asymmetric synthesis is a stoichiometric, substrate-controlled method. The chiral 
substrate of such asymmetric syntheses frequently derives from the large pool of chiral natural products. 
These starting products are often easily available in an enantiomerically (or diastereomerically) pure 
form and are, therefore, cheaper than chemically synthesized enantiomerically (or diastereomerically) 
pure starting products. Examples of such chiral natural products are carbohydrates, optically active 
carbon acids, terpenes, and sesquiterpenes. However, for many asymmetric syntheses, no suitable chiral 
substrate can be found in the chiral pool of natural products. In such a case, the advantages of reagent- 
or catalyst-controlled asymmetric syntheses are obvious: they are broadly applicable and contain a high 
flexibility with respect to the range of starting reagents and products. For asymmetric synthesis, even 
two main catalytic methods are available. The first methodology is called synthetic catalysis [16]. In 
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industrial asymmetric syntheses, more and more transition-metal catalysts with chiral ligands are 
applied. Remarkable example of an asymmetric synthesis used in a large-scale production is the 
Monsanto process for the manufacture of L-DOPA (L-dihydroxyphenylalanine) [17]. This proved 
useful in the treatment of Parkinson's disease. In one catalytical step of this asymmetric synthesis, a 
chiral rhodium catalyst is applied to a stereoselective hydrogenation of a double bond. To conclude, the 
second catalytic methodology is based on the use of enzymes. Enzymes show a high enantioselectivity 
(or diastereoselectivity) in asymmetric syntheses. However, an enzyme can often be applied only to the 
conversion of a very small group of substrates and, generally, not to a special process. In addition, they 
usually need physiologic reaction conditions, which it is a great advantage. Additionally, a common 
technique of the separation of enantiomers is the chromatography in association with a chiral stationary 
phase [18]. Such a separation is based on the differently strong interaction of the enantiomers with the 
chiral stationary phase. In this way, one enantiomer is more retarded than the other, so that they pass 
through the chromatographic column at different times. 
1.2.3. The chiral pool 
The chiral pool approach is a highly attractive methodology for the total synthesis of bioactive natural 
products with diverse and complex architectures ( [19], [8]). This strategy is one of the best methods 
available to synthetic organic chemists for establishing pivotal stereocenters in optically active 
compounds [20]. The chiral pool is a versatile tool, comprising naturally occurring chiral molecules 
such as carbohydrates, amino acids, terpenes, alkaloids, and hydroxyacids ( [20], [21]). They include 
enantiomerically enriched species that can be synthetically transformed into the desired target 
molecules. Chiral pool materials are also inexpensive and commercially available, making them 
adequate for use in accessing natural products and bioactive compounds [8]. For many decades, the 
chiral pool method was the only process of synthesis known to obtain a chiral molecule. Carbohydrates, 
amino acids, alkaloids and terpenes are very important members of the chiral pool (Figure 1.2) [8]. For 
example, Oleandomycin 6 is a medicinally important 14-membered macrolide antibiotic. In 1990, 
Tatsuta et al. reported its total synthesis by the chiral pool approach starting from methyl L-rhamnose 
7 and D-mannose 8 [22]. 
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Figure 1.2. Creativity from the chiral pool in action: Oleandomycin 6 and its carbohydrates of origin 
7 and 8 [22]. 
Moreover, it is reported that the amino alcohol (S)-tryptophanol 9 was used as starting material and as 
source of chirality in the enantioselective two-step route that brings to synthesis of indolo[2,3-
a]quinolizidine scaffold [23]. After the stereoselective cyclocondensation with methyl 4-ethyl-5-
oxopentanoate 10, the resulting indole piperidone 11 underwent intramolecular α-amidoalkylation on 
the indole 2-position under kinetic control, to give 6,12b-trans indoloquinolizidines derivative 12 
(Scheme 1.2). It is of worth to observe that the use of boron trifluoride etherate, BF3·OEt2 instead of 
chloridric acid, HCl changed the stereoselectivity producing the 6,12b-cis isomer 13. 
 
Scheme 1.2. (S)-tryptophanol 9 involved in the enantioselective synthesis of indolo[2,3-
a]quinolizidines 12 and 13 [23]. 
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In the 90s, the chiral pool synthesis was the most used method to synthesize chiral compounds with 
potential therapeutic use, representing 80% of the asymmetric synthesis methods. Currently, just 25% 
of the commercial drugs are synthesized from the chiral pool [8]. 
The methodology of enantioselective synthesis used to obtain most of the compounds synthesized in 
this thesis was based in chiral pool synthetic approach (Scheme 1.3). 
 
Scheme 1.3. Rational for the synthesis of enantiomerically pure compounds. 
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1.3. Importance of enantiopure synthesis 
It is important to promote the chiral separation and analysis of racemic drugs in pharmaceutical industry 
as well as in clinic since about more than half of the drugs currently in use are chiral compounds and 
near 90% of the last ones are marketed as racemates, consisting of an equimolar mixture of two 
enantiomers. Although they have the same chemical structure, most isomers of chiral drugs exhibit 
marked differences in biological activities such as pharmacology, toxicology, pharmacokinetics, 
metabolism, etc [17]. In contrast to chiral artificial products, all natural compounds are under single 
enantiomeric form, for example, all natural amino acids are l-isomer (laevorotatory) as well as all 
natural sugars (carbohydrates) are d-isomer (dextrorotatory). So, it is important to promote this trend 
even in organic synthesis [24]. 
There are mainly three kinds of bicyclic compounds widely studied. With the addition of a new five-
membered ring to one already there, it is possible to do it in a bridged, fused or spiro fashion. Bridged 
bicyclic compounds are just what the name implies: a bridge of atom(s) is thrown across from one side 
of the ring to the other. Fused bicyclic compounds have one bond common to both rings, while spiro 
compounds have one atom common to both rings. 
 
Figure 1.3. Possible fashions in bicyclic compounds. 
Bicyclic lactams have proven to be an exceptional chiral template for the construction of a wide variety 
of optically pure carbocycles and heterocycles. There are diversified methods developed for the 
synthesis of these functionalized building blocks ( [6], [25]). Two general methods have been developed 
for the construction of the title fused bicyclic systems and involve condensation of two optically pure 
amino alcohols and dicarbonyl compound [26]. In this case, (S)-vaninol 14, (S)-tert-leucinol 15 3-
benzoylpropionic acid 16 and Leuvinilic acid 17 were employed for the synthesis. In the first route a 
cyclodehydration process was utilized between an optically pure amino alcohol and a γ-ketoacid. This 
was performed by heating the components at reflux in toluene with azeotropic removal of water. Thus, 
condensation of a γ-ketoacid and an amino alcohol afforded the bicycle [3,3,0] octanes 18, 19, 20 (Table 
1.1) as single diastereoisomers. 
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Table 1.1. Bicyclic Lactams 18, 19, 20 via cyclodehydration of several amino alcohols and 
dicarbonyl compounds [26]. 
Dicarbonyl compound 
+ Amino alcohol 
Bicyclic Lactam formed η % 
(S)-valinol 14 
+ 
3-Benzoylpropionic acid 16 
 
85 
(S)-valinol 14 
+ 
Leuvinilic acid 17 
 
85 
(S)-tert-leucinol 15 
+ 
Leuvinilic acid 17 
 
92 
This approach is considered quite promising and practical since it involves only one step reaction, with 
the formation of a new chiral centre. It is quite feasible to get or acquire the starting materials like in 
this case amino alcohols/acids since they are abundant in nature and nowadays commercially available. 
They can also be obtained by reduction of the corresponding amino acid with lithium aluminium 
hydride, as made in this work of thesis [27]. 
In this thesis, chiral non-racemic bicyclic lactams were synthesized starting from different enantiopure 
amino alcohols, to be evaluated as potential anti-tumor agents and they have been used in the 
construction of diversified scaffold of benzoindolizinoindolones small molecules, evaluated as anti-
malarials [28].  
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1.4. The World-wide problem of cancer 
Cancer is a generic term, with a wide meaning, for a large group of diseases that can affect any part of 
the body. Other terms commonly used to express this concept are malignant tumours and neoplasms. 
Characteristic of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, 
and which can then invade adjoining parts of the body and spread to other organs, where the latter 
process is referred to as metastasizing. Metastases are the major cause of death from cancer [29]. Cancer 
figures among the leading causes of morbidity and mortality worldwide, with approximately 14 million 
new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise 
by about 70% over the next two decades. The five most common sites of cancer diagnosed in 2012 were 
lung, prostate, colorectal, stomach and liver in men and in women breast, colorectal, lung, cervix, and 
stomach, in order of trend. Around one third of cancer deaths are due to high body mass index, low fruit 
and vegetable intake, lack of physical activity, tobacco use, alcohol use, where tobacco use is the most 
important risk factor for cancer causing around 20% of global cancer deaths and around 70% of global 
lung cancer deaths. Cancer arises from one single cell. The transformation from a normal cell into a 
tumour cell is a multistage process, typically a progression from a pre-cancerous lesion to malignant 
tumours. These changes are the result of the interaction between a person’s genetic factors and three 
categories of external agents, including physical carcinogens, such as ultraviolet and ionizing radiation, 
chemical carcinogens such as asbestos, components of tobacco smoke, aflatoxin (a food contaminant) 
and biological carcinogens such as infections from certain viruses, bacteria or parasites [30]. A correct 
cancer diagnosis is essential for adequate and effective treatment because every cancer type requires a 
specific treatment regime which encompasses one or more modalities such as surgery, and/or 
radiotherapy, and/or chemotherapy. The primary goal is to cure cancer or to considerably prolong life. 
Improving the patient's quality of life is also an important goal. It can be achieved by supportive or 
palliative care and psychological support. 
1.4.1. Key role of p53 
The p53 tumor suppressor is the most frequently inactivated gene in cancer. It was first thought to be 
an oncogene, but 10 years later, team lead by Bert Vogelstein and Ray White, studying colon cancer 
showed p53 to be a tumor suppressor gene [31]. Then, several in vivo studies using three different 
approaches to engineer mice with ‘switchable’ p53, demonstrated that restoration of p53 leads to a 
substantial regression of already developed tumours-lymphomas, soft tissue sarcomas and 
hepatocellular carcinomas ( [32], [33], [34]). p53 is a potent tumor suppressor and is a subject of 
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intensive studies for more than 30 years [35]. It is well established that p53 is a transcriptional factor 
activated by different types of stresses, which regulates the expression of genes involved in the control 
 
Scheme 1.4. Schematic view of the functional domains in p53 [36]. 
control of cell cycle and cell death [36]. Most of the p53 mutations that can cause cancer are found in 
the DNA-binding domain (Scheme 1.4) [37]. Activated p53 can prevent the propagation of cells 
carrying oncogenic lesions via a multitude of pathways, i.e.: induction of growth arrest, senescence or 
apoptosis, modulation of tumor stroma, angiogenesis and metabolism, as well as the block of invasion 
and metastasis [38]. This explains why loss of p53 function is selected for during tumor development, 
resulting in the inactivation in the majority of human tumors (Figure 1.4). From the other side, 
reactivation of p53 appears to be feasible, since the p53 protein is usually expressed in tumors, although 
functionally inert. Other approaches include introduction of wild type p53 into the cells with mutant 
p53; the use of small molecules to stabilize mutant p53 in wild type, active conformation ( [39], [40]) 
and the introduction of agents to prevent degradation of p53 by proteins that normally targets it is also 
a promising strategy [36]. 
 
Figure 1.4. Outcomes triggered by p53 activation. 
In the absence of Tp53 mutations, the tumor suppressor function of p53 is frequently impaired due to 
diverse alterations which converge on two p53 inhibitors MDM2 and MDMX. It was proven through 
mouse models that MDM2 and MDMX are the major negative regulators of p53. Genetically 
engineered mice lacking either of MDM2 or MDMX die in utero and this fact underscores the 
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fundamental role of MDM2 and MDMX in p53 regulation ( [39]- [41]). MDM2 can inhibit p53 via 
several mechanisms. The most studied is MDM2 binding to the N-terminal transactivation domain of 
p53 which blocks its transcription function ( [42], [43]). MDM2 also is functional as a E3 ubiquitin 
ligase, which promotes either monoubiquitination of p53 leading to enhanced nuclear export [44], or 
polyubiquitination of p53 that targets p53 for proteasomal degradation ( [45], [46]). While MDMX also 
binds the p53 N-terminus and blocks its transcriptional function, it does not possess any intrinsic E3 
ligase activity [47] and it is unable to target p53 for degradation. From the other side, it was found that 
MDM2 forms oligomers with itself or MDMX through RING-finger domains; hetero-oligomerization 
of MDM2 and MDMX renders a more efficient E3 ligase activity towards p53 and this fact can help to 
explain the functional non-redundancy of MDM2 and MDMX observed in mouse models [48]. Human 
cancers frequently possess elevated levels of MDM2 leading to inhibition of p53 function. This 
phenomenon has been reported in sarcomas, gliomas, haematological malignancies, melanomas and 
carcinomas [49]. 
1.4.2. Targeting the p53-MDM2 interaction 
Most of the small molecules developed which target the p53/ MDM2 complex mimic three aminoacids 
of p53 peptide which interacts with MDM2. Structural studies revealed hydrophobic clefts on MDM2 
that are filled by three critical p53 amino acid residues which are Phe19, Trp23 and Leu26. This set of 
amino acids were found to interact with MDM2 and bind to its hydrophobic cleft, thus acting by steric 
hindrance [50]. Based on these findings, an impressive number of p53-MDM2 interaction inhibitors, 
from distinct chemical families, have been identified. Although many small-molecule MDM2 inhibitors 
have shown potent in vitro activity, only a limited number of compounds have demonstrated to possess 
acceptable pharmacokinetic properties for in vivo evaluation. To date, the most studied chemotypes 
have been cis-imidazolines (such as nutlins 21), benzodiazepines, and spiro-oxindoles (like compound 
22). The cis-imidazoline 21 (Figure 1.5) were the first discovered potent and selective small-molecule 
inhibitors of the p53-MDM2 interaction and they continue to show therapeutic potential. 
 
Figure 1.5. Two examples of small molecules 21 and 22 inhibitors of MDM2 [51] [52]. 
MDM2: SPR,
  
IC
50 
= 0.09 μM 
MTT,
  
IC
50 
= 1-2 μM 
in wt-p53 cancer cell 
lines. 
 
MDM2: FP, 
IC
50 
= 6.8 μM 
WST-8, SJSA-1 
IC
50 
= 0.08 μM 
RS4;11 
IC
50 
= 0.06 μM. 
cell lines. 
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Scheme 1.5. MDM2- MDMX -p53 protein-protein interaction. 
1.4.3. Targeting MDMX 
One factor which compromises the efficiency of MDM2 inhibitors is the overexpression of another 
negative p53 regulator, MDMX. MDM2 and MDMX regulate p53 in a non-redundant fashion and act 
synergistically, as already mentioned (Scheme 1.5). Anyway, due to structural differences between the 
binding pockets in MDMX and MDM2, molecules which inhibit MDM2 have low affinity to MDMX 
[53]. Therefore, the inhibition of both MDM2 and MDMX is required for a full-scale p53 activation ( 
[53], [54], [55]). A good example of small molecule targeting p53 binding site in MDMX is compound 
23 (see Figure 1.6). It is found to not kill cancer cells on its own, but has an additive effect when 
combined with MDM2 inhibitors [56]. 
1.4.4. Blocking both MDM2 and MDMX 
Recent efforts have been focused on the identification of dual MDM2/ MDMX antagonists, a ‘two-in-
one’ inhibitors which can offer an effective therapy for a broader range of tumors. This idea has been 
pursued by Vassilev and colleagues who identified compound 24 (Figure 1.6.). This compound was 
found to induce the formation of MDM2 and MDMX homo- or heterodimers which cannot bind p53. 
This leads to p53 activation, resulting in cell cycle arrest and apoptosis [57]. 
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Figure 1.6. Examples of small molecules 23, inhibitor of MDMX [56], and 24, inhibitor of both 
MDM2 and MDMX interactions with p53 [48]. 
  
MDMX: SPR, IC
50 
= 0.94 μM. 
 
MDM2: TR-FRET IC
50 
= 0.017 μM 
MDMX: TR-FRET IC
50 
= 0.025 μM. 
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1.5. The World-wide problem of malaria: how does it work? 
According to the latest information provided by the WHO about 1.2 billion people are at risk of malaria 
with the major burden disease carried by young children and pregnant women living in endemic areas 
[58]. Malaria is found to be caused by parasites of the genus Plasmodium, afflicting 350-500 million 
people annually and causing 800,000 deaths world-wide [59]. The human transmission is carried out 
by the bites of infected female Anopheles mosquitoes, which has the role of primary host. Once the 
parasite is introduced, it travels to the liver where it infects the hepatocytes cells. Hepatocytes make up 
70-85% of the liver’s mass. The parasite then grows and replicates within hepatocytes and ultimately 
spawns tons of daughter merozoites into blood stream (Figure 1.7). Now the infection passes from 
liver-stage to blood-stage, leading to symptomatic infection [60]. The genus Plasmodium is a member 
of the order Haemosporidia. 
 
Figure 1.7. Life cycle of Malaria Parasite. 
It is the largest genus within this order and currently consists of over 250 species. They cause malaria 
in many different vertebrates. There are 5 parasite species that cause malaria in humans [61]: 
 Plasmodium falciparum, which is the responsible for most of the malaria deaths globally and it 
is the most prevalent species in sub-Saharian Africa. The remaining species are not typically as 
life threatening as P. falciparum. 
 Plasmodium vivax, is the second most significant specie and is prevalent in Southeast Asia and 
Latin America. P. vivax and Plasmodium ovale have the added complication of a dormant liver 
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stage phase of the infection, which can be reactivated in the absence of a mosquito bite, leading 
to clinical symptoms. 
 P. ovale and Plasmodium malariae represent only a small percentage of infections and with P. 
vivax are milder forms of Malaria. 
 A fifth specie Plasmodium knowlesi is found to infect primates. Its exact mode of transmission 
remains unclear [59]. 
In order to study human malaria, in the contest of this thesis, it was chosen to use as model organism 
Plasmodium berghei parasite. It represents a good tool because of its similarity to the Plasmodium 
species which cause human malaria. P. berghei has a very similar life-cycle to the species that infect 
humans, and it causes disease in mice which has signs similar to those seen in human malaria. 
Importantly, P. berghei can be genetically manipulated more easily than the species that infect humans, 
making it a useful model for research into Plasmodium genetics [62]. 
1.6. The common net of cancer and malaria 
Even though still not clearly documented, from literature emerges a biological connection between 
cancer illness and the propagation of malaria starting from Plasmodium parasites infection at liver-stage 
and their replication inside hepatocytes before they invade erythrocytes and trigger clinical malaria [63]. 
Particularly, to understand the contact points, which link these two illnesses it is important to take as 
reference the system squared in Figure 1.8. In the network reported it is underlined a parasite-mediated 
signaling, which the adequate changes render the infected host cell more hospitable for the parasite. 
Zooming, when activated form of Akt and Bcl-2 increase and in contemporary the level of Bad decrease 
an input of survival response is ongoing and this assist the parasite in protecting its host cell. The process 
of autophagy is blocked and the parasite can follow its intracellular development. 
From the other side, the activation of Rb suggests the infected hepatocyte is pushed towards a 
proliferative state. Finally, the decrease in p53 levels fits into both the proliferative and anti-apoptotic 
framework. Together, the observed perturbations are consistent with a general anti-apoptotic, pro-
proliferative, anti-autophagic environment within the infected host cell. In a lysate array analysis, 
reported in literature, experiment where Nutlin-3 was used in order to exert its effects, where it binds 
selectively to the p53 - binding region of the E3-ubiquitin ligase MDM2 blocking the inhibitory 
interaction of MDM2 on p53, it is observed that protein levels of MDM2 were increased in response to 
parasite infection, indicating that the parasite might promote MDM2 mediated p53 degradation [64]. 
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Figure 1.8. Key host signaling pathways in Plasmodium infected hepatocytes. Adapted form [64]. 
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1.7. Biomedical importance of Indole-based small molecules 
Compounds with heterocyclic rings are inextricably tissue into the most basic biochemical processes of 
life. Indole is the parent substance of many important compounds that occur in nature. It has a benzene 
ring and a pyrrole ring sharing one double bond. It is a heterocyclic system with 8 electrons from four 
double bonds and the lone pair from the nitrogen atom, for a total of 10 electrons delocalized along the 
framework, giving to the system aromatic character. Indole is an important heterocyclic system because 
it is built into proteins in the form of the amino acid tryptophan. As illustrated in Figure 1.9, it provides 
the skeleton of indole alkaloids, which figure as biologically active compounds from plants. Tryptophan 
25, Strychnine 26 and LSD 27 are two main examples. In animals, serotonin 28 is a very important 
neurotransmitter in the CNS as well as in cardiovascular and gastrointestinal systems. The structurally 
similar hormone melatonin 29 is thought to control the diurnal rhythm of physiological functions. 
 
  
essential amino acid Tryptophan  Strychnine, first alkaloid 
identified by Linnaeus in 1753 
Lysergic acid diethylamide 
(LSD), a psychedelic drug 
 
  
Serotonin, monoamine neurotrasmitter Melatonin, a hormone common in animals 
Figure 1.9. Examples of compounds contain the indole frame, important in the biological world. 
21 
 
Innumerable biological functions are associated to indole-based compounds [64], including antimalarial 
and anticancer activity. Focusing only in anticancer properties of indole moiety, there are some reviews 
in the literature that report several compounds as antitumor agents containing an indole core ( [64], [65], 
[66]) Xu research group designed a novel series of N-hydroxycinnamamide-based HDACIs 30 (histone 
deacetylase inhibitors) with an indole-containing cap group (Figure 1.10). Few synthesized molecules 
among them are reported to exhibited potent in vitro and in vivo antitumor activity, where the indole 
fragment turned to be an important structural element for antitumor drug design [66]. 
 
Anticancer Activity: 
IC50 = 1.6 – 29.2 µM 
Figure 1.10. General formula for N-hydroxycinnamamide-based HDACIs 30 with an indole-
containing cap group [67]. 
A series of 3-[(4-substitutedpiperazin-1-yl)methyl]-1H-indole derivatives 31 (Figure 1.11) were 
synthesized via Mannich reaction by Akkoc group. The cytotoxicity of the derivatives was studied on 
3 cell lines and showed a variable extent of IC50 values (less than 10 µM) [68]. 
 
IC50 less than 10 µM 
Figure 1.11. Indole-based 1,4-disubstituted piperazines 31 as cytotoxic agents [68]. 
Palwinder Singh et al. reported the synthesis and anticancer activities of hybrids of indole and barbituric 
acids (Figure 1.12) compounds 32 and 33. They evaluated these molecules over 60 cell line panel of 
human cancer cells and they have identified two molecules with significant anticancer activities [69]. 
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Anticancer 
activity 
(GI50): 
A498 = 0.03 µM 
MDA-MB-468 = 0.1 µM 
IGROV1 = 0.03 µM 
MDA-MB-468 = 0.02 µM 
Figure 1.12. Two examples of hybrids of indole and barbituric acids acting as anticancer agents [69]. 
Recent discoveries by Santos’s group, led to the discovery of one enantiopure tryptophanol-derived 
oxazoloisoindolinone, compound 34, as novel anticancer small-molecule (Figure 1.13) [70]. The 
growth inhibitory potential of compound 34 and the contribution of p53 pathway to its activity were 
ascertained in p53+/+ and p53-/- HCT116 tumor cells. 
 
HCT116 p53+/+ GI50 ~ 16 µM 
HCT116 p53-/- GI50 ~ 34 µM 
activator of wt p53 
reactivator of mt p53 
Figure 1.13. Structure of 34. 
From the other side, indole-based compounds show biological versatility as antimalarials, too [71]. 
Briefly, the spiroindolone from Novartis, compound 35, which it is currently in phase I clinical trials as 
antimalarial, shows antiplasmodial activity against P. falciparum [72] and several indoloisoquinolines 
36, synthesized from enantiopure tryptophanol were recently reported to have low micromolar activity 
against a choloroquine-resistant P. falciparum strain [73]. Also, benzoindolizinoindolones 37 are found 
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to be inhibitors of P. falciparum erythrocytic-stage and P. berghei liver-stage parasites (see Figure 
1.14) [28]. 
 
  
Spiroindolinone 
35 
Synthetic indoloisoquinolines 
36 
Enantiopure indolizinoindolones 
37 
Figure 1.14. From left to right: Chemical structure of spiroindolinone 35, of indoloisoquinolines 36 
and enantiopure indolizinoindolones 37 general structures. 
Our research group has been interested in the study of tryptophanol derivatives as a source of antitumor 
and antimalarial agents [74]. Based on the tools settled in terms of knowledge in this state of art, in this 
thesis it was studied the synthesis of tryptophanol-derived bicyclic lactams, the hit-to-lead optimization 
of the most promising candidates and their evaluation in terms of activity in cancer and malaria. 
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2. Results and Discussion  
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2.1. Synthesis of a library of enantiopure tryptophanol-derived oxazoloisoindolinones 
As referred in chapter 1, from the analysis of a chemical library of novel enantiopure tryptophanol 
derived oxazoloisoindolinones, the small molecule 34 was recently identified as a novel activator of 
wild-type p53 and reactivator of mutant-type p53 (Figure 2.1) [75]. Therefore, the first objective of this 
thesis was the hit-to-lead optimization of derivative 34 to search for new leads acting as anticancer 
small molecules. Chemical modification of the nucleus present in the enantiopure tryptophanol-derived 
oxazoloisoindolinone was developed. 
 
Figure 2.1. Strategy of hit-to-lead optimization of compound 34. 
Compound 34 was modified inserting different groups in positions 9b and different protecting 
substituents in the indole nitrogen. The stereochemistry of the final compounds was also considered. 
Particularly, several alkyl substituents with increasing size and electron withdrawing/donating groups 
were selected for the protection of the indole nitrogen. To assemble the library of new analogues, a 
retrosynthetic analysis of the hit compound 34 was rationalized, finding that it is possible to obtain the 
oxazolo-isoindolinone skeleton, starting from commercially available amino alcohols and achiral 
oxoacids. As illustrated in Scheme 2.1, disconnection of the carbon-nitrogen bond through an opening 
ring process leads to intermediate 39, and through a break-down of the oxazoline ring it is obtained the 
imine 40. The imine can be obtained starting from (S)-tryptophanol 9 and from 2-acetylbenzoic acid 41 
or from the correspondent ester 42. 
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Scheme 2.1. Example of retrosynthetic analysis of compound 34 for the oxazoloisoindolinone library. 
From a cyclocondensation reaction between racemic 2-acetyl benzoic acid 41 and (S)-tryptophanol 9, 
and 2-benzoyl benzoic acid 43 and the enantiopure (S)- and (R)-tryptophanol 9 and 44 respectively, it 
was possible to build up  the starting materials derivative 34, 38 and 38’ for the development of the 
small library of bicyclic lactams (see Scheme 2.3, Scheme 2.4 and Scheme 2.5). To guarantee that the 
chemical equilibrium of this reaction promotes the products formation it is required the use of a dean-
stark apparatus which eliminates water from the reaction mixture. 1 equivalent of amino alcohol and a 
light excess of oxoacid (1.2 equivalents) are employed, affording the cyclocondensation products in 
good to excellent yields (70-80%). Since the products contain two chiral centres, it may be expected 
formation of two diastereoisomers, with 3S,9bS and 3S,9bR configurations respectively. In all the 
reactions, the exclusive formation of the 3S,9bR epimer was observed. This can be explained through 
the analysis of the mechanism of reaction, designed for the cyclocondensation reaction and reported in 
Scheme 2.2. Nucleophilic attack by the amine group of the amino alcohol (S)-tryptophanol 9 to the 
carbonyl group of 2-acetyl benzoic acid 41 leads to imine intermediate A. In this stage of reaction, a 
first exit of water from the mixture of reaction takes place. Then, as illustrated in Scheme 2.2, 
intermediate B is formed by intramolecular attack of the hydroxyl function on the iminic carbon, where 
the hydroxyl group can promote formation of intermediate B through bottom attack or above attack. At 
last, the approach of the amine to the carbonyl group of the carboxylic acid leads to formation of 
oxazoloisoindolinone 34. The determining step that promotes product formation is the exit of water, 
which brings the chemical equilibrium dislocated in direction of the product of cyclocondensation. 
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Scheme 2.2. Mechanism of cyclocondensation reaction. 
This reaction represents an interesting and functional synthetic methodology to access enantiomerically 
pure compounds. Amino alcohols, like (S)-tryptophanol 9, act as inductor of chirality where a new 
chiral centre is formed [76]. Starting from (S)-tryptophanol 9, the only product formed has configuration 
3S,9bR. This fact is correlated by the presence of the amino alcohol 
tryptophanol which acts as chiral inductor in this reaction. As it is possible to 
asseverate, the cyclocondensation reactions, performed in this work of thesis, 
are stereoselective. The control of the stereoselectivity was establish in first 
place with 1H-NMR spetroscopy, where, through comparison of the most 
characteristic signals of hit-compound 34 with the ones of the derivatives 
obtained, it was possible to establish the stereochemistry formed. Indicated 
with blue arrows are reported in Figure 2.2 the most characteristic protons for 
this class of bicyclic lactams. As illustrated specifically in the NMR spectrum 
of Figure 2.3, the multiplet at around 4.60 ppm is attributed to (H-3) hydrogen. 
Two doublet of doublets at around 4.30 ppm and around 4.18 ppm are 
associated respectively to the diastereotopic couple of hydrogens connected to carbon C-2 of the 
oxazolidine ring (they are indicated in Figure 2.2 with the abbreviation H-2) and the other two doublet 
of doublets at around 3.43 ppm and around 3.18 ppm identify the second diastereotopic couple of 
Figure 2.2. General 
structure of the (S)-
tryptophanol bicyclic 
lactams, where the 
more characteristic 
protons are reported. 
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hydrogens, connected to carbon C-10 located in the proximity of the indole nucleus (in Figure 2.2 these 
hydrogens are indicated as CH2-indole). 
 
Figure 2.3. Expansion of 1H-NMR spectrum of compound 34 in CDCl3 between 5.0 and 2.6 ppm. 
Finding correlation between the signals of the diversified derivatives is meaningful for the identification 
of the stereochemistry of these enantiopure bicyclic lactams. In addiction, it was previously confirmed 
by X-ray analysis the structure of the bicyclic lactam 34 [77]. For this reason, decisive it results the 
analysis of the 13C-NMR peaks of compound 34 for the two stereogenic carbons in position 3 and 9b, 
where carbon C-3 is detected at 56 ppm and the new chiral centre formed, C-9b, at 98.9 ppm. 
Exceptionally for (R)-tryptophanol 44, all amino alcohols and oxoacids were commercially purchased. 
(R)-tryptophanol 44 was obtained by reduction of the commercially available amino acid tryptophan 
with lithium aluminium hydride, which as reported in literature, it constitutes a recommended approach 
of preparation of this starting material [27]. After this first step of cyclocondensation, compounds 34a-
g, 38a-g and 38a’-g’ were obtained after a second synthetic protection step. The chemical derivatization, 
that it was carried out, has the scope of discovering analogues, optimized leads generation of compound 
34, which, through a SAR study of this derivative, a more potency in terms of biological activity should 
be achieved. The products are obtained by first deprotonation on the nitrogen of the indole nucleus, 
promoted by sodium hydride. Secondly, a variety of electron withdrawing and electron donating 
protecting groups of different size are introduced to construct a chemical diverse library of compounds.  
In Scheme 2.3 and in Scheme 2.4, are presented the general procedures used to obtain the new bicyclic 
lactams derived from hit compound 34. 
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Scheme 2.3. General procedure for the synthesis of (S)-tryptophanol-derived bicyclic lactams 34a-g. 
The results obtained in terms of yields of reaction are included in Table 2.1, where compounds 34a-g 
were obtained in yields between 71 and 90%. In the choice of studying exclusively the activity of (S)-
tryptophanol based bicyclic lactams there is the fact that compound 34’, enantiomer of compound 34, 
was found to be not selective for HCT116 tumor cells [75] and so the hit-to-lead optimization process 
was focused only on the (S)-tryptophanol derivatives. The choice of introducing these specific 
protecting groups was based on the interest in testing if an increase in size can improve the potency of 
the hit compound 34 as well as if introducing electron donating/withdrawing groups can implement its 
biological activity. Anyway, a study of the activity was based even in changing the substituent in 
position 9b, introducing a phenyl group. 
Table 2.1. Reaction yields for the N-protected (S)-tryptophanol derivatives 34a-g. 
Reference 
(S)-tryptophanol derivatives 
R1 η (%) 
34a Me 90.3 
34b Et 71.5 
34c Pr 75.3 
34d Ac 79.5 
34e Bn 83.9 
34f Bz 76.6 
34g Ts 85.4 
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Compounds 38a-g were afforded by cyclocondensation reaction of (S)-tryptophanol 9 and 2-benzoyl 
benzoic acid 44 (see Scheme 2.4) and the corresponding enantiomers 38a’-g’ are synthesized using the 
same route starting from (R)-tryptophanol 44, as it is possible to see in Scheme 2.5. This first 
cyclocondensation step is followed by the protection on the nitrogen of the indole nucleus. The yields 
of reaction obtained are listed in Table 2.3. 
 
Scheme 2.4. General procedure for the synthesis of (S)-tryptophanol derived bicyclic lactams 38a-g. 
Table 2.2. Reactions yields for the N-protected (S)-tryptophanol derivatives 38a-g. 
Reference 
(S)- tryptophanol derivatives 
R1 η (%) 
38 H 81.3 
38a Me 89.5 
38b Et 70.6 
38c Pr 77.0 
38d Ac 84.2 
38e Bn 96.2 
38f Bz 76.6 
38g Ts 80.1 
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Scheme 2.5. General procedure for the synthesis of (R)-tryptophanol derived bicyclic lactams 38a’-g’. 
As reported in Table 2.2 and Table 2.3, compounds 38a-g compounds 38a’-g’ were obtained in good 
to excellent yields between 77 to 96% and between 60 to 88%, respectively. This datum reflects the 
efficacy of the synthetic route, through which the library of bicyclic lactams was built. 
Table 2.3. Reaction yields and times for the N-protected (R)-tryptophanol derivatives 38a’-g’. 
Reference 
(R)- tryptophanol derivatives 
R1 η (%) 
38’ H 79.1 
38a’ Me 86.5 
38b’ Et 82.0 
38c’ Pr 70.0 
38d’ Ac 74.5 
38e’ Bn 75.5 
38f’ Bz 60.0 
38g’ Ts 87.6 
All compounds were characterized by NMR spectroscopy. As shown in Figure 2.4 and Figure 2.5, for 
bicyclic lactams the most characteristic signals appearing in 1H-NMR spectra correspond to the proton 
connected to carbon 3 (H-3), the couple of protons linked to the carbon atom next to the oxygen of the 
oxazolidine ring (H-2), and the second couple of diastereotopic hydrogens connected with the carbon 
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directly linked to the indole core (CH2-indole). For most of the compounds, it is observed that H-3 
appears as the most deshielded alkyl proton, appearing as a multiplet between 4.34 and 4.12 ppm for 
compounds 34a-g, and between 4.73 and 4.65 ppm for compounds 38a-g and 38a’-g’. Protons H-2 are 
diastereotopic protons, which means that each magnetic protonic nucleus has a different chemical and 
magnetic environment around. Since H-2 protons are diastereotopic, they also couple between each 
other. In the case of compounds 34a-g the H-2 protons appear as two doublet of doublets around 4.34 
and 4.12 ppm, while for compounds 38a-g and 38a’-g’ these two signals appear between 4.54 and 3.90 
ppm. The CH2-indole protons are also diasterotopic. For the diastereotopic H-2 hydrogens the highest 
J value observed is of around 9 Hz and lowest J value of around 7.5 Hz meanwhile CH2-indole 
hydrogens couple together with a coupling constant J of highest value of about 14 Hz and lowest value 
of 9 Hz. Sometimes H-2 protons are represented in the 1H-NMR spectrum by an apparent triplet, 
resulting from a coalescence process, where the inner peaks of the doublet of doublets melt together 
originating the false triplet. The protons of CH2-indole appear at upper fields, generally between 3.46-
2.99 ppm and at 3.21-2.58 ppm for compounds 34a-g and 38a-g, respectively (Figure 2.4 and Figure 
2.5). 
 
 
Figure 2.4. Expansion of 1H-NMR spectrum of compound 34c in CDCl3 between 5.0 and 2.6 ppm. 
 
 
Figure 2.5. Expansion of 1H-NMR spectrum of compound 38c in CDCl3 between 5.0 and 2.6 ppm. 
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To assess that the protection reaction occurred it is essential to identify the most characteristic signals 
related to the protecting substituents. In compounds 34a, 38a and 38a’, the N-methyl group can be 
identified by a singlet at about 3.75 ppm related to the methyl substituent. The presence of the N-ethyl 
group in compounds 34b, 38b and 38b’ can be established by the presence of a triplet at about 4.12 
ppm (triplet related to the two methylenic protons) and by the presence of a more shielded quartet at 
1.46 ppm attributed to the methyl frame of the N-ethyl group. These two signals are found to be coupled 
by a J coupling costant of around 7.2 Hz. For the N-propylated products, it is observed a triplet at 4.09 
ppm of the methylene protons beside the nitrogen of the indole core, a sextet at 1.89 ppm of the 
intermediary methylene protons, and a shielded triplet, at 0.96 ppm, from the methyl group of the 
propylic chain. Even for this case a J coupling constant of about 7 Hz is measured. Acetylation was 
confirmed by the presence of a deshielded singlet at about 2.60 ppm in the NMR spectra of compounds 
34d, 38d and 38d’. This signal is related to the methyl frame of the acetyl group. Quite diagnostic is 
the singlet at 5.25 ppm related to the 2 methylene protons of the benzyl substituent of compounds 34e, 
38e and 38e’. In the case of compounds 34g, 38g and 38g’, tosylation was confirmed by the presence 
of a singlet at 2.30 ppm related to the methyl group connected to the phenyl ring of the tosyl group. The 
13C-NMR is also helpful and it represents a usefull tool to understand if the compound expected is the 
diastereoisomer desired. As reported in Table 2.4 The signal of the new chiral centre, C-9b, appears 
always between 99 and 98 ppm for compounds 34a-g and at 100 ppm for compounds 38a-g, an 
indication that the specific diastereoisomers formed are the ones expected. The stereochemistry 
assessed is 3S, 9bR in the case of (S)-tryptophanol bicyclic lactams 34a-g and 38a-g. In Table 2.1-4 the 
most characteristic chemical shifts are reported. As it is possible to observe, the greatest variation 
between compounds 34a-g and 38a-g in terms of chemical shift is notable for the signal related to the 
carbon connected with the diastereotopic protons, close to the indole frame. This means that this part 
of the framework of the molecules is more sensitive to the changes in terms of magnetic and chemical 
environment, based on the proximity of these nuclei to the part of the molecule that it is optimized. 
Other curious variation observed is related with the chemical shift of C-9b of compounds 34d and 38d, 
which appears more deshielded in comparison with the ones of the starting materials, compounds 34 
and 38, respectively. 
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Table 2.4. Comparison between 13C-NMR chemical shifts of the hit-to-lead optimization products, 34a-
f and 38a-f. 
13C-NMR δ (ppm); R1 = Me 
Reference 
13C-NMR δ (ppm); R1 = Ph 
C-9b C-2 C-3 
CH2-
indole 
C-9b C-2 C-3 
CH2-
indole 
98.87 74.65 55.95 30.84 34 38 100.79 76.24 55.87 30.31 
98.96 74.80 56.22 30.67 34a 38a 100.95 76.32 55.79 30.04 
98.97 74.75 56.23 30.60 34b 38b 100.94 76.35 55.78 30.15 
98.97 74.72 56.24 30.59 34c 38c 100.93 76.32 55.78 30.12 
99.22 74.91 54.97 30.64 34d 38d 101.18 76.24 54.50 29.68 
99.05 74.79 56.23 30.72 34e 38e 100.93 76.27 55.74 30.14 
98.99 74.54 55.33 30.72 34f 38f 100.99 75.93 55.07 29.68 
98.98 74.39 55.09 30.35 34g 38g 100.95 76.00 54.61 29.88 
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2.1.1. Biological evaluation of a library of enantiopure tryptophanol-derived 
oxazoloisoindolinones 
The biological activity of compounds 34b, 34d, 34e, 38b and 38d was evaluated using a yeast-based 
screening strategy [75]. The approach is based on the restoration of the wt-like activity of mut 
p53R280K, a mutated form of p53 where an amino acidic residue of Arginine is replaced in position 
280 of the DNA binding domain of wt-p53 with a Lysine. Once the p53 is in its mutated form is tested 
how much the bicyclic lactams are able to restore the wt-like activity in this specific mutant form of 
p53. The expression of mutant was previously determined and no significative differences were 
observed compared to that of wt-p53 [75]. As expected, mut p53R280K did not considerably interfere 
with the yeast cell growth when compared to yeast transformed with the empty vector (control). 
Thereafter, this cell system was used to test 1-30 µM of compounds. Considering the activity of 
compound 34 as reactivator of mutant p53R280K [75], this compound was used as positive control. 
Results presented in Table 2.5 correspond to the maximal effect obtained with these compounds at 10 
µM. For lower comcentrations, these compounds did not significantly interfere with the yeast growth; 
higher concentrations of compounds did not increase the growth inhibitory effect, and for 30 µM 
unspecifc cytotoxic effects were detected on yeast cells transformed with the empty vector (data not 
shown). The results of this first screening are listed in Table 2.5. The obtained results are reported as 
percentage of re-establishment of wild-type p53 induced in yeast cells expressing mutant p53R280K. 
Considering the result, reported in literature for compound 34 [75], it is possible to conclude that 
between the compounds tested, the (S)-tryptophanol-derived oxazoloisoindolinone 34d is the most 
active of the tested compounds. Compound 34d restores the wt-like growth inhibitory effect to mut 
p53R280K in a percentage of 86.8%. An explicative interpretation of the results obtained can be 
researched firstly in the diversified nature of the protecting groups on the nitrogen of the indole core. 
The free nitrogen of the pyrrole ring of compound 34 and the carbonyl of the acetyl group of compound 
34d are hydrogen bond donor and acceptor respectively. Therefore, one possibility is that some 
hydrogen bonding is established, modulating the activity and this leads to a consistent growth inhibitory 
effect. Anyway, this seems significant only when the (S)-tryptophanol oxazoloisoindolinones 
derivatives include in their structures a methyl group in position 9b since in comparison compound 38d 
has by far a minor effect in the restoration of the wt-like activity of mut p53R280K. Particularly, it 
emerged that the methyl group in carbon C-9b is believed to support the growth inhibitory effect in 
comparison to the bulky phenyl group present in the chemical structure of compounds 38b and 38d. 
For example, the (S)-tryptophanol bicyclic lactam 38d restores the wt-like growth inhibitory effect just 
13.1%, meanwhile compound 38b of 9.5% only. Moreover, taking into consideration the two 
oxazoloisoindolinone derivatives ethylated 34b and 38b, it results that the ethylation does not give 
effective contribution in terms of biological anti-cancer activity. 
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Table 2.5. Percentage of re-establishment of wild-type p53-induced yeast growth inhibition in yeast 
cells expressing mutant p53R280K; p indicates the result precision. Results correspond to 3-7 
independent experiments. 
Structure % mutant Reactivation SEM p 
 
61.4 1.8 - 
 
8.7 5.4 0.772 
 
86.8 11.0 <0.0001 
 
13.4 2.1 - 
 
9.5 8.1 0.847 
 
13.1 7.9 0.845 
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2.2. Stability studies in human and rat microsomes, in human plasma and in pH 7.4 phosphate 
buffer of oxazoloisoindolinones 34 and 34e 
Biological assessment of chemical leads represents a fundamental step in drug development process. In 
this scenario, investigation of the stability profile of promising drug candidates provides important 
information about the behaviour of a compound in a certain biological context. Metabolic stability 
studies represent some of the earliest in vitro approaches, used to optimize pharmacokinetic parameters 
like bioavailability and clearance. From the other side, plasma stability plays an important role in drug 
discovery, where it is studied the degradation profile of a test compound. At last, pH-profile study is 
relevant to evaluate if the testing compound does not degrade at physiological conditions. As it emerged 
from literature and in this work of thesis, (S)-tryptophanol bicyclic lactam 34 was identified as 
promising anticancer agent [75]. Consequently, it become meaningful to investigate the in vitro stability 
of this class of compounds in rat and human microsomes in human plasma and at last in pH 7.4 
phosphate buffer. Compounds 34 and 34e were used as models. 
2.2.1. Determination of the metabolic stability of compounds 34 and 34e. Characterization of 
Phase I metabolites by LC-ESI-MS upon microsomes incubation 
Identification of metabolites is crucial in drug discovery and development process to optimize lead 
compounds for further development. The information generated in the early discovery phase of 
metabolic identification can be used to identify lead compounds and undesirable metabolic products, 
which can penalize a promising drug candidate. According to the knowledge available about these 
biological analyses, the experimental approach followed was based on determining the metabolic 
stability of compounds 34 and 34e from in vitro incubations of thawed pooled male rat and pooled 
human liver microsomes in two different experiments. In vitro interspecies metabolism studies are 
functional in order to screen for qualitative similarities and differences in metabolism between human 
and animal species [78]. The general methodology for the screening involves a period of incubation of 
a total of 180 minutes in liver microsomes supplemented with NADPH regenerating system. Test 
compounds 34 and 34e were assayed in duplicates and added at a low micromolar concentration (10 
µM) to a pH 7.4 phosphate buffer system. A NRS regenerating system was then added. The incubation 
was maintained at 37°C in a shaking water bath and the reaction was stopped by addition of a cold 
solution of Reserpine in acetonitrile, which it was used as internal standard for the determination of the 
relative amount of parent drug in each time point. The acetonitrile addition has the function of stopping 
the microsomal enzymatic activity, upon precipitation of proteins. To evaluate if the test compounds 
underwent any Phase I enzymatic modification a LC-ESI(+)-MS analytical methodology was used. 
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Particularly, the metabolic stability of compounds 34 and 34e was assessed at times 0, 120 and 180 
minutes. One additional incubation of Neviripine, a drug whose metabolic products are known, was 
used as a positive control to ensure a properly microsomal activity. In the case of compound 34, it 
resulted that after 120 minutes of experiment 57.7% of the initial quantity went under metabolic Phase 
I chemical modifications. Moreover, after 180 minutes of incubation, almost 40% of compound resulted 
unmodified. A screening of the metabolites formed during the incubation time was then performed. For 
this purpose, it is very important to know the behaviour of the parent drug under the analytical 
conditions used. Compound 34 eluted at 28.3 minutes under the chromatographic conditions was used, 
and exhibits a signal at m/z 319, compatible with its the protonated molecule in the full scan mass 
spectrum. As illustrated in Figure 2.6, the full scan ESI-MS/MS spectrum of [M+H]+ ion (m/z 319), of 
compound 34 displays abundant product ions at m/z 301 (that stems from the loss of water from the 
protonated molecule), m/z 174 (loss of the oxazoloisoindolinone moiety), m/z 156.01 (loss of the indole 
core and of the oxazolidine ring in protonated molecule form), m/z 130 (indole core). In Figure 2.7 a 
proposed ESI(+)-MS/MS mechanism of fragmentation for the protonated molecule of 34 is reported. 
 
Figure 2.6. Tandem mass spectrum obtained upon LC-ESI(+)-MS/MS analysis of m/z 319 ion 
corresponding to the protonated molecule of compound 34. 
 
Figure 2.7. Proposed ESI(+)-MS/MS fragmentation mechanisms for the protonated molecule (m/z 
319) of 34. 
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All metabolic products of compound 34 are found to be elueted prior than the parent drug, which is 
compatible with the formation of more polar products. In fact, several mono-hydroxylated metabolites 
were distinguished for this (S)-tryptophanol bicyclic lactam. The extracted ion chromatogram of Figure 
2.9 C presents three major peaks eluting at 22.90, 21.02 and 20.41 minutes. However, it was not possible 
to define precisely the site where the hydroxylation occurred in the three isomers due to the scares 
fragmentation presented when analysed under tandem mass spectrometry conditions. Nonetheless, 
when subjected to tandem mass spectrometry, the monohydroxylated metabolite eluting at 22.90 
minutes gives rise to several fragments which suggests that the hydroxylation occurred at the indole 
moiety (see Figure 2.8 A and B). 
 
 
 
Figure 2.8. A) Tandem mass spectrum obtained by ESI(+) for the mono-hydroxylated metabolite of 34 
eluting at 22.90 minutes; B) Proposed fragmentation mechanism for this metabolite. 
A 
B 
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Additionally, several di-hydroxylated metabolites of compound 34 were detected. As depicted in the 
extracted ion chromatogram of m/z 351 (Figure 2.9 D), six different di-hydroxylated metabolites were 
formed eluting at 19.6, 19.4, 18.3, 15.8, 15.2 minutes. The main peak, which it appears at 19.6 minutes 
was selected and its fragmentation pattern is reported in Figure 2.11 B. In this case, it can be suggested 
that di-hydroxylation occurs on the oxazolidine ring and on the carbon which links the indole core to 
the oxazoloisoindolinone frame, based on the fragmentation pattern obtained under tandem ESI(+) 
analysis of this metabolite. 
 
Figure 2.9. A) Total ion chromatogram obtained by LC-ESI(+)-MS of compound 34 under microsomes 
incubations; B) Extracted ion chromatogram of ion m/z 319 corresponding to the protonated molecule 
of 34; C) Extracted ion chromatogram at m/z 335 corresponding to the protonated molecules of 
hydroxylated metabolites of 34; D) Extracted ion chromatogram at m/z 351 corresponding to the 
protonated molecules of dihydroxylated metabolites of 34. 
 
 
Figure 2.10. A) Tandem mass spectrum obtained by ESI(+) for the dihydroxylated metabolite of 34 
eluting at 19.6 minutes; 
A 
B 
C 
D 
A 
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Figure 2.11. B) Proposed fragmentation mechanism for this metabolite. 
A similar study was performed for compound 34e. In first approach, the percentage of compound lost 
over the time in the presence of metabolically active microsomes was determined. In this case, in the 
first 120 minutes of experiment it was found that 69.3% of this compound is present in the samples 
analysed by LC-ESI-MS, and after 180 minutes of experiment only 26.3% of test molecule was found 
to remain unmetabolized. Subsequently, an attempt to identify some of the metabolites formed was 
undergone. Compound 34e eluted at 35 minutes, under the chromatographic conditions used, and, as 
illustrated in Figure 2.12, the tandem mass spectrum of m/z 409 ion, corresponding to the protonated 
molecule of compound 34e displays abundant product ions at: m/z 391 (loss of the oxygen on the 
oxazolidine ring as H2O), m/z 264 (loss of the oxazoloisoindolinone frame) and m/z 220 (indole core 
benzylated). In Figure 2.13, is reported a possible mechanism of fragmentation for this specie. 
B 
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Figure 2.12. Tandem mass spectrum obtained by ESI(+) of ion at m/z 409, corresponding to the 
protonated molecule of compound 34e. 
 
Figure 2.13. Proposed ESI(+)-MS fragmentation mechanism of compound 34e. 
From the extracted ion chromatogram of m/z 425 ion (Figure 2.14 D) it is possible to observe that 
several mono-hydroxylated metabolites of compound 34e are formed. They eluted at 30.0, 31.1 and 
32.5 minutes, where the main monohydroxylated metabolite is detected at retention time 30.0 minutes. 
From its fragmentation profile obtained upon ESI(+)-MS/MS, it emerges that probably the mono-
hydroxylation occurs on the junction carbon between the indole core a fragmentation profile where 
abundant product ions at m/z 407, m/z 280, m/z 262, m/z 236 are observable (Figure 2.15). The 
mechanism of fragmentation is reported in Figure 2.16, where the proposed structure for fragments at 
m/z 262 and 236 are compatible with the position of hydroxylation assigned. 
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Figure 2.14. A) Total ion chromatogram obtained by ESI(+)-MS for 34e incubations; B) Extracted 
ion chromatogram at m/z 409, corresponding to the protonated molecule of 34e; C) Extracted ion 
chromatogram at m/z 319 corresponding to the debenzylation metabolic product of 34e 
(corresponding to 34); D) Extracted ion chromatogram at m/z 425 corresponding to the protonated 
molecule of hydroxylated metabolites of 34e. 
 
Figure 2.15. Fragmentation pattern obtained by LC-ESI-MS/MS of ion at m/z 425 eluting at 30.1 
minutes. 
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Figure 2.16. Proposed ESI(+)-MS/MS fragmentation mechanisms of ion m/z 425, eluting at 30.1 
minutes, corresponding to the protonated molecule of the main hydroxylated metabolite of 34e. 
 
Unfortanetly, the other two mono-hydroxylated metabolites of 34e eluting at 31.1 and 32.5 minutes, 
despite exhibiting full mass spectra compatible with the occurrence of hydroxylation exhibited under 
tandem mass spectrometry only few product ions (Figure 2.17) which precluded the assignment of the 
position of hydroxylation. 
 
Figure 2.17. Tandem mass spectra obtained by ESI(+) of ion m/z 425 corresponding to the 
monohydroxylated metabolites of compound 34e eluting at 31.10 min (A) and 32.47 min (B). 
Additionally, it was detected at retention time of 26.4 minutes, a product of debenzylation of the 
protonated molecule 34e, exhibiting a signal in the full scan spectrum at m/z 319 (Figure 2.14 C) which 
corresponds to the protonated molecule of 34. Nonetheless, no dihydroxylated metabolites where 
detected for this compound.  
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2.2.2. Determination of the stability of compounds 34 and 34e in human plasma 
In the early phase of drug discovery process, investigation of the stability in plasma is performed with 
the goal of evaluating the potential degradation of a new chemical entity by plasmatic enzymes. 
Compounds 34 was identified as bioactive molecule, where after optimization of this hit compound, 
bicyclic lactam 34e was used as model to determine the stability profile of the oxazoloisoindolinone 
bicyclic lactams. For this reason, it emerged of primary importance to study the stability profile of these 
two compounds. To assess the stability in human plasma of compounds 34 and 34e, the standard 
experimental approach followed was based on the use of diluted thawed human plasma in pH 7.4 
phosphate buffer [79]. It is important to adjust to physiological pH of the plasma since the result can be 
complicated by the pH effect. Furthermore, dilution of plasma reduces viscosity and increases pipetting 
accuracy [79]. Procaine was used as reference drug to verify the adequate plasmatic activity. Test 
compounds 34 and 34e were assayed in duplicates and added at low micromolar concentration (40 µM). 
This concentration was chosen to avoid any side effect of the substrate concentration on plasma activity. 
Moreover, a set of buffer samples were prepared in duplicate to test the stability of compound 34 and 
34e in the absence of plasma enzymes. The incubation was maintained at 37°C shaking water bath for 
a total time of 48 hours. This was possible since plasma is a quite robust biological component. Its 
enzymatic composition allows long incubation times, turning the plasma usefull to monitor slow 
degradation processes. In this experimental context plasma stability of compounds 34 and 34e were 
studied at 0, 30, 60, 120, 180 minutes, 24 and 48 hours. To evaluate analytically if the test compounds 
underwent the usual plasma biotransformations both LC-ESI-MS and HPLC-DAD instrumental 
approaches were employed. A solution of Reserpine in acetonitrile was added at each aliquot. 
Acetonitrile is functional to arrest the enzymatic activity to proceed to further analysis. Calculations of 
the percentage of each testing compound were made as ratio of the peak areas obtained for each 
compound on the peak area of the internal standard Reserpine. As documented, the main chemical 
reactions in plasma that affect the stability of a drug are oxidation and hydrolysis. Hydrolysis is the 
most common pathway for drug breakdown and it was observed in this study. In general, both (S)-
tryptophanol derivatives 34 and 34e were found to be stable in human plasma, according to HPLC-
DAD analysis and this result make of these compounds promising leads in anticancer research. 
Particularly, it was found that results obtained through LC-ESI-MS were not consistent since the buffer 
used was observed to suppress the signals. Derivatives 34 and 34e were identified through their UV-vis 
profiles. The percentage of compound present unmodified was evaluated confirming the stability in 
plasma after the first 180 minutes of experiment.  
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Synthesis of a library of indolizinoindolones 
Indole-based compounds are known to possess a wide range of biological activities [80], including 
activity as antimalarials [81]. Moreover, a class of synthetic indoloisoquinolines as well as indolo[2,3-
a] quinolizidines derivatives arose for their broad bioactivity profile [82]. Recently, our research group 
reported that enantiopure benzoindolizinoindolones, synthesized starting from (S)-tryptophanol-derived 
bicyclic lactams display in vitro activity against erythrocytic and liver stages of malaria parasites [77]. 
Compounds 45 and 46 emerged as the most promising active derivatives. Taking advantage of the 
tryptophanol-derived bicyclic lactams developed in chapter 2.1 of this thesis, we decided to develop a 
hit-to-lead optimization of compounds 45 and 46, to develop more potent antimalarials, as reported in 
Scheme 2.6. 
 
Scheme 2.6. Rational for the synthesis of the benzoindolizinoindolones library. 
The indolizinoindolones were prepared by an enantioselective two-step route which involved in first 
place the stereoselective cyclocondensation of a racemic keto-acid with enantiopure (S)-tryptophanol 
9, leading to compounds 34, 38, 38’ and from 47a to 47e and secondly a subsequent stereocontrolled 
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intramolecular cyclization on the aromatic ring occurs, taking advantage of the masked N-acyliminium, 
present in the tricyclic compounds. It is important to underline the fact that the amino alcohol 
tryptophanol used to obtain the cyclocondensation starting materials acts as chiral inductor that not only 
constitutes the source of chirality but it is also used to assemble the final polycyclic indolizinoindolones 
derivatives. Anyway, several methodologies are reported to succeed in the synthesis of these kind of 
complex indole-based compounds [83]. As reported in literature, when the intramolecular cyclization 
of tryptophanol-derived bicyclic lactams is moved by a starting material with 3S,9bR stereochemistry, 
BF3·OEt2-promoted α-amidoalkylation reaction on the indole 2-position takes place affording 7,13b-cis 
indole derivatives, as single stereoisomers and they are detectable by NMR experiment [77]. From the 
other side, it was discovered that 7,13b-trans indole derivatives can be obtained directly by 
cyclocondensation of (S)-tryptophanol 9 with 2-formylbenzoic acid [77]. To obtain both cis- and trans- 
diasteroisomers in one step reaction, it was found as promising synthetic approach the use of BF3·OEt2 
on the correspondent oxazoloisoindolinone bicyclic lactams, 34a, 38b and 48a to 48e. In the case of 
compounds 45 and 46 it was found that after initial treatment of the relative cyclocondensation 
compound with the lewis acid the two epimeric indole derivatives were formed in a moderate 
diastereoselectivity (ratio of 2.5:1), where the trans-indolizinoindolone 45 was formed as major product 
[77]. For this reason, the first goal of the hit-to-lead optimization was to test different substituents in 
carbon 13b and study if this chemical modification improves the efficiency in terms of 
diastereoselectivity and biological activity. In particular, introduction of a methyl group and a set of 
diversified para and meta substituted phenyl groups led to synthesis of compounds 49a and 49b and 
51a-51b to 54a-54b. Secondly, optimization of the indolinone framework led to compounds 50a and 
50b. Cyclization of (R)-tryptophanol derived bicyclic lactam, compound 47c’, led to formation of 
indolizinoindolones 52a’ and 52b’, having stereochemistry (7R, 13bS) and (7R, 13bR), respectively. 
Elongation of the alkyl chain, protecting the indole core was experimented and, introduction of an ethyl 
group, on the indole nucleus of the cyclocondensation compound 38 led to product 38b, which, 
cyclization led to synthesis of compounds 55a and 55b, Same synthetic route, starting from the (R)-
tryptophanol-derived cyclocondensation product 38’ led to the formation of products 55a’and 55b’, 
after protection step forming compound 38b’. The general procedures followed for the synthesis of the 
cyclized analogues are reported in Scheme 2.7 and in Scheme 2.8. 
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Scheme 2.7. General procedure for the synthesis of indolizinoindolones 49-55a and 49-55b. 
 
Scheme 2.8. General procedure for the synthesis of indolizinoindolones 52a’, 55a’ and 52b’, 55b’. 
The yields obtained, listed in Table 2.6, are good where trans-diastereoisomers 50-56a were obtained 
between 17 to 80% and diastereoisomers cis 49-54b were obtained in yields between 5 and 67%. The 
diastereoselectivity of these reactions is observed to depend strongly by the nature of the substituent 
inserted in position 13b. Particularly, the dimensions of the methyl group seem to promote medium 
stereoselectivity, and compounds 49a and 49b are formed in yields 40 and 28% (d.r. 1.5:1), respectively. 
When a phenyl group is introduced in the molecular framework it is noticed, as reported in literature 
that the indole derivatives 45 and 46 are formed in a ratio of 2.5:1 [77]. When the bulky phenyl ring is 
introduced substituted only in para position is observed a light increase in diastereoselectivity where 
for example trans-diastereoisomers 51a and 54a figure as major products obtained. At last, when the 
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phenyl group is substituted in para position with a chlorine atom and, in addition, in meta position with 
a nitro group the intramolecular cyclization promotes the massive formation of the cis-diastereoisomer 
53b with a yield of 67%. Moreover, when the indolizinoindolone framework is varied as in compounds 
50a and 50b, the stereoselectivity increases significantly in favour of formation of the trans-isomer 50a, 
which it is observed to form in a ratio 13:1, meaning that the phenyl frame, adjacent to the oxazolidine 
ring, is a decisive diastereoselective element of the cyclization reaction. 
Table 2.6. Reaction yields for the diastereoselective intramolecular cyclized indolizinoindolones 49-
55a and 49-55b. 
Reference R1 R2 
η (%) 
d.r. 
a (trans) b (cis) 
49 Me Me 40 28 1.5:1 
50 Ph Me 64.7 5.1 13:1 
51 p-F-Ph Me 51.1 25.2 2:1 
52 p-Cl-Ph Me 46.0 43.7 1:1 
53 p-Cl, m-NO2-Ph Me 17.0 67.0 1:4 
54 p-CH3-Ph Me 80.0 12.5 6.4:1 
55 Ph Et 68.0 ND ND 
 
Table 2.7. Reaction yields for the diastereoselective intramolecular cyclized indolizinoindolones 
52a’, 55a’ and 52b’ and 55b’. 
Reference R1 R2 
η (%) 
d.r. 
a’ (trans) b’ (cis) 
52 p-Cl-Ph Me 59.6 28.4 2.1:1 
55 Ph Et 68.7 ND ND 
To understand clearly the stereochemistry of the products obtained the mechanism of reaction is 
reported in Scheme 2.9. First event, the oxygen of the oxazolidine ring attacks the boron atom of the 
lewis acid BF3·OEt2 by direct addition, where after formation of adduct A, boron trifluoride exits 
bringing to formation of an N-acyliminium intermediate B [84]. Cyclization can now occur by direct 
attack at the indole 3-position to generate, after rearrangement to position 2, diastereoisomers a and b 
[85]. 
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Scheme 2.9. Mechanism of reaction of cyclization reaction. 
The relative configuration of the formed products can be rationalized based on a stereoelectronically 
controlled axial approach [86] of the indole ring to the electrophilic carbon centre of the N-acyliminium 
specie A. The new ring can be formed by above approach, leading to 7S,13bR product or by bottom 
approach, forming 7S,13bS product. As it is possible to notice, the nature of R1 group is functional 
element for the diastereoselectivity of this reaction as well as the hydroxymethyl substituent seems to 
play a decisive role as stereocontrol element in determining the relative stereochemistry of the chiral 
centres generated in the cyclization step [86]. As it is possible to notice even the dimensions of the 
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protecting group can affect the diastereoselectivity of this reaction. The yields obtained can be 
consistent based on what reported. The 15 benzoindolizinoindolones were characterized by 1H-NMR 
and 13C-NMR spectroscopy. The stereochemistry of products 49-51a and 49-51b was evaluated by 
comparing the 1H-NMR chemical shifts with the ones obtained for derivatives 45 and 46. The structures 
of these two compounds were previously determined by X-ray analysis [77]. An illustrative 
representation of the protons, which correspond to the most characteristic signals in the 1H-NMR 
analysis, are given in Figure 2.18. In Figure 2.19 is reported an 1H-NMR spectrum expansion of 
compound 52a 1H-NMR spectrum, where the signals of these peaks can be identified. In specific, trans-
diastereoisomers 49-55a are characterized by a very deshielded triplet at around 5.00 ppm related to the 
hydroxylic proton. To this signal is associated a coupling constant J of about 6 Hz, typical of this kind 
of proton. A multiplet between 4.30 and 4.07 ppm is attributed to the diastereotopic couple of protons 
linked to the hydroxylic group, (H-2). When not overlapped by other signals, a multiplet which appears 
between 3.18 and 3.96 ppm is assigned to proton (H-7). A multiplet around 3.00 ppm is attributed to 
the diasterotopic protons next the indole core (see Table 2.8). Moreover, N-methyl indole derivatives 
are recognized by a singlet, deshielded at about 3.70 ppm related to the methyl group bounded to the 
nitrogen atom of the indole nucleus, while N-ethyl indole compound 55a is identified by the presence 
of a triplet at 4.25 ppm, attributed to the methylene frame of the alkyl chain and a quartet at 1.10 ppm 
assigned to the terminal methyl group of the chain. These two signals show a coupling constant, J, of 
about 7 Hz, typical value for a simple alkyl chain. 
Table 2.8. 1H-NMR most characteristic signals for compounds 49-55a. 
Substitution in 
position 13b 
trans-diastereoisomer a 
 
Figure 2.18. Most characteristic 1H-
NMR signals for the 
indolizinoindolones scaffold. 
OH H-2 H-7 CH2-indole 
45* Ph1 4.99 4.26 4.01 3.33 3.05 2.96 
49a Me1 5.18 4.39-4.24 3.18 2.99-2.83 
50a Ph2 4.86 3.86 3.09 3.96 2.99 2.90 
51a p-F-Ph1 4.97 4.26 4.07 3.41 3.00 
52a p-Cl-Ph1 4.96 4.26 4.07 3.29 3.00 
53a p-Cl, m-
NO2-Ph1 
4.91 4.23-4.13 ND 2.98 
54a p-CH3-Ph1 5.00 4.28 4.00 ND 3.00 
55a Ph3 4.98 4.25 4.02 3.26 3.02 
*compound reported in literature [77]. 
1oxazoloisoindoline framework; 2pyrrolidone ring only; 3R2=Et; 
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Figure 2.19. Expansion of 1H-NMR spectrum of compound 52a in DMSO between 5.2 and 2.8 ppm. 
At 3.33 ppm appears the signal of water of the solvent. 
As illustrated in Figure 2.20, stereoisomerism cis is identified when, as in the case of compounds 49-
55b, (H-7) is observed as a doublet of a doublet of doublets at 4.90 ppm. This is valid limited to 
compounds 51b to 54b, which R1 is a substituted phenyl ring meanwhile in the case of derivative 49b 
this signal is shielded and it appears at 3.63 ppm. Moreover, peculiar is the multiplet at 4.75 ppm related 
to the hydroxylic proton (in 49b this signal appears deshielded at 5.05 ppm). Multiplets at 2.68 and 2.92 
ppm are assigned, respectively to each H-2 diastereotopic proton and to the two diastereotopic protons 
located next the indole moiety (see Table 2.9). 
Table 2.9. 1H-NMR most characteristic signals for compounds 49-54b. 
Substitution in 
position 13b 
cis-diastereoisomer b 
OH H-2 H-7 CH2-indole 
46* Ph 4.75 3.12-3.05 2.61 4.90 3.12-3.05 2.92 
49b Me 5.05 4.97 3.63 2.98 2.78 
50b Ph ND ND ND ND 
51b p-F-Ph 4.75 3.15-3.01 2.68 4.88 3.15-3.01 2.92 
52b p-Cl-Ph 4.76 3.14-3.01 2.68 4.88 3.14-3.01 2.92 
53b p-Cl, m-
NO2-Ph 
4.74 3.01-2.94 2.80 4.91 3.14 3.01-2.94 
54b p-CH3-Ph 4.88 3.14-3.01 2.68 4.76 3.14-3.01 2.92 
*compound reported in literature [77]. 
OH 
H-7 
H-2 
CH2-indole 
N-CH
3
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In general, it was observed that N-methyl cis-indole derivatives, 49-54b is detected by the presence of 
a singlet at 3.90 ppm, attributed to the methyl protecting group (see Figure 2.20). 
 
Figure 2.20. Expansion of 1H-NMR spectrum of compound 52b in DMSO between 5.2 and 2.6 ppm. 
At 3.33 ppm appears the signal of water of the solvent. 
The 13C-NMR is also an essential tool to distinguish each diastereoisomer formed. The signal of the 
new chiral centre, C-13b, appears for compounds 49-55a at about 72 ppm meanwhile for derivatives 
49-54b this signal is identified shielded at around 69 ppm. The second chiral centre C-7, introduced 
with the amino alcohol tryptophanol and present in the structure of the bicyclic lactams 48a-48e, starting 
material of the cyclization reaction, appears at around 50 and 55 ppm for compounds 49a-55a and 49-
54b respectively. More shielded, between 60 and 62 ppm are detectable the signals related to (C-2) 
independently from the stereochemistry of the products obtained. At last, the most shielded signal, 
characterizing this library of cyclized tryptophanol derivatives, appears at around 25 ppm in the case of 
trans-diastereoisomers 49-54a, meanwhile for cis-diastereoisomers 49-54b appears slightly shielded at 
22 ppm. This last signal is attributed to CH2-indole hydrogens This spectral characterization finds 
coherence with the 13C-NMR description given for compounds 45 and 46 in literature [77].  
OH 
H-7 
N-CH
3
 
H-2 
CH2-indole 
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2.2.3. Biological evaluation and SAR study of a library of indolizinoindolones 
The 15 enantiopure indolizinoindolones were screened in vitro as liver-stage antimalarials by evaluating 
their ability to inhibit the infection of Huh7 human hepatoma cell line by rodent P. berghei parasites. 
In an initial screening, it was determined the effect of all compounds at 1 µM, 5 µM and 10 µM 
concentrations on infection and cell-confluency. 
 
 
Figure 2.21. First in vitro screening of indolizinoindolones 49a, 49b, 50a, 51a, 51b, 52a, 52b, 52a’, 
52b’, 53a, 53b, 54a, 54b, 55a, 55a’ against liver-stage P. berghei parasites. Activity (infection scale, 
bars) and toxicity to Huh-7 human hepatoma cells (cell-confluency scale, circles) are reported. 
 
In
fe
ct
io
n
 (
%
 o
f 
co
n
tr
o
l)
 
Infection 
C
el
l-
co
n
fl
u
en
cy
 (
%
 o
f 
co
n
tr
o
l)
 
Confluency 
Compound at concentrations: a) 1 µM; b) 5 µM; c) 10 µM; 
* Compound did not dissolve completely in DMSO. 
a  b  c  
DMSO 
b  b  b  b  b  b  b b b b b a  a  a  a  a  a  a  a  a  a  a  c  c  c  c  c  c  c  c  c  c  c  
52a 52b 52a’*
h 
52b’ 53a
* 
53b 51a 51b 54a 54b 55a* 55a’* 
0 
20 
40 
60 
80 
100 
120 
140 
0 
20 
40 
60 
80 
100 
120 
140 
49a 49b 50a 
58 
 
As illustrated in Figure 2.21, all compounds display good activity at concentrations of 5 and 10 µM. 
While indolizinoindolone 50a seems to exhibit no significant effect at 10 µM concentration against the 
infection when compared to the respective control, compounds 49a, 49b, 51a, 52a, 52a’, 52b’, 53a, 
54a and 55a’ exhibit a good to excellent effect at this concentration against the Huh-7 human hepatoma 
cell proliferation with little or no toxicity. As resulted in the first screening performed, the percentage 
of infection at 10 µM is at least below 50% for these derivatives and the IC50 values auspicated for these 
compounds are in the range of 1-5 µM [28]. Furthermore, it emerges that indolizinoindolones 51b, 52b 
and 54b display somewhat higher activity than the compounds reported lately. For these three 
derivatives, the percentage of infection at 10 µM resulted to be decrease below50% and the estimated 
IC50 values are probably equal or inferior to 1 µM. At last, compounds 53b and 55a present the strongest 
activity, with only derivative 53b showing toxicity solely at 10 µM. Particularly, compound 53b 
resulted to decrease the infection below 5% at all concentrations experimented, while 
indolizinoindolone 55a resulted to bring the infection below 20% at concentration 1 µM, close to 5% 
at concentration 5 µM and below 10% at 10 µM. The expected IC50 values for these two testing-
compounds is likely lower than 1 µM. The IC50 values were determined for the most active compounds. 
Since the screening results of this scaffold are quite recent, only for derivative 49b the results of the 
second in vitro screening are available. In this case, the IC50 for the inhibition of hepatic P. berghei 
infection was determined and for compound 49b it has a value of 0.56 ± 0.17 µM. The results obtained 
have been rationalized in a SAR study as illustrated in Figure 2.22, Figure 2.23, Figure 2.24. It 
emerges that cis-diastereoisomers 49b, 51b, 52b, 52b’, 53b, and 54b appear more active than the 
parental derivatives with trans- conformation. Beside this, all (S)-tryptophanol-derived 
indolizinoindolones seem to be more bioactive than the (R)-tryptophanol derivatives, suggesting that 
the (S)-stereochemistry of the chiral centre in position 7 is quite important. In particular, comparing 
compounds 56 with 60, 59 with, 63, 57 with 61 and 62 with 58, the (S)-tryptophanol derivatives report 
higher activity. Interestingly, once 52b and 52b’ are compared it results that the (7R,13bR) 
indolizinoindolones 52b’ seems to be more bioactive than its enantiomer, compound 52b. In this way, 
it is demonstrated the functionality of the presence of a bulky group in position 13b. Moreover, it 
emerges that the nature of the substituent on the new stereogenic centre, formed in position 13b, is of 
primary relevance. As a matter of fact, it appears that the presence of a Hydrogen atom in this position 
does not promote antiplasmodial activity. A methyl and a phenyl substitution ensures good to high 
activity, where a methyl substituent seems decisively to improve the bioactivity of compounds 60, 61, 
62 and 49b. A para-substituted phenyl ring, introduced in position 13b, show high activity, and at last 
bi-substitution, as it appears in compound 53b, emerges to endorse significantly the antiplasmodial 
activity. This conclusion is consistent for both cis- and trans- diastereoisomers synthesized. The nature 
of the protection group on the nitrogen of the indole core is also crucial. N-methyl idole derivatives 46 
59 
 
and 49b show higher activity (IC50=0.6 µM) than the moderately active, compounds 61 and 64. 
Interestingly, an increase of the alkyl chain, protecting the indole moiety turns the trans-diastereoisomer 
55a strongly active. Considering, the result obtained for the correspondent N-methyl indole derivative 
45, and once compounds 61 and 64 are compared with compound 55a it emerges that specifically in 
trans-diastereoisomers seem to be required a bulky group, protecting the indole core. Addictionally, 
from comparison of the two enantiomers, compounds 55a and 55a’, it resulted that the biological 
activity is promoted by stereochemistry (7S, 13bR). Moreover, it emerged that N-protected indole 
derivatives with the hydroxyl group unprotected show good to high activity. At last, modification of the 
indolinone framework, as it was experimented in compound 50a, seems to be not functional and it does 
not improve the antiplasmodial activity of the correspondent hit compound 45. 
 
Figure 2.22. SARs (Structure-activity relationships) of (7R, 13bR) indolizinoindolone derivatives. 
(Results reported in percentage of infection). 
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Figure 2.23. SARs (Structure-activity relationships) of (7S, 13bS) indolizinoindolone derivatives. 
(Results reported in percentage of infection). 
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Figure 2.24. SARs (Structure-activity relationships) of (7S, 13bR) indolizinoindolone derivatives. 
(Results reported in percentage of infection.)  
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3. Conclusions  
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In this master thesis, a first objective settled consisted in the synthesis of a small set of (S)- and (R)- 
enantiopure tryptophanol-derived bicyclic lactams. These derivatives have been used to develop a leads 
generation where a diversified set of N-protected oxazoloisoindolinones small molecules were obtained. 
The mechanism of reaction through which the amino alcohol tryptophanol, which acts as chiral inductor 
and the set of 2-substituted benzoic acids chosen bring to the cyclocondensation products was studied 
as well as the best procedure of protection on the nitrogen of the indole moiety was evaluated, resulting 
in a wide library of compounds, hit-to-lead optimization of compounds 34. 
The derivatives composing this scaffold were then biologically evaluated as anticancer agents, where 
through a yeast-based screening strategy it was found that compound 34d at a concentration of 10 µM 
increases the wt p53-induced yeast growth inhibition and it restores the wt-like growth inhibitory effect 
to mut p53R280K in about 86%. 
 
Furthermore, the stability profile of compounds 34 and 34e was assessed. Microsomal stability, plasma 
stability and buffer stability were evaluated. Biological verification of these two chemical leads 
represents a fundamental step in terms of drug development process and crucial in the drug discovery 
process to optimized lead compounds for further development. 
 
At last, a novel library of enantiopure benzoindolizinoindolones was synthesized. Cyclization of 
oxazoloisoindolinones derived from enantiopure tryptophanol allowed the enantioselective synthesis of 
indolizinoindolones derivatives. In all cases both trans- and cis- diastereoisomers were isolated, where 
diastereoisomer trans- was found to be the major product formed. Only in case of compounds 53a and 
53b it was found that the cis- stereochemistry was preferred. 
Then, the in vitro activity against liver stages of P. berghei was tested for this class of compounds and 
from this study derivatives 53b and 55a emerged as most promising derivatives. This confirmed that 
there is a preference for the 7,13b-cis diastereoisomer, demonstrating that the stereochemistry of the 
target compounds has a critical role in the antiplasmodial activity in liver stage. In the case of trans-
conformation emerged that elongation of the alkyl chain protecting the indole core favoured the 
antiplasmodial bioactivity. 
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4. Experimental Procedure  
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4.1. General Methods 
All reagents and solvents were obtained from commercial suppliers and were used without further 
purification. (R)-tryptophanol 44 was obtained by reduction with Litium Aluminium hydride. Melting 
points were determined using a Kofler camera Bock monoscope M. Analysis Merck Silica Gel 60 F254 
plates were used as analytical thin layer chromatography and flash chromatography was performed on 
Merck Silica Gel (200- 400 mesh). 1H and 13C NMR spectra were recorded on a Bruker Magnet System 
300 MHz/54mm Ultra-Shield, long hold time. 1H nuclear magnetic resonance spectra were recorded at 
300 MHz and 13C nuclear magnetic resonance spectra were recorded at 100 MHz. 1H and 13C NMR 
chemical shifts are reported in parts per million (ppm, δ) referenced to the solvent used and the proton 
coupling constants J in hertz (Hz). Spectras were assigned using appropriate COSY, DEPT, HMQC 
and HMBC sequences. Microanalysis was performed in a Flash2000 ThermoScientific elemental 
analyzer and are within ±0.4% of theoretical values. 
4.2. Experimental procedure chapter 2.1 Oxazoloisoindolinones scaffold 
4.2.1.  General procedure for cyclocondensation reactions 
To a solution of a particular aminoalcohol (0.660mmol, 1 equivalent) in toluene (5ml) was added the 
appropriate oxocarboxylic acid (0,730mmol). The mixture was heated at reflux for 10-24h under dean-
stark apparatus, until total consumption of the starting aminoalcohol. The solvent was evaporated and 
the residue was dissolved in ethylacetate. The organic phase was washed with saturated aqueous 
solutions of sodium monohydrogen carbonate, NaHCO3 and sodium chloride, NaCl, dried with 
anhydrous magnesium sulfate, filtered and evaporated. The crude was absorbed on silica and purified 
by flash chromatography using ethyl acetate/ n-hexane as eluent. 
 
Scheme 4.1. General procedure for the preparation of (S)- and (R)-tryptophanol bicyclic lactams. 
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(3S,9bR)-3-((1H-indol-3-yl)methyl)-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 34 
and(7S,13bS)-7-(hydroxymethyl)-13b-methyl-7,8,13,13b-tetrahydro-5Hbenzo[1,2]indolizino[8,7-
b]indol-5-one 66: Following the general procedure, to a solution of (S)-tryptophanol 9 (0.218 g, 1.15 
mmol) in toluene (10 mL) was added 2-acetylbenzoic acid (0.207 g, 1.38 mmol). Reaction time: 16.5 
hours. Eluent for flash chromatography: ethyl acetate/ n-hexane, 1:1. 
 
34: The product was obtained as a white solid (0.254 g, 70%). 1H NMR (300 MHz, CDCl3): δ 8.13 (s, 
1H, NH), 7.78 (dd, J = 6.7, 1.9 Hz, 1H, ArH), 7.73 (d, J = 7.8 Hz, 1H, ArH), 
7.64 – 7.57 (m, 1H, ArH), 7.54 (s, 1H, ArH), 7.50 (dd, J = 7.2, 1.3 Hz, 1H, 
ArH), 7.38 (d, J = 7.6 Hz, 1H, ArH), 7.26 (s, 1H, ArH), 7.23 (dd, J = 7.0, 1.2 
Hz, 1H, ArH), 7.18 (dd, J = 3.9, 1.4 Hz, 1H, ArH), 7.14 (dd, J = 7.1, 1.1 Hz, 
1H, ArH), 4.60 (m, 1H, H-3), 4.32 (dd, J = 8.8, 7.4 Hz, 1H, H-2), 4.18 (dd, J 
= 8.9, 6.4 Hz, 1H, H-2), 3.43 (dd, J = 14.8, 5.7 Hz, 1H, CH2--indole), 3.18 
(dd, J = 14.8, 8.6 Hz, 1H, CH2-indole), 1.70 ppm (s, 3H, CH3), as previously 
described in literature [75]. 
 
 
68: The product was obtained as white solid (0.0145 g, 4.20%). 1H NMR (300 MHz, DMSO-d6) δ  
11.28 (s, 1H, NH), 8.29 (d, J = 7.7 Hz, 1H, ArH), 7.72 (td, J = 7.6, 1.1 Hz, 
1H, ArH), 7.52 (t, J = 7.4 Hz, 1H, ArH), 7.40 (d, J = 7.7 Hz, 1H, ArH), 7.35 
(d, J = 8.0 Hz, 1H, ArH), 7.08 (t, J = 8.2 Hz, 1H, ArH), 6.97 (t, J = 7.9 Hz, 
1H, ArH), 5.15 (dd, J = 6.9, 5.5 Hz, 1H, OH), 4.32 (dd, J = 11.5, 6.1 Hz, 
2H, H-2), 3.84 (ddd, J = 15.0, 9.3, 5.4 Hz, 1H, H-3), 2.93 (dd, J = 15.3, 3.7 
Hz, 1H, CH2-indole), 2.77 (dd, J = 15.3, 11.3 Hz, 1H, CH2-indole), 1.88 (s, 
3H, C13b-CH3).  
 
(3S,9bR)-3-((1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isondol-5(9bH)-one 38: 
Following the general procedure, to a solution of (S)-tryptophanol 9 (0.202 g, 
1.06 mmol) in toluene (10 mL) was added 2-benzoylbenzoic acid (0.286 g, 
1.26 mmol). Reaction time:16 hours. Eluent for flash chromatography: ethyl 
acetate/ n-hexane 6:4. The product was obtained as white crystals (0.328 g, 
81.3%). 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H, NH), 7.84 – 7.79 (m, 1H, 
ArH), 7.69 – 7.62 (m, 2H, ArH), 7.54 – 7.48 (m, 3H, ArH), 7.46 – 7.33 (m, 
4H, ArH), 7.19 (m, 5H, ArH), 4.73 (dddd, J = 13.9, 8.7, 7.29, 6.6 Hz, 1H, H- 
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3), 4.49 (dd, J = 8.6, 7.6 Hz, 1H, H-2), 4.01 (dd, J = 8.7, 6.7 Hz, 1H, H-2), 3.19 (dd, 1H, J = 14.7, 6.3 
Hz, CH2-indole), 2.68 ppm (dd, J = 14.8, 9.1 Hz, 3.19 (dd, 1H, J = 14.7, 6.3 Hz, CH2-indole), 2.68 ppm 
(dd, J = 14.8, 9.1 Hz, 1H, CH2-indole), as described in literature [28]. 
 
(3R,9bS)-3-((1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one  
38’: Following the general procedure to a solution of (R)-tryptophanol 44 
(0,199 g, 1.04 mmol) in toluene (10 mL) was added 2-benzoylbenzoic acid 
(0.286 g, 1.27 mmol). Reaction time: 19 hours. Eluent for flash 
chromatography ethyl acetate/ n-hexane, 1:1. The product was obtained as 
white powder (0.314 g, 79.1%). The 1H-NMR spectrum was found to be 
identical to the one of compound 38. 
 
4.2.2. General procedure for indole protection reactions 
 
Scheme 4.2. (S) and (R)-tryptophanol-derived bicyclic lactams protected on the indole core. 
4.2.2.1. General procedure for N-methylation 
To a stirred solution of the appropriate (S)- or (R)- oxazoloisoindolinone derivative (0.320 mmol, 1 
equivalent) in dry dimethylformamide, DMF (3 mL) under inert atmosphere of nitrogen and ice bath 
was added sodium hydride, NaH (2 equivalents, 95% anhydrous reagent). The mixture was allowed to 
stir for 30 minutes and then methyl iodide (2 equivalents) was added. The reaction was kept stirring at 
room temperature for 30 minutes. After this period, ethyl acetate was added to the crude of reaction and 
then extracted with room temperature deionized water. The organic phase was washed firstly with a 
aqueous saturated solution of sodium monohydrogen carbonate, NaHCO3 and then with brine solution 
(saturated aqueous solution of sodium chloride, NaCl); dried with sodium sulphate, NaSO4 and in the 
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end the solvent was evaporated. The crude was absorbed in silica, purified by flash chromatography 
using ethyl acetate/ n-hexane as eluent mixture and recrystallized. 
 
(3S,9bR)-9b-methyl-3-((1-methyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one, 34a: Following the general procedure, starting from compound 
34 (0.102 g, 0.320 mmol), sodium hydride, NaH 95%, (0.0154 g, 0.640 mmol) 
and methyl iodide (0.040 mL, 0.640 mmol, d = 2.28 gmL-1) were added. 
Reaction time: 1.5 hours. Eluent for flash chromatography: 7:3, n-hexane/ 
ethyl acetate. Recrystallization: n-hexane/ ethyl acetate. The product was 
obtained as a white light solid (0.0962 g, 90.3%); mp: 168 - 170 ºC; 1H NMR 
(300 MHz, CDCl3) δ 7.78 (dd, J = 7.0, 1.5 Hz, 1H, ArH), 7.72 (d, J = 7.8 Hz, 
1H, ArH), 7.64 – 7.57 (m, 1H, ArH), 7.54 (s, 1H, ArH), 7.51 (dd, J = 7.1, 1.2   
Hz, 1H, ArH), 7.31 (d, J = 8.1 Hz, 1H, ArH), 7.28 – 7.21 (m, 1H, ArH), 7.18 – 7.12(m, 1H, ArH), 7.11 
(s, 1H, CH-indole), 4.63 – 4.53 (m, 1H, H-3), 4.30 (dd, J = 8.8, 7.4 Hz, 1H, H-2), 4.17 (dd, J = 8.9, 6.3 
Hz, 1H, H-2), 3.78 (s, 3H, NCH3), 3.44 (dd, J = 14.8, 5.6 Hz, 1H, CH2-indole), 3.15 (dd, J = 14.7, 8.9 
Hz, 1H, CH2-indole), 1.72 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 174.37 (C=O), 147.42 (ArC), 
136.96 (ArC), 133.19 (ArC), 131.71 (ArC), 130.13 (ArC), 128.10 (ArC), 127.19 (s), 124.29 (ArC), 
122.11 (ArC), 121.76 (ArC), 119.06 (ArC), 119.00 (ArC ), 110.21 (ArC), 109.24 (ArC), 98.96 (C-9b), 
74.80 (C-2), 56.22 (C-3), 32.73 (N-CH3), 30.67 (CH2-indole), 23.22 (C-CH3). 
 
(3S,9bR)-3-((1-methyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one, 38a: Following the general procedure, starting from compound 
38 (0.104 g, 0.273 mmol), sodium hydride, NaH 95%, (0.0140 g, 0.583 mmol) 
and methyl iodide (0.034 mL, 0.546 mmol, d = 2.28 gmL-1) were added. 
Reaction time: one hour. Eluent for flash chromatography: 1:1, n-hexane/ 
ethyl acetate. Recrystallization: n-hexane/ ethyl acetate. The product was 
obtained as a white crystalline solid (0.0963 g, 89.5%); mp: 132-136 ºC; 1H 
NMR (300 MHz, CDCl3) δ 7.83 – 7.79 (m, 1H, ArH), 7.65 – 7.61 (m, 2H, 
ArH), 7.49 (ddd, J = 5.5, 3.0, 1.9 Hz, 3H, ArH), 7.40 (d, J = 1.8 Hz, 1H, ArH),   
7.38 (d, J = 2.0 Hz, 1H, ArH), 7.28 – 7.17 (m, 2H, ArH), 7.08 (m, 1H, ArH), 6.96 (s, 1H, CH-indole), 
4.69 (ddd, J = 13.4, 9.2, 6.7 Hz, 1H, H-3), 4.45 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.98 (dd, J= 8.7, 6.7 Hz, 
1H, H-2), 3.72 (s, 3H, NCH3), 3.21 (dd, J = 14.6, 5.9 Hz, 1H, CH2-indole), 2.65 (dd, J = 14.7, 9.3 Hz, 
1H, CH2-indole), as described in literature [28]. 
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(3R,9bS)-3-((1-methyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-
5(9bH)-one 38a’: Following the general procedure, starting from compound 38’ (0.060 g, 0.158 mmol), 
sodium hydride, NaH 95%, (0.008 g, 0.315 mmol) and methyl iodide (0.022 mL, 0.347 mmol, d = 2.28 
gmL-1) were added. Reaction time: 2 hours. Eluent for flash chromatography: ethyl acetate/ n-hexane, 
3:7. Recrystallization: ethyl acetate/ n-hexane. The compound was obtained as a white crystalline solid 
(0.0591g, 86.5%); mp: 148-150 ºC; 1H NMR (300 MHz, CDCl3) δ 7.83 – 7.79 
(m, 1H, ArH), 7.63 (m, 2H, ArH), 7.52 – 7.45 (m, 3H, ArH), 7.42 – 7.36 (m, 
3H, ArH), 7.29 – 7.17 (m, 3H, ArH), 7.12 – 7.05 (m, 1H, ArH), 6.96 (s, 1H, 
CH-indole), 4.69 (ddd, J = 13.4, 9.2, 6.7 Hz, 1H, H-3), 4.46 (dd, J = 8.7, 7.5 
Hz, 1H, H-2), 3.99 (dd, J= 8.7, 6.7 Hz, 1H, H-2), 3.72 (s, 3H, NCH3), 3.21 
(dd, J = 14.6, 5.9 Hz, 1H, CH2-indole), 2.65 ppm (dd, J = 14.7, 9.3 Hz, 1H, 
CH2-indole); 13C NMR (75 MHz, CDCl3) δ 174.61 (C=O), 147.18 (Cq), 
138.86 (Cq), 136.87 (Cq), 133.27 (ArC), 131.11 (Cq), 130.09 (Cq), 128.77   
(ArC), 128.65 (ArC), 127.90 (ArC), 126.90 (CH-indole), 125.81 (ArC), 124.37 (ArC), 123.45 (ArC), 
121.64 (ArC), 118.90 (ArC), 110.18 (Cq), 109.15 (ArC), 100.95 (C-9b), 76.32 (CH-2), 55.79 (CH-3), 
32.67 (s), 30.04 (CH2-indole). 
 
4.2.2.2. General procedure for N-ethylation 
To a stirred solution of the appropriate (S)- or (R)-oxazoloisoindolinone derivative (0.320 mmol, 1 
equivalent) in anhydrous dimethylformamide, DMF (3 mL) under inert atmosphere of nitrogen and ice 
bath was added sodium hydride, NaH (2 equivalents, 95% anhydrous reagent). The mixture was allowed 
to stir for 30 minutes and then ethyl iodide (2 equivalents, d = 1.95 gmL-1) was added. The reaction was 
kept stirring at room temperature till total consumption of the limitant reagent. After this period, ethyl 
acetate was added to the crude of reaction and then extracted with deionized water. The organic phase 
was washed then with a saturated aqueous solution of sodium chloride, NaCl (brine), dried with sodium 
sulphate, NaSO4 and at least, the solvent was evaporated. The crude was absorbed in silica and purified 
by flash chromatography using ethyl acetate/ n-hexane as mixture of eluent and recrystallized. 
 
(3S,9bR)-3-((1-ethyl-1H-indol-3-yl)methyl)-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol-
5(9bH)-one 34b: Following the general procedure starting from compound 34 (0.0509 g, 0.157 mmol), 
dissolved in dimethylformamide, DMF (2 mL) sodium hydride, NaH 95% (0.008 g, 0.315 mmol) and 
ethyl iodide (0.025 mL, 0.314 mmol, d = 1.95 gmL-1) were added. Reaction time: 2 hours. Eluent for 
flash chromatography: ethyl acetate/ n-hexane, 3:7. Recrystallization solvents: ethyl acetate/ n-hexane. 
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The product was obtained as white crystalline solid (0.0398g, 71.5%); mp: 161-164 ºC; [α]20D = + 24.7º 
(c = 0.39, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.80 – 7.69 (m, 2H, ArH), 7.64 – 7.57 (m, 1H, ArH),  
7.55 – 7.48 (m, 2H, ArH), 7.34 (d, J = 8.1 Hz, 1H, ArH), 7.26 – 7.19 (m, 1H, 
ArH), 7.17 (s, 1H, ArH), 7.16 – 7.10 (m, 1H, ArH), 4.62 – 4.52 (m, 1H, H-3), 
4.30 (dd, J = 8.85, 7.35 Hz, 1H, H-2), 4.16 (q, J = 7.24 Hz, 3H, H-2 and 
CH2CH3 aliphatic), 3.43 (dd, J = 14.7, 5.3 Hz,, 1H, CH2-indole), 3.17 (dd, J = 
14.7, 8.8 Hz, 1H, CH2-indole), 1.68 (s, 3H, C-9bCH3), 1.46 ppm (t, J = 7.24 
Hz, 3H, CH2CH3); 13C NMR (75 MHz, CDCl3) δ 174.33 (C=O), 147.33 (Cq), 
135.88 (Cq), 133.14 (ArC), 131.67 (Cq), 130.09 (ArC), 128.20 (Cq), 125.44 
(ArC), 124.24 (ArC), 122.06 (ArC), 121.55 (ArC), 119.06 (ArC), 118.96 
 
(ArC),110.16 (Cq), 109.27 (ArC), 98.91 (C-9b), 74.69 (C-2), 56.17 (C-3), 40.80 (CH2CH3), 30.54 (CH2-
indole), 23.09 (C-9bCH3), 15.50 (CH2CH3). Anal. Calc. (C22H22N2O2): C, 76.28%; H, 6.40%; N, 8.09%. 
Found C, 76.34%; H, 6.50%; N, 8.08%. 
 
(3S,9bR)-3-((1-ethyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)- 
one 38b: To a solution of compound 38 (0.0533 g, 0.140 mmol) in anhydrous 
dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, (0.007 g, 0.280 
mmol) and ethyl iodide (0.022 mL, 0.280 mmol, d = 1.95 gmL-1) were added. 
Reaction time: 30 minutes. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 3:7. The product was obtained as a light white solid (0.0404 g, 70.6%). 
The 1H-NMR spectrum was found to be identical to the one of compound 38b’. 
 
(3R,9bS)-3-((1-ethyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)- 
one 38b’: To a solution of compound 38’ (0.150 g, 0.394 mmol) in anhydrous 
dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, (0.019 g, 0.789 
mmol) and ethyl iodide (0.063 mL, 0.789 mmol, d = 1.95 gmL-1) were added. 
Reaction time: 3 hours. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 2:8. The product was obtained as a light white solid (0.132 g, 82.0%); 
mp: 58 - 61 ºC; 1H NMR (300 MHz, CDCl3) δ 7.85 – 7.78 (m, 1H, ArH), 7.67 
– 7.62 (m, 2H, ArH), 7.52 – 7.45 (m, 3H, ArH), 7.43 – 7.37 (m, 3H, ArH), 
7.29 (d, J = 8.2 Hz, 1H, ArH), 7.26 – 7.21 (m, 1H, ArH), 7.18 (d, J = 8.1 Hz,  
 
1H, ArH), 7.08 (t, J = 7.5 Hz, 1H, ArH), 7.03 (s, 1H, CH-indole), 4.70 (dq, J = 13.4 6.8 Hz, 1H, H-3), 
4.45 (t, J = 8.1 Hz, 1H, H-2), 4.10 (q, J = 7.3 Hz, 2H, CH2CH3), 3.99 (dd, J = 8.2, 7.2 Hz, 1H, H-2), 
3.23 (dd, J = 14.6, 5.8 Hz, 1H, CH2-indole), 2.65 (dd, J = 14.6, 9.4 Hz, 1H, CH2-indole), 1.42 (t, J = 
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7.3 Hz, 3H, CH2CH3); 13C NMR (75 MHz, CDCl3) δ 174.60 (C=O), 147.16 (ArC), 138.88 (ArC), 135.90 
(ArC), 133.27 (ArC), 131.12 (ArC), 130.09 (ArC), 128.78 (ArC), 128.68 (ArC), 128.01 (ArC), 125.82 
(ArC), 125.10 (CH-indole), 124.38 (ArC), 123.45 (ArC), 121.51 (ArC), 119.01 (ArC), 118.86 (ArC), 
110.27 (ArC), 109.23 (ArC), 100.94 (C-9b), 76.35 (CH-2), 55.78 (CH-3), 40.79 (CH2CH3), 30.15 (CH2-
indole), 15.49 (CH2CH3). 
 
4.2.2.3. General procedure for N-propylation 
To a stirred solution of the appropriate (S)- or (R)- oxazoloisoindolinone derivative (0.320 mmol, 1 
equivalent) in anhydrous dimethylformamide, DMF (3 mL) under inert atmosphere of nitrogen and in 
ice bath was added sodium hydride, NaH (2 equivalents, 95% anhydrous solid reagent). The mixture 
was allowed to stir for 30 minutes and then propyl bromide (2 equivalents, d = 1.35 gmL-1) was added. 
The reaction was kept stirring at room temperature till total consumption of the limitant reagent. After 
this period of time, ethyl acetate was added to the crude of reaction and then extracted with deionized 
water. The organic phase was washed then with bicarbonate of sodium, NaHCO3, then with a saturated 
aqueous solution of sodium chloride, NaCl (brine), dried with sodium sulphate, NaSO4 solid reagent 
and at last, the solvent was evaporated, after filtration of the drying solid agent. The crude was absorbed 
in silica and purified by flash chromatography using ethyl acetate/ n-hexane as mixture of eluent, and 
when required recrystallized using ethyl acetate/ n-hexane mixture of solvents. 
 
(3S,9bR)-9b-methyl-3-((1-propyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol-  
5(9bH)-one 34c: Following the general procedure starting from compound 34 
(0.0628 g, 0.197 mmol), dissolved in dimethylformamide, DMF (3 mL) 
sodium hydride, NaH 95%, (0.0096 g, 0.400 mmol) and propyl bromide (0.036 
mL, 0.396 mmol, d = 1.35 gmL-1) were added. Reaction time: 1 hour. Eluent 
of flash chromatography: ethyl acetate / n-hexane, 3:7. The solid was obtained 
as a white crystalline solid (0.0535 g, 75.3%); mp: N. D.; 1H NMR (300 MHz, 
CDCl3) δ 7.81 (d, J = 7.2 Hz, 1H, ArH), 7.75 (d, J = 7.8 Hz, 1H, ArH), 7.66 – 
7.58 (m, 1H, ArH), 7.57 – 7.50 (m, 2H, ArH), 7.36 (d, J = 8.1 Hz, 1H, ArH),   
7.28 – 7.21 (m, 1H, ArH), 7.20 – 7.12 (m, 2H, ArH), 4.65 – 4.54 (m, 1H, H-3), 4.32 (t, J = 8.1 Hz, 1H, 
H-2), 4.20 (dd, J = 8.8, 6.5 Hz, 1H, H-2), 4.09 (t, J = 7.2 Hz, 2H, CH2CH2CH3), 3.46 (dd, J = 14.7, 5.3 
Hz, 1H, CH2-indole), 3.20 (dd, J = 14.7, 8.9 Hz, 1H, CH2-indole), 1.89 (sextet, J = 7.2 Hz, 2H, 
CH2CH2CH3), 1.71 (s, 3H, C9b-CH3), 0.96 (t, J = 7.2 Hz, 3H, CH2CH2CH3); 13C NMR (75 MHz, 
CDCl3) δ 174.39 (C=O), 147.43 (Cq), 136.30 (Cq), 133.20 (ArC), 131.74 (ArC), 130.14 (ArC), 128.22 
(Cq), 126.34 (ArC), 124.30 (ArC), 122.13 (ArC), 121.59 (ArC), 119.09 (ArC), 118.98 (ArC), 110.02 
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(Cq), 109.48 (ArC), 98.97 (C-9b), 74.72 (CH-2), 56.24 (CH-3), 47.96 (CH2CH2CH3), 30.59 (CH2-
indole), 23.61 (CH2CH2CH3), 23.16 (C9b-CH3), 11.59 (CH2CH2CH3). 
 
(3S,9bR)-9b-phenyl-3-((1-propyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 38c: Following the general procedure starting from compound 38 
(0.0592 g, 0.156 mmol), dissolved in dimethylformamide, DMF (3 mL) 
sodium hydride, NaH, 95% (0.008 g, 0.311 mmol) and propyl bromide (0.028 
mL, 0.311 mmol, d = 1.35 gmL-1) were added. Reaction time: 1 hour. Eluent 
for flash chromatography: ethyl acetate/ n-hexane, 3:7. The compound was 
obtained as a white crystalline solid (0.0506 g, 77.0%); 1H NMR (300 MHz, 
CDCl3) δ δ 7.83 – 7.79 (m, 1H, ArH), 7.65 (dd, J = 2.7, 1.9 Hz, 1H, ArH), 7.63  
 
(d, J = 1.8 Hz, 1H, ArH),), 7.51 – 7.46 (m, 3H, ArH), 7.41 (dd, J = 4.9, 1.9 Hz, 1H, ArH), 7.38 (d, J = 
1.8 Hz, 2H, ArH), 7.28 (d, J = 8.3 Hz, 1H, ArH), 7.25 – 7.21 (m, 1H, ArH), 7.21-7.15 (m, 1H, ArH), 
7.07 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H, ArH), 7.01 (s, 1H, CH-indole), 4.69 (ddd, J = 13.2, 9.4, 6.9 Hz, 1H, 
H-3), 4.43 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 4.01 (t, J = 7.26 Hz, 2H, CH2CH2CH3), 3.97 (dd, J = 8.8, 6.7 
Hz, 1H, H-2), 3.23 (ddd, J = 14.6, 5.8, 0.7 Hz, 1H, CH2-indole), 2.63 (dd, J = 14.6, 9.4 Hz, 1H, CH2-
indole), 1.89 – 1.75 (sextet, J = 7.26 Hz, 2H, CH2CH2CH3), 1.57 (s, 3H, C9b-CH3), 0.90 (t, J = 7.26 
Hz, 3H, CH2CH2CH3), the 1H-NMR spectrum was found to be identical to the one of compound 38c’. 
 
(3R,9bS)-9b-phenyl-3-((1-propyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 38c’: Following the general procedure starting from compound 
38’ (0.080 g, 0.210 mmol), dissolved in dimethylformamide, DMF (3 mL) 
sodium hydride, NaH 95%, (0.012 g, 0.500 mmol) and propyl bromide (0.0386 
mL, 0.311 mmol, d = 1.35 gmL-1) were added. Reaction time: 3 hours. Eluent 
for flash chromatography: ethyl acetate/ n-hexane, 3:7. The product was 
obtained as a white crystalline solid (0.0619 g, 70.0%); mp: 54-56 ºC; 1H NMR 
(300 MHz, CDCl3) δ 7.83 – 7.79 (m, 1H, ArH), 7.65 (dd, J = 2.7, 1.9 Hz, 1H, 
ArH), 7.63 (d, J = 1.8 Hz, 1H, ArH), 7.51 – 7.46 (m, 3H, ArH), 7.41 (dd, J =  
 
4.9, 1.9 Hz, 1H, ArH), 7.38 (d, J = 1.8 Hz, 2H, ArH), 7.28 (d, J = 8.2 Hz, 1H, ArH), 7.25 – 7.21 (m, 
1H, ArH), 7.21 – 7.15 (m, 1H, ArH), 7.07 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H, ArH), 7.01 (s, 1H, CH-
indole)4.69 (ddd, J = 13.2, 9.4, 6.7 Hz, 1H, H-3), 4.44 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 4.01 (t, J = 7.26 
Hz, 2H, CH2CH2CH3), 3.98 (dd, J = 8.8, 6.7 Hz, 1H, H-2), 3.23 (dd, J = 14.6, 5.9 Hz, 1H, CH2-indole), 
2.64 (dd, J = 14.7, 9.5 Hz, 1H, CH2-indole), 1.83 (sextet, J = 7.26 Hz 2H, CH2CH2CH3), 0.90 (t, J = 
7.26 Hz, 3H, CH2CH2CH3); 13C NMR (75 MHz, CDCl3) δ 174.57 (C=O), 147.18 (Cq), 138.90 (Cq), 
136.20 (Cq), 133.25 (ArC), 131.11 (ArC), 130.07 (ArC), 128.77 (ArC), 128.66 (ArC), 127.94 (ArC), 
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125.94 (Cq), 125.81 (CH-indole), 124.37 (ArC), 123.44 (ArC), 121.46 (ArC), 118.96 (ArC), 118.80 
(ArC), 110.04 (Cq), 109.36 (ArC), 100.93 (C-9b), 76.32 (CH-2), 55.78 (CH-3), 47.90 (CH2CH2CH3), 
30.12 (CH2-indole), 23.51 (CH2CH2CH3), 11.54 (CH2CH2CH3). 
 
4.2.2.4. General procedure for N-acetylation 
To a stirred solution of the appropriate (S)- or (R)-oxazoloisoindolinone derivative (0.32 mmol, 1 
equivalent) in dry dimethylformamide, DMF (5 mL) under inert atmosphere of nitrogen and ice bath 
was added sodium hydride, NaH (2 equivalents, 95% anhydrous reagent). The mixture was allowed to 
stir for 30 minutes and then acetic anhydride (2 equivalents, d = 1.08 gmL-1) was added. The reaction 
was kept stirring at room temperature for 3 hours. After this period of time, ethyl acetate was added to 
the crude of reaction and then dimethylformamide was extracted with room temperature deionized 
water. The organic phase was washed then with brine, dried with sodium sulphate, NaSO4, solid reagent 
and at last the solvent was evaporated. The crude was absorbed in silica and purified by flash 
chromatography using ethyl acetate/ n-hexane as mixture of eluents. Recrystallization was made using 
ethyl acetate/ n-hexane as solvents. 
 
(3S,9bR)-3-((1-acetyl-1H-indol-3-yl)methyl)-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 34d: To a solution of compound 34 (0.0517 g, 0.162 mmol) in 
anhydrous DMF (5 mL) sodium hydride, NaH 95%, (0.00779 g,0.325 mmol) 
and acetic anhydride (0.0307 mL, 0.280 mmol, d = 1.08 gmL-1) were added. 
Reaction time: 3 hours. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 3:7. Recrystallization: ethyl acetate/ n-hexane. The product was 
obtained as a white light solid (0.0465g, 79.5%); mp: 65-68 ºC; [α]20D = + 
25.3º (c = 0.53, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.38 (d, J = 7.8 Hz,  
 
4H, ArH), 7.33 – 7.17 (m, 2H, ArH), 4.62 – 4.52 (m, 1H, H-3), 4.34 (dd, J = 8.7, 7.6 Hz 1H, H-2), 4.10 
(dd, J = 8.8, 5.8 Hz, 1H, H-2), 3.23 (dd, J = 14.7, 7.9 Hz, 1H, CH2-indole), 2.99 (dd, J = 14.4, 6.2 Hz, 
1H, CH2-indole), 2.60 (s, 3H, NCH3), 1.68 ppm (s, 3H, C-9bCH3); 13C NMR (75 MHz, CDCl3) δ 174.62 
(ring-C=O), 168.84 (protecting acylic group-C=O), 147.26 (Cq), 135.80 (Cq), 133.49 (ArC), 131.34 
(Cq), 130.68 (Cq), 130.32 (ArC), 125.41 (ArC), 124.36 (ArC), 123.60 (ArC), 123.34 (ArC), 122.20 
(ArC), 118.66 (Cq), 118.46 (ArC), 116.77 (ArC), 99.22 (C-9b), 74.91 (CH-2), 54.97 (CH-3), 30.64 
(CH2-indole), 24.15 (CH3C=O), 23.33 (C-9bCH3); Anal. Calc. (C22H20N2O3): C, 73.32%; H, 5.59%; N, 
7.77%. Found C, 73.11%; H, 5.67%; N, 7.71%. 
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(3S,9bR)-3-((1-acetyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-  
5(9bH)-one 38d: To a solution of compound 38 (0.0522 g, 0.137 mmol) in 
anhydrous dimethyl formamide, DMF (5 mL), sodium hydride, NaH 95%, 
(0.00395 g, 0.165 mmol) and acetic anhydride (0.0150 mL, 0.159 mmol, d = 
1.08 gmL-1) were added. Reaction time: 3 hours. Eluent for flash 
chromatography: ethyl acetate/ n-hexane, 3:7. The product was obtained as a 
white light solid (0.0488g 84.2%); mp: 140-143 ºC; [α]20D = + 141.3º (c = 0.56, 
CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.33 (d, J = 7.4 Hz, 1H, H-ar), 7.71 
(dd, J = 5.3, 2.9 Hz, 1H, H-ar), 7.65 (s, 1H, H-ar), 7.49 – 7.36 (m, 6H, H-ar H-   
ar), 7.26 (d, J = 0.9 Hz, 7H, H-ar), 7.20 – 7.11 (m, 4H, H-ar), 4.68 (ddd, J = 14.2, 7.5, 6.4 Hz, 1H, H-
3), 4.54 (dd, J = 8.4, 7.6 Hz, 1H, H-2), 3.92 (dd, J = 8.5, 6.4 Hz, 1H, H-2), 2.81 (dd, J = 15.6, 8.1 Hz, 
1H, CH2- indole), 2.62 (dd, J = 15.3, 6.2 Hz, 1H, CH2-indole), 2.57 ppm (s, 3H, Ac-CH3), the 1H-NMR 
spectrum was found to be identical to the one of compound 38c’; Anal. Calc. (C27H22N2O3): C, 76.76%; 
H, 5.25%; N, 6.63%. Found C, 76.91%; H, 5.31%; N, 6.69%. 
 
(3R,9bS)-3-((1-acetyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 38d’: To a solution of compound 38’ (0.081 g, 0.210 mmol) in 
anhydrous ,DMF (5 mL), sodium hydride, NaH 95%, (0.00102 g, 0.426 mmol) 
and acetic anhydride (0.0403 mL, 0.426 mmol, d = 1.08 gmL-1) were added. 
Reaction time: 3 hours. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 2:8. The product was obtained as a white light solid (0.067g, 74.5%); 
mp: 85-87 ºC; 1H NMR (300 MHz, CDCl3) δ 8.33 (d, J = 7.9 Hz, 1H, ArH), 
7.71 (dd, J = 5.3, 2.9 Hz, 1H, ArH), 7.64 (s, 1H, CH-indole), 7.44 (dt, J = 5.8,  
 
2.3 Hz, 2H, ArH), 7.39 (dd, J = 5.4, 3.3 Hz, 2H, ArH), 7.31 – 7.20 (m, 5H, ArH), 7.19--7.10 (m, 2H, 
ArH), 4.68 (ddd, J = 14.2, 7.5, 6.4 Hz, 1H, H-3), 4.54 (dd, J = 8.4, 7.6 Hz, 1H, H-2), 3.92 (dd, J = 8.5, 
6.4 Hz, 1H, H-2), 2.81 (dd, J = 15.6, 8.1 Hz, 1H, CH2-indole), 2.62 (dd, J = 15.3, 6.2 Hz, 1H, CH2-
indole), 2.56 (s, 3H, Ac-CH3); 13C NMR (75 MHz, CDCl3) δ 174.79 (ring-C=O), 168.76 (Ac-C=O), 
146.98 (Cq), 138.44 (Cq), 135.71 (Cq), 133.49 (ArC), 130.75 (Cq), 130.62 (ArC), 130.25 (ArC), 128.83 
(ArC), 125.80 (ArC), 125.66 (ArC), 125.27 (CH-indole), 124.41 (ArC), 123.50 (Cq), 123.46 (ArC), 
123.20 (ArC), 118.59 (ArC), 118.45 (ArC), 116.66 (ArC), 101.18 (C-9b), 76.24 (CH-2), 54.50 (CH-3), 
29.68 (CH2-indole), 24.13 (CH3C=O). 
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4.2.2.5. General procedure for N-benzylation 
To a stirred solution of 1 equivalent of the adequate (S)- or (R)- oxazoloisoindolinone derivative (0.320 
mmol, 1 equivalent) in pure dimethylformamide, DMF (3 mL), under inert atmosphere and ice bath 
sodium hydride, NaH (2.2 equivalents, 95% anhydrous reagent) was added and the mixture was stirred 
for 30 minutes. After this period benzyl bromide (1.5 equivalents) was added and the reaction was 
allowed to stand at room temperature till total consumption of the limitant reagent. At the end of the 
reaction an aliquot of 20 mL of ethyl acetate was added to the mixture or reaction and extracted with 
room temperature deionized water. The organic phase was washed then with brine (saturated aqueous 
solution of NaCl), dried with sodium sulphate, NaSO4, solid reagent and at last the solvent was 
evaporated. The crude was absorbed in silica and purified by flash chromatography using ethyl acetate/ 
n-hexane as mixture of eluent, and when required recrystallized using ethyl acetate/ n-hexane mixture 
of solvents. 
 
(3S,9bR)-3-((1-benzyl-1-H-indol-3-yl)methyl-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 34e: To a solution of compound 34 (0.100 g, 0.310 mmol) in 
anhydrous dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, 
(0.028 g, 0.690 mmol) and benzyl bromide (0.0560 mL, 0.470 mmol, d = 1.44 
gmL-1) were added. Reaction time: 3 hours. Eluent for flash chromatography: 
ethyl acetate/ n-hexane, 1:2. The product was obtained as a pale yellow solid 
(0.108g, 83.9%); mp: 50-52 ºC; 1H-NMR (300 MHz, CDCl3) δ 7.80 – 7.72 (m, 
2H, ArH), 7.64 – 7.57 (m, 1H, ArH), 7.54 – 7.49 (m, 2H, ArH), 7.34 – 7.24  
 
(m, 4H, ArH), 7.14 – 7.11 (m, 5H, ArH), 5.31 (s, 2H, benzyl-CH2), 4.64 – 4.51 (m, 1H, H-3), 4.30 (dd, 
J = 8.9, 7.4 Hz, 1H, H-2), 4.17 (dd, J = 8.9, 6.5 Hz, 1H, H-2),3.44 (dd, J = 14.7, 5.3 Hz, 1H, CH2-
Indole), 3.17 (dd, J = 14.7, 8.9 Hz, 1H, CH2-Indole), 1.68 (s, 3H, C-9bCH3), 13C-NMR (75 MHz, CDCl3) 
δ 174.48 (C=O), 147.45 (Cq), 137.66 (ArC), 136.70 (Cq), 133.31 (ArC), 131.80 (Cq), 130.25 (ArC), 
128.88 (ArC),128.47 (ArC), 127.73 (Cq), 126.92 (ArC), 126.71 (ArC), 124.41 (ArC),122.22 (ArC), 
122.10 (ArC), 119.46 (ArC), 119.28 (ArC), 111.01 (ArC), 109.86 (Cq), 99.05 (C-9b), 74.79 (CH-2), 
56.23 (CH-3), 50.10 (benzyl-CH2), 30.72 (CH2-Indole), 23.23 (C-9bCH3). MS (ESI) m/z calcd for 
C27H24N2O2: 408, found 409 [M + H]+. 
 
(3S,9bR)-3-((1-benzyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-
5(9bH)-one, 38e: according to the general procedure, to a solution of 0.0636 g of 38 (0.167 mmol) in 
dimethylformamide, DMF (3 mL) in ice bath and under inert atmosphere of nitrogen, 0.0089 g of 
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sodium hydride, NaH 95%, (0.368 mmol) were added. After stirring for 30 minutes 0.030 mL of benzyl 
bromide (0.251 mmol, 1.44 gmL-1) were added. Reaction time: 2 hours. Eluent for flash chromatogra- 
-phy: ethyl acetate/ n-hexane, 3:7. Recrystallization: in acetate/ n-hexane. The 
product was obtained as a white light solid (0.0757 g, 96.2%); mp: 61- 64 ºC; 
1H NMR (300 MHz, CDCl3) δ 7.84 – 7.77 (m, 1H, ArH), 7.67 – 7.60 (m, 2H, 
ArH), 7.53 (d, J = 7.6 Hz, 1H, ArH), 7.48 (dd, J = 5.6, 3.1 Hz, 2H, ArH), 7.42 
– 7.35 (m, 4H, ArH), 7.28 (m, 1H, ArH), 7.25 – 7.20 (m, 3H, ArH), 7.17 (dd, 
J = 6.9,1.0 Hz, 1H, ArH), 7.13 (dd, J = 5.6, 1.3 Hz, 1H, ArH), 7.08 (d, J = 7.6 
Hz, 2H, ArH), 7.01 (s, 1H, CH-indole), 5.25 (s, 2H, Bn-CH2), 4.70 (dq, J = 
9.4, 6.8 Hz, 1H, H-3), 4.44 (dd, J = 8.6, 7.5 Hz, 1H, H-2), 3.99 (dd, J = 8.7, 
 
6.7 Hz, 1H, H-2), 3.23 (dd, J = 14.5, 5.9 Hz, 1H, CH2-indole), 2.66 (dd, J = 14.6, 9.5 Hz, 1H, CH2-
indole); 13C NMR (75 MHz, CDCl3) δ 174.55 (C=O), 147.18 (Cq), 138.89 (Cq), 137.59 (Cq), 136.56 
(Cq), 133.26 (ArC), 131.09 (Cq), 130.08 (ArC), 128.77 (ArC), 128.74 (ArC), 128.67 (ArC), 128.12 
(Cq), 127.56 (Cq), 126.75 (ArC), 126.26 (CH-indole), 125.80 (ArC), 124.37 (ArC), 123.45 (ArC), 
121.89 (ArC), 119.21 (ArC), 119.04 (ArC), 110.97 (ArC), 109.66 (ArC), 100.93 (C-9b), 76.27 (CH-2), 
55.74 (CH-3), 49.93 (Bn-CH2), 30.14 (CH2-indole). 
 
(3R,9bS)-3-((1-benzyl-1H-indol-3yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one, 38e’: To a solution of compound 38’ (0.0619 g, 0.210 mmol) in 
anhydrous dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, 
(0.0091 g, 0.158 mmol) and benzyl bromide (0.0280 mL, 0.237 mmol, d = 
1.44 gmL-1) were added. Reaction time: 1.5 hours. Eluent for flash 
chromatography: ethyl acetate/ n-hexane, 3:7. The product was obtained as a 
white light solid (0.0578 g, 75.5%); mp: 61- 64 ºC; 1H NMR (300 MHz, 
CDCl3) δ 7.82 – 7.78 (m, 1H, ArH), 7.65 – 7.61 (m, 2H, ArH), 7.53 (d, J = 7.6  
 
Hz, 1H, ArH), 7.48 (dd, J = 5.6, 3.1 Hz, 2H, ArH), 7.42 – 7.35 (m, 4H, ArH), 7.28 (m, 1H, ArH), 7.25-
-7.20 (m, 3H, ArH), 7.17 (dd, J = 6.9, 1.0 Hz, 1H, ArH), 7.13 (dd, J = 5.6, 1.3 Hz, 1H, ArH), 7.08 (d, J 
= 7.6 Hz, 2H, ArH), 7.01 (s, 1H, CH-indole), 5.25 (s, 2H, Bn-CH2) 4.70 (dq, J = 9.4, 6.8 Hz, 1H, H-3), 
4.44 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.98 (dd, J = 8.7, 6.7 Hz, 1H, H-2), 3.23 (dd, J = 14.7, 5.9, 1H, 
CH2-indole), 2.65 ppm (dd, J = 14.6, 9.5 Hz, 1H, CH2-indole), the 1H-NMR spectrum was found to be 
identical to the one of compound 38e. 
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4.2.2.6. General procedure for N-benzoylation 
To a stirred solution of the appropriate (S)- or (R)-oxazoloisoindolinone derivative (0.320 mmol, 1 
equivalent) in dry dimethylformamide, DMF (5 mL) under inert atmosphere of nitrogen and ice bath 
was added sodium hydride, NaH (2 equivalents 95% anhydrous reagent). The mixture was allowed to 
stir for 30 minutes and then acetic anhydride (2 equivalents, d = 1.08 gmL-1) was added. The reaction 
was kept stirring at room temperature for 3 hours. After this period, ethyl acetate was added to the crude 
of reaction and then dimethylformamide was extracted quantitatively with room temperature deionized 
water. The organic phase was washed then with brine, dried with sodium sulphate, NaSO4, solid reagent 
and at last the solvent was evaporated. The crude was absorbed in silica and purified by flash 
chromatography using ethyl acetate/ n-hexane as mixture of eluent, and when required recrystallized 
using ethyl acetate/ n-hexane mixture of solvents. 
 
(3S,9bR)-3-((1-benzoyl-1H-indol-3-yl)methyl)-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 34f: To a solution of compound 34 (0.0558 g, 0.175 mmol) in 
anhydrous dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, 
(0.0097g, 0.158 mmol) and benzoyl chloride (0.0408 mL, 0.351 mmol, d = 
1.21 gmL-1) were added. Reaction time: 2 hours. Eluent for flash 
chromatography: ethyl acetate/ n-hexane, 3:7. The product was obtainied as a 
white light solid (0.0567g, 76.6%); mp: 56- 58 ºC; 1H NMR (300 MHz, 
CDCl3) δ 8.39 (dd, J = 7.0, 1.3 Hz, 1H, ArH), 7.78 – 7.70 (m, 4H, ArH), 7.66  
 
– 7.49 (m, 6H, ArH), 7.45 – 7.33 (m, 3H, ArH), 4.54 (dq, J = 8.3, 6.2 Hz, 1H, H-3), 4.31 (dd, J = 8.9, 
7.4 Hz, 1H, H-2), 4.12 (dd, J = 8.9, 6.2 Hz, 1H, H-2), 3.34 (dd, J = 14.9, 6.0 Hz, 1H, CH2-indole), 3.08 
(dd, J = 14.9, 8.5 Hz, 1H, CH2-indole), 1.72 (s, 3H, C-9bCH3); 13C-NMR (75 MHz, CDCl3) δ 174.36 
(ring-C=O), 168.51 (Bz-C=O), 147.26 (Cq), 136.32 (Cq), 134.57 (Cq)133.37 (ArC), 131.93 (Cq), 
131.41 (ArC), 130.89 (ArC), 130.59 (Cq), 130.24 (ArC), 129.23 (ArC), 128.89 (ArC), 128.66 (ArC), 
125.34 (ArC), 125.25 (Cq), 124.34 (ArC), 123.99 (ArC), 122.17 (ArC), 119.05 (ArC), 117.86 (s), 
116.59 (ArC), 98.99 (C-9b), 74.54 (CH-2), 55.33 (CH-3), 30.52 (CH2-indole), 23.25 (C-9bCH3). 
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(3S,9bR)-3-((1-benzoyl-1H-indol-3yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 38f: To a solution of compound 38 (0.0558 g, 0.175 mmol) in 
anhydrous dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, 
(0.0097g, 0.158 mmol) and benzoyl chloride (0.0408 mL, 0.351 mmol, d = 
1.21 gmL-1) were added. Reaction time: 2 hours. Eluent for flash 
chromatography: ethyl acetate/ n-hexane, 3:7. The product was obtained as a 
white light solid (0.0567g, 76.6%); mp: 55- 57 ºC; 1H NMR (300 MHz, CDCl3) 
δ 8.37 (d, J = 8.2 Hz, 1H, ArH), 7.80 – 7.76 (m, 1H, ArH), 7.72 (t, J = 1.4 Hz,  
 
1H, ArH), 7.70 (t, J = 1.9 Hz, 1H, ArH), 7.61 (dt, J = 2.9, 2.1 Hz, 1H, ArH), 7.55 (dd, J = 7.5, 1.4 Hz, 
3H, ArH), 7.51 (dd, J = 2.6, 1.4 Hz, 2H, ArH), 7.48 (dd, J = 5.5, 3.2 Hz, 3H, ArH), 7.42 – 7.35 (m, 1H, 
ArH), 7.35 – 7.30 (m, 4H, ArH), 7.22 – 7.19 (m, 1H, ArH), 7.19 (s, 1H, CH-indole), 4.65 (ddd, J = 
14.7, 8.0, 6.6 Hz, 1H, H-3), 4.50 (dd, J = 8.6, 7.5 Hz, 1H, H-2), 3.94 (dd, J = 8.7, 6.7 Hz, 1H, H-2), 
3.02 (dd, J = 14.8, 6.4 Hz, 1H, CH2-indole), 2.67 (dd, J = 14.7, 8.8 Hz, 1H, CH2-indole), the 1H-NMR 
spectrum was found to be identical to the one of compound 38f’. 
 
(3R,9bS)-3-((1-benzoyl-1H-indol-3-yl)methyl)-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 38f’: To a solution of compound 38’ (0.0830 g, 0.220 mmol) in 
anhydrous dimethylformamide, DMF (3 mL), sodium hydride, NaH 95%, 
(0.0120g, 0.500 mmol) and benzoyl chloride (0.0488 mL, 0.420 mmol, d = 
1.21 gmL-1) were added. Reaction time: 1.5 hours. Eluent for flash 
chromatography ethyl acetate/ n-hexane, 2:8. The product was obtained as a 
white light solid (0.0567g, 60.0%); mp: 55- 57 ºC; 1H NMR (300 MHz, CDCl3) 
δ 8.37 (d, J = 8.2 Hz, 1H, ArH), 7.80 – 7.76 (m, 1H, ArH), 7.72 (t, J = 1.4 Hz,  
 
1H, ArH), 7.70 (t, J = 1.9 Hz, 1H, ArH), 7.61 (dt, J = 2.9, 2.1 Hz, 1H, ArH), 7.55 (dd, J =7.5, 1.4 Hz, 
3H, ArH), 7.51 (dd, J = 2.6, 1.4 Hz, 2H, ArH), 7.48 (dd, J = 5.5, 3.2 Hz, 3H, ArH), 7.42 – 7.35 (m, 1H, 
ArH), 7.35 – 7.30 (m, 4H, ArH), 7.22 – 7.19 (m, 1H, ArH), 7.19 (s, 1H, CH-indole), 4.65 (ddd, J = 
14.7, 8.0, 6.6 Hz, 1H, H-3), 4.50 (dd, J = 8.6, 7.5 Hz, 1H, H-2), 3.94 (dd, J = 8.7, 6.7 Hz, 1H, H-2), 
3.02 (dd, J = 14.8, 6.4 Hz, 1H, CH2-indole), 2.67 (dd, J = 14.7, 8.8 Hz, 1H, CH2-indole); 13C NMR (75 
MHz, CDCl3) δ 174.65 (ring-C=O), 168.43 (Bz-C=O), 147.13 (Cq), 138.65 (Cq), 136.24 (Cq), 134.59 
(Cq), 133.43 (ArC), 131.86 (ArC), 130.84 (Cq), 130.78 (ArC), 130.18 (ArC), 129.24 (ArC), 128.79 
(ArC), 128.74 (ArC), 128.61 (ArC), 125.65 (ArC), 125.22 (ArC), 125.11 (ArC), 124.39 (ArC), 123.88 
(Cq), 123.50 (Cq), 118.96 (ArC), 117.77 (ArC), 116.53 (ArC), 100.99 (C-9b), 75.93 (CH-2), 55.07 
(CH-3), 29.68 (CH2-indole). 
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4.2.2.7. General procedure for N-tosylation 
To a stirred solution of the appropriate (R)-oxazoloisoindolinone derivative (0.320 mmol, 1 equivalent) 
in anhydrous dimethylformamide, DMF (2 mL) under inert atmosphere of nitrogen and ice bath was 
added sodium hydride, NaH (2 equivalents, 95% anhydrous reagent). The mixture was allowed to stir 
for 30 minutes and then p-toluene sulfonyl chloride (2 equivalents) was added. The reaction was kept 
stirring at room temperature for 1 hour and a half. After this period, ethyl acetate was added to the crude 
of reaction and then extracted at room temperature with deionized water. The organic phase was washed 
then with a saturated aqueous solution of sodium chloride, NaCl (brine), dried with sodium sulphate, 
NaSO4 and in the end the solvent was evaporated in rotavapor. The crude was absorbed in silica and 
purified by flash chromatography using ethyl acetate/ n-hexane as mixture of eluent. 
 
(3S,9bR)-9b-methyl-3-((1-tosyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3a]isoindol-5(9bH)-  
one 34g: To a solution of compound 34 (0.1 g, 0.263 mmol) in anhydrous 
dimethylformamide, DMF (2 mL), sodium hydride, NaH 95%, (0.0013 g, 
0.542 mmol) and p-toluenesulfonyl chloride (0.0501 g, 0.263 mmol) were 
added. Reaction time: 3 hours. Eluent for flash chromatography: ethyl acetate/ 
n-hexane, 3:7. The product was obtained as a white light solid (0.0967g, 
77.8%). Recrystallization in ethyl acetate/ n-hexane provided 0.0854g of the 
compound; mp: 220 - 222 ºC; 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.2  
 
Hz, 1H, ArH), 7.81 – 7.75 (m, 3H, ArH), 7.65 – 7.59 (m, 3H, ArH), 7.53 (t, J = 7.0 Hz, 2H, ArH), 7.36 
– 7.30 (m, 1H, ArH), 7.29 – 7.23 (m, 1H, ArH), 7.20 (d, J = 8.1 Hz, 2H, ArH), 4.55 – 4.47 (m, 1H, H-
3), 4.31 (dd, J = 8.8, 7.6 Hz, 1H, H-2), 4.10 (dd, J = 8.9, 6.5 Hz, 1H, H-2), 3.28 (dd, J = 14.9, 5.0 Hz, 
1H, CH2-indole), 3.09 (dd, J = 14.9, 8.3 Hz, 1H, CH2-indole), 2.32 (s, 3H, phenyl-CH3), 1.61 (s, 3H, C-
9bCH3); 13C NMR (101 MHz, CDCl3) δ 174.39 (ring-C=O), 147.21 (Cq), 144.87 (Cq), 135.20 (Cq), 
133.37 (ArC), 131.43 (Cq), 130.91 (Cq), 130.26 (ArC), 129.84 (ArC), 126.83 (ArC), 124.94 (ArC), 
124.36 (ArC), 124.07 (ArC), 123.97 (Cq), 123.32 (ArC), 122.17 (ArC), 119.62 (ArC), 118.54 (Cq), 
113.79 (ArC), 98.98 (C-9b), 74.39 (CH-2), 55.09 (CH-3), 30.35 (CH2-indole), 22.97 (phenyl-CH3), 
21.57 (C-9bCH3). 
 
(3S,9bR)-9b-phenyl-3-((1-tosyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-
one 38g: To a solution of compound 38 (0.101 g, 0.266 mmol) in anhydrous dimethylformamide, DMF 
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(2 mL), sodium hydride, NaH, 95% (0.0013 g, 0.531 mmol) and p-
toluenesulfonyl chloride (0.0506 g, 0.266 mmol) were added. Reaction time: 
3 hours. Eluent for flash chromatography: ethyl acetate/ n-hexane, 3:7. The 
product was obtained as a white light solid (0.0987g, 70.5%). Recrystallization 
in ethyl acetate/ n-hexane provided 0.0844g of the compound; mp: 218 - 220 
ºC; 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.3 Hz, 1H, ArH), 7.81 (d, J = 
3.5 Hz, 1H, ArH), 7.73 (d, J = 7.9 Hz, 2H, ArH), 7.58 – 7.45 (m, 5H, ArH),  
 
7.41 (d, J = 7.8 Hz, 1H, ArH), 7.37 (s, 3H, ArH), 7.30 (t, J = 7.7 Hz, 1H, ArH), 7.22 (d, J = 7.5 Hz, 2H, 
ArH), 7.17 (d, J = 7.9 Hz, 2H, ArH), 4.81 – 4.54 (m, 1H, H-3), 4.46 (t, J = 8.0 Hz, 1H, H-2), 4.00 – 
3.79 (dd, J = 8.5, 6.5 Hz, 1H, H-2), 3.01 (dd, J = 14.9, 6.5 Hz, 1H, CH2-indole), 2.58 (dd, J = 14.9, 8.5 
Hz, 1H, CH2-indole), 2.29 (s, 3H, phenyl-CH3); 13C NMR (101 MHz, CDCl3) δ 174.51 (ring-C=O), 
147.07 (Cq), 144.78 (Cq), 138.55 (Cq), 135.20 (Cq), 135.17 (ArC), 133.44 (ArC), 130.79 (Cq), 130.71 
(Cq), 130.20 (ArC), 129.78 (ArC), 128.84 (ArC), 128.82 (ArC), 126.80 (ArC), 125.64 (ArC), 124.84 
(ArC), 124.39 (ArC), 123.79 (ArC), 123.51 (Cq), 123.21 (ArC), 119.38 (ArC), 118.64 (Cq), 113.79 
(ArC), 100.95 (C-9b), 76.00 (CH-2), 54.61 (CH-3), 29.88 (CH2-indole), 21.55 (phenyl-CH3). 
 
(3R,9bS)-9b-phenyl-3-((1-tosyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-  
one 38g’: To a solution of compound 38’ (0.0694 g, 0.182 mmol) in anhydrous 
dimethylformamide, DMF (2 mL), sodium hydride, NaH 95%, (0.00102 g, 
0.425 mmol) and p-toluenesulfonyl chloride (0.0603 g, 0.280 mmol) were 
added. Reaction time: 1.5 hours. Eluent for flash chromatography: ethyl 
acetate/ n-hexane, 3:7. The product is obtained as a white light solid (0.0854g, 
87.6%). Recrystallization in ethyl acetate/ n-hexane provided 0.0554g of the 
compound; mp: 215 - 217 ºC; 1H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 8.1 
Hz, 1H, ArH), 7.81 (dd, J = 5.6, 3.1 Hz, 1H, ArH), 7.73 (d, J = 8.3 Hz, 2H,  
 
ArH), 7.58 – 7.45 (m, 5H, ArH), 7.44 – 7.28 (m, 6H, ArH), 7.24 – 7.14 (m, 4H, ArH), 4.71 – 4.60 (m, 
1H, H-3), 4.49 – 4.42 (dd, J = 8.8, 7.4 Hz, 1H, H-2), 3.93 (dd, J = 8.83, 6.4 Hz, 1H, H-2), 3.01 (dd, J = 
14.9, 6.7 Hz, 1H, CH2-indole), 2.58 (dd, J = 15.0, 8.5 Hz, 1H, CH2-indole), 2.29 ppm (s, 3H, phenyl-
CH3).  
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4.3. Experimental procedure chapter 2.3 indolizinoindolones scaffold 
4.3.1. General procedure for cyclocondensation reactions 
To a solution of a particular aminoalcohol (0.660mmol, 1 equivalent) in toluene (5ml) was added the 
appropriate oxocarboxylic acid (0,730mmol). The mixture was heated at reflux for 10-24h under dean-
stark apparatus, until total consumption of the starting aminoalcohol. The solvent was evaporated and 
the residue was dissolved in ethyl acetate. The organic phase was washed with saturated aqueous 
solutions of NaHCO3 and NaCl, dried with anhydrous magnesium sulfate, filtered and evaporated. The 
crude was absorbed on silica and purified by flash chromatography using ethyl ethyl acetate /n-hexane 
as eluent. 
 
Scheme 4.3. (S)-tryptophanol-derived bicyclic lactams cyclocondensation reaction procedure. 
34: for the preparation see pg. 60. 
 
38: for the preparation see pg. 60. 
 
38’: for the preparation see pg. 61. 
 
(3S, 7aS)-3-((1H-indol-3-yl)methyl)-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one, 47a: 
Following the general procedure, to a solution of (S)-tryptophanol 9 
(0.155 g, 0.816 mmol) in toluene (7.5 mL) was added benzylpropionic 
acid (0.175 g, 0.980 mmol). Reaction time: 16 hours. Eluent for flash 
chromatography: ethyl acetate/ n-hexane, 1:1. The product was obtained 
as a white amorphous solid (0.196 g, 72.3%); pf 153-156 °C; [α]20D = + 
40.7º (c = 0.21, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H, NH),  
 
7.53 – 7.48 (m, 2H, ArH), 7.40 (tdd, J = 6.7, 5.8, 2.7 Hz, 4H, ArH), 7.33 (d, J = 8.1 Hz, 1H, ArH), 4.58 
(dq, J = 9.3, 6.8 Hz, 1H, H-3), 4.16 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.61 (dd, J = 8.8, 6.9 Hz, 1H, H-2), 
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3.08 (dd, J = 14.7, 6.2 Hz, 1H, CH2-indole), 2.92 – 2.77 (m, 1H, H-6), 2.63 (dd, J = 10.0, 3.4 Hz, 1H, 
CH2-indole), 2.57 – 2.41 (m, 2H, H-6 and H-7), 2.28 – 2.19 ppm (m, 1H, H-7); as previously described 
in literature [77]. 
 
(3R,9bS)-3-((1H-indol-3-yl)methyl)-9b-(4-fluorophenyl)-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 47b: Following the general procedure, to a solution of (S)-
tryptophanol 9 (0.172 g, 0.905 mmol) in toluene (5 mL) was added 2-
(4-fluorobenzoyl)benzoic acid (0.412 g, 1.09 mmol). Reaction time: 23 
hours. Eluent for flash chromatography: ethyl acetate/ n-hexane, 1:1. 
The product was obtained as a white solid (0.207 g, 65.9%); mp: 203-
207 ºC; 1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H, NH), 7.83 – 7.76 
(m, 1H, ArH), 7.63 – 7.54 (m, 2H, ArH), 7.54 – 7.45 (m, 3H, ArH), 
7.38 – 7.30 (m, 1H, ArH), 7.21 (dt, J = 4.4, 2.7 Hz, 2H, ArH), 7.18 –  
 
7.09 (m, 2H, ArH), 7.06 (ddd, J = 9.8, 5.9, 2.6 Hz, 2H, ArH), 4.72 (dq, J = 8.8, 6.5 Hz, 1H, H-3), 4.47 
(dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.98 (dd, J = 8.8, 6.7 Hz, 1H, H-2), 3.17 (ddd, J = 14.8, 6.3, 0.9 Hz, 1H, 
CH2-indole), 2.68 (dd, J = 14.7, 9.0 Hz, 1H, CH2-indole); 13C NMR (75 MHz, CDCl3) δ 174.69 (C=O), 
164.72 (ArC), 147.19 (ArC), 136.26 (ArC), 134.89 (ArC), 133.52 (ArC), 131.06 (ArC), 130.34 (ArC), 
127.88 (ArC), 127.77 (ArC), 127.58 (ArC), 124.56 (ArC), 123.47 (ArC), 122.30 (ArC), 122.24 (ArC), 
119.64 (ArC), 118.85 (ArC), 116.00 (ArC), 115.71 (ArC), 111.84, 111.24 (C-9b), 76.40 (C-2), 55.88 
(C-3). Anal. Calcd. (C23H19FN2O2•0.15H2O): C, 74.90%; H, 4.86%; N, 6.99%. Found C, 74.31%; H, 
5.10%; N, 7.16%. 
 
(3S,9bR)-3-((1H-indol-3-yl)methyl)-9b-(4-chlorophenyl)-2,3-dihydrooxazolo[2,3-a]isoindol-  
5(9bH)-one 47c: Following the general procedure, to a solution of 
(S)-tryptophanol 9 (0.113 g, 0.593 mmol) in toluene (5 mL). Reaction 
time: 16 hours. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 4:6. The product was obtained as a white solid (0.209 g, 
85.0%). The 1H-NMR spectrum was found to be identical to the one 
of compound 47c’. 
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(3R,9bS)-3-((1H-indol-3-yl)methyl)-9b-(4-chlorophenyl)-2,3-dihydrooxazolo[2,3-a]isoindol-  
5(9bH)-one 47c’: Following the general procedure, to a solution of 
(R)-tryptophanol 44 (0.0952 g, 0.500 mmol) in toluene (5 mL) was 
added 2-(4-chlorobenzoyl)benzoic acid (0.177 g, 0.681 mmol). 
Reaction time: 15.5 hours. Eluent for flash chromatography: ethyl 
acetate/ n-hexane, 1:1. The product was obtained as a white crystalline 
solid (0.1452 g, 70%); mp: 84-86 ºC; 1H NMR (300 MHz, CDCl3) δ 
8.08 (s, 1H, NH), 7.84 – 7.77 (m, 1H, ArH), 7.56 – 7.51 (m, 3H, ArH), 
7.51 – 7.46 (m, 2H, ArH), 7.38 – 7.30 (m, 3H, ArH), 7.23 – 7.16 (m,  
 
2H, ArH), 7.16 – 7.07 (m, 2H, ArH), 4.72 (dq, J = 8.7, 6.6 Hz, 1H, H-3), 4.47 (dd, J = 8.7, 7.5 Hz, 1H, 
H-2), 3.98 (dd, J = 8.8, 6.7 Hz, 1H, H-2), 3.22 –3.10 (dd, J = 14.8, 5.7 Hz, 1H, CH2-indole),2.70 (dd, J 
= 14.8, 8.8 Hz, 1H, CH2-indole); 13C NMR (75 MHz, CDCl3) δ 174.70 (C=O), 146.92 (ArC), 137.67 
(ArC), 136.23 (ArC), 134.71 (ArC), 133.55 (ArC), 131.01 (ArC), 130.41 (ArC), 129.08 (ArC), 127.49 
(ArC), 127.35 (ArC), 124.54 (ArC), 123.46 (ArC), 122.31 (ArC), 122.21 (ArC), 119.55 (ArC), 118.79 
(ArC), 111.57 (ArC), 111.27 (ArC), 100.66 (C-9b), 76.36 (C-2), 55.91 (C-3), 30.15 (ArCH2); Anal. 
Calc. (C25H19ClN2O2•0.25CH2Cl2): C, 69.53%; H, 4.52%; N, 6.42%. Found C, 69.18%; H, 4.63%; N, 
6.21%. 
 
(3S,9bR)-3-((1H-indol-3-yl)methyl)-9b-(4-chloro-3-nitrophenyl)-2,3-dihydrooxazolo[2,3-a]isoindol- 
5(9bH)-one 47d: Following the general procedure, to a solution of (S)-
tryptophanol 9 (0.101 g, 0.526 mmol) in toluene (5 mL) was added 2-
(4-chloro-3-nitrobenzoyl)benzoic acid (0.412 g, 1.35 mmol). Reaction 
time: 19.5 hours. Eluent for flash chromatography: ethyl acetate/ n-
hexane, 1:1. The product was obtained as a bright yellow solid (0.119 
g, 49.1%); mp: 94-98 ºC; 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 
2.1 Hz, 1H, ArH), 7.96 (s, 1H, NH), 7.85 – 7.80 (m, 1H, ArH), 7.52 
(ddd, J = 7.8, 2.9, 1.9 Hz, 3H, ArH), 7.37 (dd, J = 8.4, 2.1 Hz, 1H, ArH),  
7.30 (t, J = 7.7 Hz, 2H, ArH), 7.22 – 7.02 (m, 4H, ArH), 4.72 (dt, J = 12.6, 7.4 Hz, 1H, H-3), 4.53 (dd, 
J = 8.8, 7.5 Hz, 1H, H-2), 4.09 (dd, J = 8.4, 6.6 Hz, 1H, H-2), 3.06 (dd, J = 14.9, 5.3 Hz, 1H, CH2-
indole), 2.89 (dd, J = 14.7, 8.0 Hz, 1H, CH2-indole); 13C NMR (75 MHz, CDCl3) δ 174.72 (C=O), 
147.87 (ArC), 146.27 (ArC), 140.19 (ArC), 136.13 (ArC), 133.89 (ArC), 132.05 (ArC), 130.92 (ArC), 
130.88 (ArC), 130.51 (ArC), 127.55 (ArC), 126.98 (ArC), 124.80 (ArC), 123.45 (ArC), 122.73 (ArC), 
122.26 (ArC), 119.67 (ArC), 118.70 (ArC), 111.32 (ArC), 110.88 (ArC), 99.89 (C-9b), 75.98 (C-2), 
56.62 (C-3), 29.36 (ArCH2); Anal. Calc. (C25H18ClN3O4•0.5CH2Cl2): C, 60.96%; H, 3,82%; N, 8.37%. 
Found C, 61.32%; H, 3.89%; N, 8.09%. 
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(3R,9bS)-3-((1H-indol-3-yl)methyl)-9b-(p-tolyl)-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, 
47e: Following the general procedure, to a solution of (S)-tryptophanol 9 (0.177 g, 0.931 mmol) in 
toluene (7.5 mL) was added 2-(4-methylbenzoyl)benzoic acid (0.412 g, 1.09 mmol). Reaction time: 17  
hours. Eluent for flash chromatography: ethyl acetate/ n-hexane, 6:4. 
The product was obtained as a white solid (0.302 g, 82.1%); mp: 155-
157 ºC 1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H, NH), 7.81 – 7.77 (m, 
1H, ArH), 7.52 (d, J = 8.1 Hz, 3H, ArH), 7.49 – 7.45 (m, 2H, ArH), 7.34 
(d, J = 8.0 Hz, 1H, ArH), 7.25 – 7.22 (m, 1H, ArH), 7.20 (d, J = 7.8 Hz, 
3H, ArH), 7.16 (d, J = 1.5 Hz, 1H, ArH), 7.14 – 7.07 (m, 1H, ArH), 4.70 
(dq, J = 8.8, 6.6 Hz, 1H, H-3), 4.46 (dd, J = 8.7, 7.5 Hz, 1H, 3.99 (dd, J 
= 8.7, 6.7 Hz, 1H, H-2), 3.20 (dd, J = 14.7, 6.3 Hz, 1H, CH2- indole), 
 
2.67 (dd, J = 14.7, 8.9 Hz, 1H, CH2-indole), 2.38 (s, 3H, ArCH3); 13C NMR (75 MHz, CDCl3) δ 174.62 
(C=O), 147.29 (ArC), 138 (ArC), 136.12 (ArC), 135.78 (ArC), 133.27 (ArC), 131.05 (ArC), 130.02 
(ArC), 129.50 (ArC), 127.45 (ArC), 125.73 (ArC), 124.32 (ArC), 123.38 (ArC), 122.09 (ArC), 119.43 
(ArC), 118.82 (ArC), 111.99 (ArC), 111.08 (ArC), 101.01 (C9b), 76.36 (CH-2), 55.62 (CH-3), 30.20 
(CH2-indole), 21.24 (ArCH3). 
4.3.2. General procedure for N-methylation and N-ethylation 
 
Scheme 4.4. (S) and (R)-tryptophanol-derived bicyclic lactams protected on the indole moiety. 
 
To a stirred solution of the appropriate (S)- or (R)- oxazoloisoindolinone derivative (0.320 mmol, 1 
equivalent) in dry dimethylformamide, DMF (3 mL) under inert atmosphere of nitrogen and ice bath 
was added sodium hydride, NaH (2 equivalent, 95% anhydrous reagent). The mixture was allowed to 
stir for 30 minutes and then methyl iodide (2 equivalents) was added. The reaction was kept stirring at 
room temperature for 30 minutes. After this period, ethyl acetate was added to the crude of reaction and 
then extracted with room temperature deionized water. The organic phase was washed firstly with an 
aqueous saturated solution of sodium monohydrogen carbonate, NaHCO3 and then with brine solution 
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(saturated aqueous solution of sodium chloride, NaCl); dried with sodium sulphate, NaSO4 and in the 
end the solvent was evaporated. The crude was absorbed in silica, purified by flash chromatography 
using ethyl acetate/n-hexane as eluent mixture and recrystallized. 
 
(3S,7aS)-3-((1-methyl-1H-indol-3-yl)methyl)-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-  
one 48a: Following the general procedure, starting from compound 47a 
(0.0692 g, 0.208 mmol), sodium hydride, NaH 95%, (0.010 g, 0.416 
mmol) and methyl iodide (0.026 mL, 0.416 mmol, d = 2.28 gmL-1) were 
added. Reaction time: 1.5 hours. Eluent for flash chromatography: 1:1, 
n-hexane/ ethyl acetate. Recrystallization with the same combination of 
solvents. The product was obtained as a white light solid (0.0605 g, 
83.9%). 1H NMR (300 MHz, CDCl3) δ 7.52 – 7.48 (m, 2H, ArH), 7.43 –   
7.35 (m, 4H, ArH), 7.25 (d, J = 6.2 Hz, 2H, ArH), 7.22 – 7.16 (m, 1H, ArH), 7.06 (ddd, J = 7.9, 6.7, 
1.3 Hz, 1H, ArH), 6.89 (s, 1H, CH-indole), 4.54 (ddd, J = 13.1, 9.5, 7.0 Hz, 1H, H-3), 4.15 (dd, J = 8.8, 
7.5 Hz, 1H, H-2), 3.70 (s, 3H, NCH3), 3.60 (dd, J = 8.8, 6.9 Hz, 1H, H-2), 3.09 (dd, J = 14.5, 5.8 Hz, 
1H, CH2-indole), 2.93 – 2.80 (m, 1H, H-6), 2.63 (dd, J = 14.0, 9 Hz, 1H, CH2-indole), 2.57 – 2.41 (m, 
2H, H-6 and H-7), 2.28 – 2.19 ppm (m, 1H, H-7). 
 
(3S,9bR)-9b-((4-fluorophenyl)-3-((1-methyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-  
a]isoindol-5(9bH)-one 48b: Following the general procedure, 
starting from compound 47b (0.104g, 0.338 mmol), sodium hydride, 
NaH 95%, (0.0126 g, 0.523 mmol) and methyl iodide (0.033 mL, 
0.523 mmol, d = 2.28 gmL-1) were added. Reaction time: 20 minutes. 
Eluent for flash chromatography 6:4, n-hexane/ ethyl acetate. 
Recrystallization with the same combination of solvents. The product 
appears as a white light solid (0.101 g, 93.9%); 1H NMR (300 MHz, 
CDCl3) δ 7.83 – 7.77 (m, 1H, ArH), 7.59 – 7.52 (m, 2H, ArH), 7.51 –  
 
7.46 (m, 3H, ArH), 7.24 (d, J =,1.0 Hz, 1H, ArH), 7.21 (dd, J = 1.7, 0.9 Hz, 1H, ArH), 7.19 (dd, J = 
3.4, 1.8 Hz, 1H, ArH), 7.12 – 7.06 (m, 2H, ArH), 7.03 (d, J = 8.7 Hz, 2H, ArH), 6.95 (s, 1H, CH-indole), 
4.68 (ddd, J = 13.1, 10.9, 6.3 Hz, 1H, H-3), 4.45 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.98 (dd, J = 8.8, 6.8 
Hz, 1H, H-2), 3.72 (s, 3H, NCH3), 3.17 (dd, J = 14.5, 5.9 Hz, 1H, CH2-indole), 2.67 (dd, J = 14.6, 9.2 
Hz, 1H, CH2-indole). 
 
(3S,9bR)-9b-((4-chlorophenyl)-3-((1-methyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3-
a]isoindol-5(9bH)-one, 48c: Following the general procedure, starting from compound 47c (0.140g, 
90 
 
0.338 mmol), sodium hydride, NaH, 95% anhydrous reagent 
(0.0162 g, 0.676 mmol) and methyl iodide (0.042 mL, 0.677 mmol, 
d = 2.28 gmL-1) were added. Reaction time: 30 minutes. Eluent for 
flash chromatography 7:3, n-hexane/ ethyl acetate Recrystallization 
with the same mixture of solvents. The product was obtained as a 
white cry--stalline light solid (0.127 g, 87.6%). The 1H-NMR 
spectrum was found to be similar to the one for 48c’. 
 
(3R,9bS)-9b-((4-chlorophenyl)-3-((1-methyl-1H-indol-3-yl)methyl)-2,3-dihydrooxazolo[2,3- 
a]isoindol-5(9bH)-one 48c’: Following the general procedure, 
starting from compound 47c’ (0.129 g,0.310 mmol), sodium 
hydride, NaH 95%, (0.0149 g, 0.621 mmol) and methyl iodide 
(0.0193 mL, 0.310 mmol, d = 2.28 gmL-1) were added. Reaction 
time:30 minutes. Eluent for flash chromatography: 7:3, n- hexane/ 
ethyl acetate and recrystallization using the same combination of 
solvents a white crystalline light solid (0.117 g, 87.5%); mp: 70-73 
°C; 1HNMR (300 MHz, CDCl3) δ 7.80 – 7.76 (m, 1H, ArH), 7.49 –  
 
7.43 (m, 4H, ArH), 7.31 – 7.26 (m, 2H, ArH), 7.23 (dd, J = 1.8, 1.0 Hz, 2H, ArH), 7.20 (dd, J = 6.6, 
1.1 Hz, 1H, ArH), 7.17 – 7.12 (m, 1H, ArH), 7.07 (ddd, J = 8.0, 6.6, 1.4 Hz, 1H, ArH), 6.90 (s, 1H, 
CH-indole), 4.70 – 4.60 (m, 1H, H-3), 4.43 (dd, J = 8.7, 7.5 Hz, 1H, H-2), 3.96 (dd, J = 8.8, 6.8 Hz, 
1H, H-2), 3.68 (s, 3H, NCH3), 3.13 (dd, J = 14.7, 5.7  Hz, 1H, CH2-indole), 2.68 (dd, J = 14.7, 8.9 Hz, 
1H, CH2-indole); 13C NMR (75 MHz, CDCl3) δ 174.60 (C=O), 146.89 (ArC), 137.62 (ArC), 136.87 
(ArC), 134.50 (ArC), 133.39 (ArC), 130.99 (ArC), 130.28 (ArC), 128.90 (ArC), 127.93 (ArC), 127.24 
(ArC), 126.98 (CH-indole), 124.47 (ArC), 123.34 (ArC), 121.70 (ArC), 118.97 (ArC), 118.89 (ArC), 
109.87 (ArC), 109.16 (ArC), 100.56 (C-9b), 76.16 (CH-2), 56.00 (CH-3), 44.52, 32.64 (NCH3), 29.82 
(CH2-indole). 
 
(3S,9bR)-9b-((4-chloro-3-nitrophenyl)-3-((1-methyl-1H-indol-3-yl)methyl)-2,3-
dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 48d: Following the general procedure, starting from 
compound 47d (0.0762 g, 0.166 mmol), sodium hydride, NaH, 95% anhydrous reagent (0.0080 g, 0.332 
mmol) and methyl iodide (0.042 mL, 0.663 mmol, d = 2.28 gmL-1) were added. Reaction time: 1 hour. 
Eluent fot flash chromatography 7:3, n-hexane/ ethyl acetate and recrystallization with the same mixture 
of solvents a light crystalline yellow solid (0.0548 g, 69.8%). 1H NMR (300 MHz, CDCl3) δ 8.01 (dd, 
J = 10.7, 2.0 Hz, 1H, ArH), 7.83 (dd, J = 5.0, 3.8 Hz, 1H, ArH), 7.55-7.48 (m, 3H, ArH), 7.37 (dd, J = 
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J = 8.4, 2.1 Hz, 1H, ArH), 7.30 (t, J = 5.2 Hz, 1H, ArH), 7.24 – 7.16 (m, 
2H, ArH), 7.16 – 7.03 (m, 3H, ArH), 6.84 (s, 1H, CH-indole), 4.70 (td, 
J = 15.1, 7.2 Hz, 1H, H-3), 4.53 (dd, J = 8.8, 7.5 Hz, 1H, H-2), 4.10 (dd, 
J = 14.0, 7.9 Hz, 1H, H-2), 3.67 (s, 3H, NCH3), 3.06 (ddd, J = 14.9, 7.8 
Hz, 1H, CH2-indole), 2.88 (dd, J = 14.8, 8.0 Hz, 1H, CH2-indole). 
 
3R,9bS)-3-((1-methyl-1H-indol-3-yl)methyl)-9b-(p-tolyl)-2,3-dihydrooxazolo2,3-a]isoindol- 
5(9bH)-one 48e: Following the general procedure, starting from 
compound 47e (0.150 g, 0.379 mmol), sodium hydride, NaH 95%, 
(0.0182 g, 0.759 mmol) and methyl iodide (0.047 mL, 0.759 mmol, 
d = 2.28 gmL-1) were added. Reaction time: 30 minutes. Eluent for 
flash chromatography 6:4, n-hexane/ ethyl acetate and 
recrystallization with the same combination of solvents a white light 
solid (0.129 g, 83.5%).; mp: 150 - 151 ºC; 1H NMR (300 MHz, 
CDCl3) δ 7.82 – 7.77 (m, 1H, ArH), 7.51 (d, J = 8.1 Hz, 3H, ArH),  
 
7.49 – 7.45 (m, 2H, ArH), 7.29 – 7.16 (m, 6H, ArH), 7.09 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H, ArH), 6.97 (s, 
1H, CH-indole), 4.67 (dq, J = 9.2, 6.8 Hz, 1H, H-3), 4.45 (dd, J= 8.7, 7.5 Hz, 1H, H-2), 3.99 (dd, J = 
8.7, 6.8 Hz, 1H, H-2), 3.73 (s, 3H, NCH3), 3.22 (dd, J = 14.6, 6.0 Hz, 1H, CH2-indole), 2.66 (dd, J = 
14.7, 9.2 Hz, 1H, CH2-indole), 2.39 (s, 3H, ArCH3); 13C NMR (75 MHz, CDCl3) δ 174.62 (C=O), 
147.34 (ArC), 138.45 (ArC), 136.88 (ArC), 135.82 (ArC), 133.24 (ArC), 131.09 (ArC), 129.99 (ArC), 
129.46 (ArC), 127.90 (ArC), 126.91 (CH-indole), 125.73 (ArC), 124.31 (ArC), 123.37 (ArC), 121.63 
(ArC), 118.94 (ArC), 118.87 (ArC), 110.28 (ArC), 109.13 (ArC), 100.99 (C-9b), 76.32 (CH-2), 55.78 
(CH-3), 32.65 (NCH3), 30.09 (CH2-indole), 21.23 (ArCH3). 
4.3.3. General procedure for cyclization reactions 
In inert atmosphere of Nitrogen and in stirring conditions the adequate oxazoloisoindolinone derivative 
(0.290 mmol, 1 equivalents) was added to a stoichiometric quantity of dry dichloromethane (5 mL each 
0.14 mmol of compound to cyclize). The so formed solution is kept at room temperature and pure boron 
trifluoride diethyl etherate, 98+% (4 equivalents) is added to the mixture of reaction in order to afford 
the cyclized final product. The solvent of reaction was evaporated in rotavapor and the crude of reaction 
is dissolved in ethyl acetate. The organic phase was washed with brine solution (saturated aqueous 
solution of sodium chloride, NaCl); dried with sodium sulphate, Na2SO4 drying solid reagent, filtered 
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and in the end evaporated in rotavapor once again. The crude was absorbed in silica and purified by 
flash chromatography using ethyl acetate/ n-hexane as eluent mixture, followed by recrystalization. 
 
Scheme 4.5. (S)-tryptophanol-derived bicyclic lactams and their cyclized products. 
 
(7S,13bS)-7-(hydroxymethyl)-13,13b-dimethyl-7,8,13,13b-tetrahydro-5H-benzoλ1,2indoli-
zino[8,7-b]indol-5-one 50a) and (7S,13bR)-7-( hydroxymethyl)-13,13b-dimethyl-7,8,13,13b-
tetrahydro-5H-benzo[1,2indoli-zino[8,7-b]indol-5-one 49b: Following the general procedure, to a 
solution of 38 (0.0962 g, 0.289 mmol) in pure dichloromethane (10 mL) was added BF3·OEt2 (145.40 
µL, 1.16 mmol). Reaction time: 1 hour and 20 minutes. On the crude of reaction was performed the 
work up reported above and then, after drying it has been isolated compounds, purified by flash 
chromatography (ethyl acetate/ n-hexane, 1:1). 
 
49a: Obtained as a white solid (0.037 g, 40%); mp: 224-228 ºC; [α]20D = - 83.2º (c =0.33, MeOH); 1H  
NMR (300 MHz, DMSO-d6) δ 8.27 (d, J = 7.8 Hz, 1H, ArH), 7.73 (t, J = 7.6 
Hz, 1H, ArH), 7.69 (d, J = 7.7 Hz, 1H, ArH), 7.55 (td, J = 7.6, 0.5 Hz, 1H, 
ArH), 7.43 (t, J = 7.3 Hz, 2H, ArH), 7.18 – 7.12 (m, 1H, ArH), 7.05 – 6.99 
(m, 1H, ArH), 5.18 (t, J = 6.0 Hz, 1H, OH), 4.39 – 4.24 (m, 2H, CH2-OH), 
4.02 (s, 3H, NCH3), 3.81 (td, J = 10.5, 5.1 Hz, 1H, H-7), 2.99 – 2.83 (m, 2H, 
CH2- indole), 2.02 (s, 3H, C13b-CH3); 13C NMR (75 MHz, DMSO-d6) δ 
168.5 (C=O), 148.1 (Cq), 138.8 (Cq), 137.7 (Cq), 134.4 (Cq), 132.4 (Cq),   
129.4 (ArC), 129.0 (ArC), 128.1 (ArC), 125.5 (Cq), 125.5 (ArC), 123.4 (ArC),122.4 (ArC), 119.5 
(ArC), 118.7 (ArC), 111.3 (Cq), 109.9 (ArC), 71.8 (C-13b), 61.8 (CH2-OH), 54.5 (CH-7), 33.6 (N-
CH3), 24.7 ppm (CH2-indole), 21.15 ppm (C-13bCH3). 
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49b: Obtained as a white solid (0.026 g, 28%); mp: 254-258 ºC; [α]20D = + 155.5º (c = 0.27, MeOH);  
1H NMR (300 MHz, DMSO-d6) δ 8.24 (d, J = 8.3 Hz, 1H, ArH), 7.73 (t, J = 
7.8 Hz, 2H, ArH), 7.55 (t, J = 7.4 Hz, 1H, ArH), 7.45 (t, J = 7.6 Hz, 2H, 
ArH), 7.17 (t, J = 7.9 Hz, 1H, ArH), 7.03 (t, J = 7.5 Hz, 1H, ArH), 5.05 (t, J 
= 5.5 Hz, 1H, OH), 4.97 (dd, J = 14.3, 7.4 Hz, 1H, CH2-OH), 4.12 (s, 3H, 
NCH3), 3.63 (dd, J = 7.2, 5.8 Hz, 2H, H-7 and CH2-OH), 2.98 (d, J = 15.8 
Hz, 1H, CH2-indole), 2.78 (dd, J = 15.7, 6.8 Hz, 1H, CH2-indole), 1.99 ppm 
(s, 3H, C13b-CH3); 13C NMR (75 MHz, DMSO-d6) δ 168.1 (C=O), 149.0  
 
(Cq), 140.7 (Cq), 137.8 (Cq), 132.9 (ArC), 131.8 (Cq), 131.1 (Cq), 129.3 (ArC), 128.6 (ArC), 126.1 
(Cq), 125.3 (ArC), 123.5 (ArC), 122.6 (ArC), 118.7 (ArC), 110.0 (ArC), 108.4 (Cq), 68.9 (C-13b), 61.0 
(CH2-OH), 50.2 (CH-7), 34.4 (N-CH3), 22.2 (CH2-indole), 21.10 ppm (C-13bCH3). 
 
(5S,11bR)-5-(hydroxymethyl)-11-methyl-11b-phenyl-1,2,5,6,11,11b-hexahydro-3H-indoli-
zino[8,7-b]indol-3-one 50a and (5S,11bS)-5-(hydroxymethyl)-11-methyl-11b-phenyl-
1,2,5,6,11,11b-hexahydro-3H-indoli-zino[8,7-b]indol-3-one 50b: Following the general procedure, 
to a solution of 48a (0.0605 g, 0.376 mmol) in pure dichloromethane (13.5 mL) was added BF3·OEt2 
(189.11 µL, 1.51 mmol). The reagents have been kept reacting for 2 hours and 15 minutes. On the crude 
of reaction was performed the work up reported above and then the compound was purified by flash 
chromatography in first attempt (ethyl acetate/n-hexane, 1:1) and then in second solution by preparative 
chromatography (ethyl acetate/n-hexane, 1:2). 
 
50a: Obtained as a white solid (0.084 g, 64.7%); mp: 261-263 ºC; [α]20D = - 37.1º (c = 0.49, MeOH);  
1H NMR (300 MHz, DMSO-d6) δ 7.49 (dd, J = 10.5, 8.2 Hz, 2H, ArH), 
7.42 – 7.33 (m, 3H, ArH), 7.21 (d, J = 7.2 Hz, 1H, ArH), 7.16 (d, J = 7.6 
Hz, 2H, ArH), 7.08 (t, J = 7.4 Hz, 1H, ArH), 4.86 (t, J = 6.3 Hz, 1H, OH), 
3.96 (dt, J = 11.5, 5.8 Hz, 1H, H-5), 3.90 – 3.81 (m, 1H, CH2-OH), 3.54 
(s, 3H, NCH3), 3.09 (dt, J = 11.5, 6.0 Hz, 1H, CH2-OH), 2.99 (dd, J = 
12.8, 5.0 Hz, 1H, CH2-indole), 2.94 – 2.85 (m, 1H, CH2-indole), 2.85 - 
2.79 (m, 2H, CH2), 2.79 - 2.67(m, 1H, CH2), 2.46 – 2.39 (m, 1H, CH2). 
 
 
(7S,13bS)-13b-(4-fluorophenyl)-7-(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-5H-benzo 
[1,2]indolizino[8,7-b]indol-5-one 51a and (7S,13bS)-13b-(4-fluorophenyl)-7-(hydroxymethyl)-13-
methyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 51b: Following the 
general procedure, to a solution of 48b (0.1012 g, 0.245 mmol) in pure dichloromethane (8.80 mL) was 
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added BF3·OEt2 (123.3 µL, 0.981 mmol). Reaction time: 15 minutes. Eluent for flash chromatography: 
ethyl acetate/n-hexane, 4:6. 
 
51a: Obtained as a white solid (0.0517 g, 51.1 %); mp: 247-250 ºC; [α]20D = - 43.5º (c = 0.35, MeOH);  
1H NMR (300 MHz, DMSO-d6) δ 7.90 (d, J = 7.8 Hz, 1H), 7.79 (d, 
J = 7.9 Hz, 1H, ArH), 7.72 (td, J = 7.5, 1.3 Hz, 1H, ArH), 7.62 (td, 
J = 7.3, 0.5 Hz, 1H, ArH), 7.54 (d, J = 7.7 Hz, 1H, ArH), 7.45 (d, J 
= 8.3 Hz, 1H, ArH), 7.21 (t, J = 8.6 Hz, 3H, ArH), 7.09 (t, J = 7.1 
Hz, 1H, ArH), 6.92 (dd, J = 8.8, 5.3 Hz, 2H, ArH), 4.97 (t, J = 6.0 
Hz, 1H, OH), 4.26 (dt, J = 12.4, 6.3 Hz, 1H, CH2-OH), 4.09 – 4.01 
(m, 1H, CH2- OH), 3.73 (s, 3H, NCH3), 3.41 (m, 1H, H-7) 3.00 (qd,   
J = 15.4, 7.7 Hz, 2H, CH2-indole); 13C NMR (75 MHz, DMSO-d6) δ 168.42 (C=O), 147.89 (Cq), 137.63 
(Cq), 135.04 (Cq), 134.26 (Cq), 132.62 (ArC), 132.26 (ArC), 130.43 (Cq), 130.32 (ArC), 129.43 (ArC), 
125.38 (ArC), 123.40 (ArC), 122.41 (ArC), 119.51 (ArC), 118.65 (ArC), 117.41 (ArC), 115.92 (ArC), 
115.63 (ArC), 111.3 (Cq) 109.91 (ArC), 71.13 (C-13b), 61.70 (CH2-OH), 54.43 (CH-7), 33.47 (N-CH3), 
24.57 (CH2-indole). 
 
51b: Obtained as a white solid (0.0255 g, 25.2 %); mp: 259-261 ºC; [α]20D = + 41.7º (c = 0.35, MeOH);  
1H NMR (300 MHz, DMSO-d6) δ 7.85 (d, J = 5.8 Hz, 2H), 7.65 (dt, 
J = 14.0, 7.3 Hz, 2H, ArH), 7.53 (t, J = 8.0 Hz, 2H, ArH), 7.29 – 
7.21 (m, 1H, ArH), 7.12 (dd, J = 17.6, 8.4 Hz, 3H, ArH), 6.92 – 6.82 
(m, 2H, ArH), 4.88 (ddd, J = 10.6, 6.1, 4.5 Hz, 1H, H-7), 4.75 (dd, J 
= 6.3, 4.3 Hz, 1H, OH), 3.90 (s, 3H, NCH3), 3.15 – 3.01 (m, 2H, 
CH2- indole and CH2-OH), 2.92 (dd, J = 15.1, 6.9 Hz, 1H, CH2-
indole), 2.68 (ddd, J = 12.9, 7.3, 5.7 Hz, 1H, H-2); 13C NMR (75   
MHz, DMSO-d6) δ 168.48 (C=O), 149.26 (Cq), 138.21 (Cq), 135.04 (Cq), 133.41 (ArC), 132.09 (Cq), 
131.41 (Cq), 130.71 (Cq), 130.60 (ArC), 129.85 (ArC), 126.51 (ArC), 125.75 (ArC), 123.96 (ArC), 
123.05 (ArC), 119.90 (ArC), 119.19 (ArC), 116.04 (ArC), 115.76 (ArC), 110.44 (ArC), 108.89 (Cq), 
68.78 (C-13b), 61.45 (CH2-OH), 50.59 (CH-7), 34.71 (N-CH3), 22.57 (CH2-indole). 
 
(7S,13bS)-13b-(4-chlorophenyl)-7-(hydroxymethyl)-13-methyl-7,8,13,13b-hexahydro-5H-
benzo[1,2]indolizino[8,7-b]indol-5-one 52a and (7S,13bR)-13b-(4-chlorophenyl)-7-
(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one, 
52b: Following the general procedure, to a solution of 48c (0.1102 g, 0.256 mmol) in pure 
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dichloromethane (12.2 mL) was added BF3·OEt2 (129 µL, 1.03 mmol). Reaction time: 15 minutes. 
Eluent for flash chromatography in first attempt (ethyl acetate/ n-hexane, 3:7). 
 
52a: Obtained as a white solid (0.0654 g, 59.5 %); [α]20D = - 58.5º (c = 0.41, MeOH); 1H NMR (300  
MHz, DMSO-d6) δ 7.92 (d, J = 7.8 Hz, 1H, ArH), 7.79 (d, J = 7.6 
Hz, 1H, ArH), 7.72 (td, J = 7.6, 1.3 Hz, 1H, ArH), 7.63 (t, J = 7.6 
Hz, 1H, ArH), 7.54 (d, J = 7.5 Hz, 1H, ArH), 7.45 (d, J = 8.6 Hz, 
3H, ArH), 7.25 – 7.18 (m, 1H, ArH), 7.12 – 7.05 (m, 1H, ArH), 6.90 
(d, J = 8.6 Hz, 2H, ArH), 4.96 (t, J = 6.0 Hz, 1H, OH), 4.30 – 4.20 
(m, 1H, H-2), 4.11 – 4.00 (m, 1H, H-2), 3.73 (s, 3H, NCH3), 3.22 
(ddd, J = 12.1, 8.2, 2.6 Hz, 1H, H-7), 3.00 (qd, J = 15.3, 7.4 Hz, 2H,   
CH2-indole). As reported, the 1H-NMR spectrum is found to be equal to the one of compound 52a’. 
 
52b: Obtained as a white solid (0.0312 g, 28.4 %); [α]20D = + 40.0º (c = 0.48, MeOH); 1H NMR (300  
MHz, DMSO-d6) δ 7.87 (d, J = 4.2 Hz, 1H, ArH), 7.86 – 7.83 (m, 
1H, ArH), 7.69 (td, J = 7.6, 1.4 Hz, 1H, ArH), 7.65 – 7.59 (m, 1H, 
ArH), 7.53 (t, J = 7.9 Hz, 2H, ArH), 7.37 (d, J = 8.8 Hz, 2H, ArH), 
7.28 – 7.21 (m, 1H, ArH), 7.13 – 7.06 (m, 1H, ArH), 6.86 (d, J = 
8.2 Hz, 2H, ArH), 4.88 (ddd, J = 10.6, 6.1, 4.5 Hz, 1H, H-7), 4.76 
(dd, J = 6.3, 4.3 Hz, 1H, OH), 3.89 (s, 3H, NCH3), 3.14 – 3.01 (m, 
2H, CH2-indole and H-2), 2.92 (dd, J = 16.1, 6.9 Hz, 1H, CH2-   
indole), 2.72 – 2.63 (m, 1H, CH2-OH); 13C NMR (75 MHz, DMSO-d6) δ 168.53 (C=O), 149.06 (Cq), 
142.50 (Cq), 140.21 (Cq), 138.22 (ArC), 133.65 (Cq), 133.45 (ArC), 131.80 (Cq), 131.39 (Cq), 130.32 
(ArC), 129.07 (ArC), 126.49 (Cq), 125.77 (ArC), 124.00 (ArC), 119.91 (ArC), 119.20 (ArC), 111.86 
(ArC), 110.47 (ArC), 108.94 (Cq), 68.75 (C-13b), 61.45 (CH2-OH), 50.61 (CH-7), 34.72 (NCH3), 22.55 
(CH2-indole). 
 
(7R,13bS)-13b-(4-chlorophenyl)-7-(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-5H-
benzo[1,2]indolizino[8,7-b]indol-5-one 52a’ and (7R,13bR)-13b-(4-chlorophenyl)-7-
(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 
52b’: Following the general procedure, to a solution of 48c’ (0.0903 g, 0.211 mmol) in pure 
dichloromethane (9.20 mL) was added BF3·OEt2 (105.8 µL, 0.842 mmol). Reaction time: 15 minutes. 
Eluent for flash chromatography (ethyl acetate/n-hexane, 1:1). 
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52a’: Obtained as a white solid (0.0433 g, 46.0%); mp: 246-248 ºC; [α]20D = - 52.1º (c = 0.37, MeOH);  
1H NMR (300 MHz, DMSO-d6) δ 7.91 (d, J = 7.7 Hz, 1H, ArH), 
7.79 (d, J = 7.4 Hz, 1H, ArH), 7.72 (td, J = 7.6, 1.3 Hz, 1H, ArH), 
7.62 (t, J = 7.0 Hz, 1H, ArH), 7.54 (d, J = 7.7 Hz, 1H, ArH), 7.45 
(d, J = 8.6 Hz, 3H, ArH), 7.24 – 7.18 (m, 1H, ArH), 7.12 – 7.05 (m, 
1H, ArH), 6.90 (d, J = 8.6 Hz, 2H, ArH), 4.96 (t, J = 6.0 Hz, 1H, 
OH), 4.26 (dt, J = 12.6, 6.3 Hz, 1H, H-2), 4.11 – 4.02 (m, 1H, H-2), 
3.73 (s, 1H, NCH3), 3.31 – 3.26 (m, 1H, H-7), 3.00 (qd, J = 15.4,   
7.7 Hz, 2H, CH2-indole); 13C NMR (75 MHz, DMSO-d6) δ 168.92 s(C=O), 148.16 (Cq), 138.33 (Cq), 
138.12 (Cq), 134.46 (Cq), 134.18 (ArC), 133.13 (Cq), 132.75 (ArC), 130.49 (Cq), 129.97 (Cq), 129.42 
(Cq), 125.92 (Cq), 125.86 (ArC), 123.90 (ArC), 122.92 (ArC), 119.99 (ArC), 119.13 (ArC), 111.87 
(Cq), 110.41 (ArC), 71.58 (C-13b), 62.17 (CH2-OH), 55.04 (CH-7), 33.96 (NCH3), 25.02 (CH2-indole). 
 
52b’: Obtained as a white solid (0.0395 g, 43.7%); mp: 282-285 ºC; [α]20D = - 37.5º (c = 0.48, MeOH) 
1H NMR (300 MHz, DMSO-d6) δ 7.89 – 7.83 (m, 2H, ArH), 7.69 
(td, J = 7.5, 1.5 Hz, 1H, ArH), 7.62 (td, J = 7.3, 0.8 Hz, 1H, ArH), 
7.53 (t, J = 7.8 Hz, 2H, ArH), 7.37 (d, J = 8.9 Hz, 2H, ArH), 7.25 
(ddd, J = 8.2, 7.1, 1.2 Hz, 1H, ArH), 7.09 (dd, J = 11.4, 4.3 Hz, 1H, 
ArH), 6.86 (d, J = 8.2 Hz, 2H, ArH), 4.92 – 4.84 (m, 1H, H-7), 4.78 
(dd, J = 6.3, 4.4 Hz, 1H, OH), 3.89 (s, 3H, NCH3), 3.14 – 3.02 (m, 
2H, CH2-indole and CH2-OH), 2.92 (dd, J = 16.0, 6.9 Hz, 1H, CH2-  
indole), 2.71 – 2.63 (m, 1H, CH2-OH). As reported, the 1H-NMR spectrum is found to be equal to the 
one of compound 53b. 
 
(7S,13bS)-13b-(4-chloro-3-nitrophenyl)-7-(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-
5H-benzo[1,2]indolizino[8,7-b]indol-5-one 53a and (7S,13bR)-13b-(4-chloro-3-nitrophenyl)-7-
(hydroxymethyl)-13-methyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 
53b: Following the general procedure, to a solution of 48d (0.0687 g, 0.145 mmol) in pure 
dichloromethane (6.10 mL) was added BF3·OEt2 (85.5 µL, 0.680 mmol). Reaction time:1 hour and 20 
minutes. Eluent for flash chromatography: ethyl acetate/ n-hexane, 4:6. 
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53a: Obtained as a yellow solid (0.0117 g, 17.0%); mp: 153-155 ºC; 1H NMR (300 MHz, DMSO-d6) 
δ 7.97 (d, J = 7.8 Hz, 1H, ArH), 7.82 – 7.70 (m, 3H, ArH), 7.65 (td, 
J = 7.4, 0.7 Hz, 1H, ArH), 7.57 (d, J = 2.3 Hz, 1H, ArH), 7.55 (d, J 
= 7.8 Hz, 1H, ArH), 7.48 (d, J = 8.3 Hz, 1H, ArH), 7.26 –7.18 (m, 
2H, ArH), 7.12 – 7.06 (m, 1H, ArH), 4.91 (t, J = 6.1 Hz, 1H, OH), 
4.23 – 4.13 (m, 2H, CH2-OH), 3.76 (s, 3H, NCH3), 2.98 (ddd, J = 
22.3, 16.8 9.3 Hz, 2H, CH2-indole). 
 
53b: Obtained as a yellow pale solid (0.0460 g, 67.0%); mp: 168-170 ºC; [α]20D = + 53.7º (c = 0.41,  
MeOH); recrystallized in dichloro- methane/ n-hexane; 1H NMR 
(300 MHz, DMSO-d6) δ 7.94 (d, J = 7.6 Hz, 1H, ArH), 7.87 (dd, J 
= 7.3, 1.0 Hz, 1H, ArH), 7.71 (td, J = 7.5, 1.5 Hz, 1H, ArH), 7.69 
(d, J = 8.5 Hz, 1H, ArH), 7.64 (dd, J = 7.4, 0.7 Hz, 1H, ArH), 7.54 
(dd, J = 7.8, 3.4 Hz, 3H, ArH), 7.26 (ddd, J= 8.3, 7.1, 1.0 Hz, 1H, 
ArH), 7.17 (d, J = 8.8 Hz, 1H, ArH), 7.11 (t, J = 7.2 Hz, 1H, ArH), 
4.95 – 4.87 (m, 1H, H-7), 4.74 (dd, J = 5.7, 4.6 Hz, 1H, OH), 3.91   
(s, 3H, NCH3), 3.14 (td, J = 9.9, 6.0 Hz, 1H, CH2-indole), 3.01 – 2.94 (m, 2H, CH2-indole and CH2-
OH), 2.80 (dt, J = 10.3, 5.3 Hz, 1H, CH2-OH); 13C NMR (75 MHz, DMSO-d6) δ 168.30 (C=O), 147.83 
(Cq), 147.44 (Cq), 141.89 (Cq), 137.91 (Cq), 133.26 (ArC), 133.15 (ArC), 131.89 (Cq), 130.83 (ArC), 
130.35 (ArC), 129.79 (ArC), 125.91 (ArC), 125.32 (ArC), 125.18 (Cq), 124.98 (Cq), 123.73 (ArC), 
122.80 (ArC), 119.52 (ArC), 118.83 (ArC), 110.17 (ArC), 108.99 (Cq), 67.71 (C-13b), 60.75 (CH2-
OH), 50.23 (CH-7), 34.20 (N-CH3), 22.00 (CH2-indole). 
 
(7S,13bS)-7-(hydroxymethyl)-13-methyl-13b-(p-tolyl)-7,8,13,13b-tetrahydro-5H-benzo[1,2] 
indolizino[8,7-b]indol-5-one 54a and (7S,13bR)-7-(hydroxymethyl)-13-methyl-13b-(p-tolyl)-
7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 54b: Following the general 
procedure, to a solution of 48e (0.0964 g, 0.236 mmol) in pure dichloromethane (8.80 mL) was added 
BF3·OEt2 (119.0 µL, 0.944 mmol). Reaction time: 15 minutes. On the crude of reaction was performed 
Eluent fot flash chromatography: ethyl acetate/n-hexane, 4:6. 
 
54a: Obtained as a white solid (0.0771 g, 80.0 %); mp: 247-250 ºC; [α]20D = - 82.0º (c = 0.50, MeOH); 
1H NMR (300 MHz, DMSO-d6) δ 7.87 (d, J = 7.7 Hz, 1H, ArH), 7.78 (d, J = 7.3 Hz, 1H, ArH), 7.70(t, 
J = 7.3 Hz, 1H, ArH), 7.61 (t, J = 7.3 Hz, 1H, ArH), 7.53 (d, J= 7.7 Hz, 1H, ArH), 7.43 (d, J = 8.1 Hz, 
1H, ArH), 7.20 (t, J = 8.9 Hz, 3H, ArH), 7.08 (t, J = 7.4 Hz, 1H, ArH), 6.76 (d, J = 7.9 Hz, 2H, ArH) 
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5.00 (t, J = 5.8 Hz, 1H, OH), 4.33 – 4.22 (m, 1H, CH2-OH), 4.05 
– 3.95 (m, 1H, CH2-OH), 3.72 (s, 3H, NCH3), 3.09 – 2.90 (m, 2H, 
CH2-indole), 2.30 (s, 3H, p-CH3); 13C NMR (75 MHz, DMSO-d6) 
δ 168.89 (C=O), 148.62 (Cq), 138.92 (Cq), 138.08 (Cq), 136.24 
(Cq), 135.06 (Cq), 132.98 (ArC), 132.82 (Cq), 129.93 (ArC), 
129.75 (ArC), 128.43 (ArC), 125.98 (Cq), 125.86 (ArC), 123.80 
(ArC), 122.77 (ArC), 119.91 (ArC), 119.06 (ArC), 111.64 (Cq),  
110.33 (ArC), 72.05 (C-13b), 62.24 (CH2-OH), 33.93 (N-CH3), 25.12 (CH2-indole), 21.13 (p-CH3). 
 
54b: Obtained as a white solid (0.0120 g, 12.5 %); mp: 259-261 ºC; 1H NMR (300 MHz, DMSO-d6) δ  
7.87 (d, J = 4.2 Hz, 1H, ArH), 7.86 – 7.83 (m, 1H, ArH), 7.69 (td, 
J = 7.6, 1.4 Hz, 1H, ArH), 7.65-7.59 (m, 1H, ArH), 7.53 (t, J = 7.9 
Hz, 2H, ArH), 7.37 (d, J = 8.8 Hz, 2H, ArH), 7.28 – 7.21 (m, 1H, 
ArH), 7.13 – 7.06 (m, 1H, ArH), 6.86 (d, J = 8.2 Hz, 2H, ArH), 
4.88 (ddd, J = 10.6, 6.1, 4.5 Hz, 1H, H-7), 4.76 (dd, J = 6.3, 4.3 
Hz, 1H, OH), 3.89 (s, 3H, NCH3), 3.14-3.01 (m, 2H, CH2-indole 
and CH2-OH), 2.92 (dd, J = 16.1, 6.9 Hz, 1H, CH2-indole), 2.72 – 
2.63 (m, 1H, CH2-OH); 
 
 
(7S,13bS)-13-ethyl-7-(hydroxymethyl)-13b-phenyl-7,8,13,13b-tetrahydro-5H-
benzo[1,2]indolizino[8,7-b]indol-5-one 55a and (7S,13bR)-13-ethyl-7-(hydroxymethyl)-13b-
phenyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 55b: Following the 
general procedure, to a solution of 38b (0.101 g, 0.248 mmol) in pure dichloromethane (9.00 mL) was 
added BF3·OEt2 (124.6 µL, 0.992 mmol). Reaction time: 15 minutes. Eluent for flash chromatography: 
ethyl acetate/n-hexane, 4:6). 
 
55a: Obtained as a white solid (0.0689 g, 68.0 %); mp: 273-275 ºC; 1H NMR (300 MHz, DMSO-d6) 
δ 7.79 (dd, J = 7.1, 6.0 Hz, 2H), 7.75 – 7.69 (m, 1H), 7.63 (td, J = 7.3, 1.0 
Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.42 – 7.35 
(m, 3H), 7.24 – 7.17 (m, 1H), 7.11 – 7.05 (m, 1H), 6.89 – 6.85 (m, 2H), 
4.98 (t, J = 6.0 Hz, 1H, OH), 4.25 (td, J = 14.2, 7.4 Hz, 3H, CH2CH3 and 
H-2), 4.07 – 3.97 (m, 1H, H-2), 3.28 – 3.24 (m, 1H, H-7), 3.02 (dd, J = 
13.9, 10.5 Hz 2H, CH2-indole), 1.10 (t, J = 6.9 Hz, 3H, CH2CH3). 
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(7R,13bR)-13-ethyl-7-(hydroxymethyl)-13b-phenyl-7,8,13,13b-tetrahydro-5H-
benzo[1,2]indolizino[8,7-b]indol-5-one 55a’ and (7R,13bS)-13-ethyl-7-(hydroxymethyl)-13b-
phenyl-7,8,13,13b-tetrahydro-5H-benzo[1,2]indolizino[8,7-b]indol-5-one 55b’: Following the 
general procedure, to a solution of 38b’ (0.0711 g, 0.174 mmol) in pure dichloromethane (6.20 mL) 
was added BF3·OEt2 (87.5 µL, 0.696 mmol). Reaction time: 15 minutes. Eluent for flash 
chromatography in first attempt (ethyl acetate/n-hexane, 4:6). 
 
55a’: Obtained as a white solid (0.0651 g, 64.3 %); 1H NMR (300 MHz, DMSO-d6) δ 7.83 – 7.68 (m,  
1H, ArH), 7.63 (t, J = 6.8 Hz, 1H, ArH), 7.54 (d, J = 7.8 Hz, 1H, ArH), 
7.47 (d, J = 8.3 Hz, 1H, ArH), 7.38 (dd, J = 8.3, 2.8 Hz, 1H, ArH), 7.24 
– 7.17 (m, 1H, ArH), 7.08 (t, J = 7.6 Hz, 1H, ArH), 6.87 (dd, J = 7.4, 1.7 
Hz, 1H, ArH), 4.98 (t, J = 5.9 Hz, 1H, OH), 4.25 (td, J = 14.2, 7.4 Hz, 
3H, CH2CH3 and H-2), 4.05 – 3.97 (m, 1H, H-2), 3.28 – 3.24 (m, 1H, H-
7) 3.05 – 2.94 (m, 2H, CH2-indole), 1.10 (t, J = 6.9 Hz, 3H, CH2CH3). 
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4.4. Experimental procedure for the in-vitro yeast based screening assay of compounds 34, 34b, 
34d, 34e, 38b and 38d 
Plasmids: the yeast expression vector pLS76-(LEU2) encoding human mutant p53R280K under 
GAL1-10 inducible promoter (kindly provided by Dr. Gilberto Fronza; IST Istituto Nazionale per la 
Ricerca sul Cancro), was used. 
Yeast transformation: the plasmids used for yeast transformation process were amplified in 
Escherichia coli DH5α from Lucigen (Frilabo), and thereafter extracted using the GenEluteTM HP 
Plasmid Miniprep Kit (Sigma-Aldrich). After extraction, yeast strains were transformed using the 
LiAc/SS Carrier DNA/PEG method. In order to select transformed yeast, cells were routinely grown in 
selective minimal medium with 2% (w/w) glucose (Sigma-Aldrich), 0.7% (w/w) yeast nitrogen base 
without amino acids from Difco (Quilaban), and all the aminoacids required for yeast growth (50 
μg/mL), except leucine, and incubated at 30 ºC, under continuous orbital shaking (200 rpm). 
Yeast-based screening assay: for expression of human proteins, cells (routinely grown in minimal 
selective medium) were diluted to 0.05 OD600 in induction selective medium containing 2% (w/w) 
galactose (Sigma-Aldrich), 1% (w/w) raffinose (Acros Organics), 0.7% (w/w) yeast nitrogen base 
without amino acids from Difco (Quilaban), and all the amino acids required for yeast growth (50 
µg/mL), as referred above. Cells transformed with empty vector were used as control. Yeast cells were 
incubated at 30 ºC under continuous orbital shaking (200 rpm) in the presence of 1-30 µM of compounds 
or 0.1% DMSO only, for approximately 48 h (time required by control yeast, incubated with DMSO 
only, to achieve 0.4 OD600). Yeast growth was analyzed by counting the number of colony-forming 
units (CFU) after 2 days of incubation at 30ºC on Sabouraud Dextrose Agar plates (Liofilchem). 
4.5. Experimental procedure of the stability studies 
4.5.1. Metabolic stability assay – Identification of Phase I metabolites by LC-ESI-MS upon 
microsomes incubation of compounds 34 and 34e 
4.5.1.1. Materials 
Pooled male rat liver microsomes and Vivid regeneration system were acquired from ThermoFischer 
Scientific (Spain). Pooled donor human liver microsomes were acquired from BD Biosciences (US). 
Nicotinamide-Adenine Dinucleotide Phosphate in its reduced form (NADPH) and Neviripine were 
acquired from Sigma-Aldrich (Germany). Neviripine was purchased from Cipla (Mumbai, India). 100 
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mM of Phosphate Buffer solution was prepared adding in 90 mL of deionized water 1.42g of Na2HPO4 
and 1.56g of NaH2PO4·2H2O. The pH was adjusted to 7.4 with a solution of NaOH(aq) 250 mM and 
the volume completed to 100 mL. All drugs, chemical and solvents were acquired from commercial 
suppliers at highest purity available. 
4.5.1.2. Methods 
To separate and identify the structures of compounds 34 and 34e and its metabolites, an Ionization-
Tandem Mass Spectrometry (LC-ESI-MS/MS) was used. LC-ESI-MS/MS analyses were performed 
with ion trap LCQ Fleet Mass Spectrometer (Thermo Scientific) fitted with an Ultimate 3000RS LC 
nano HPLC system (Thermo Scientific) was used. The HPLC system was equipped with a Luna C18(2) 
column (2.0 mm i.d. x 50 mm, 100 Å pore size) using a gradient elution of 0.1% formic acid in water 
(mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) at a flow rate of 200 μL/min. 
Gradient condition were as follows: 5-70% mobile phase B for 30 min, 70-100% mobile phase B for 2 
min, 100% mobile phase B for 8 min, 100-5% mobile phase B for 5 min and finally 5% mobile phase 
B for 7min. The column and the sampler were maintained at a constant temperature of 40 °C and 8 °C 
respectively. Mass spectra were obtained with the electrospray ionization source (ESI) in both negative 
and positive modes optimized with the following settings: sheath gas flow rate, 40 (arbitrary units); 
auxiliary gas flow rate, 10 (arbitrary units); spray voltage, 4.5 kV; capillary voltage, -18/16 V; tube lens 
voltage, -125/63 V; skimmer voltage, 28 V; vaporizer temperature: 185 °C; capillary temperature, 300 
°C. Data were acquired using Xcalibur software (ThermoFischer Scientific). Internal calibration was 
performed for sodium formate/acetate clusters. 
In rat microsomes: Thawed male rat pooled liver microsomes (20 mg protein/ mL), a solution of 
NADPH (16.7mg in 1 mL of 100 mM phosphate buffer 7.4) regenerating system, NRS regenerating 
system and 5 mM stock solution of compounds 34 and 34e (100% DMSO) are prepared. To reach the 
final volume of 500 µL, for the drug incubation, the reaction mixture at the end contains 449 µL of 100 
mM phosphate buffer pH 7.4, 20 µL of male rat microsomes (0.8 mg protein/ mL final concentration), 
1 µL of 5 mM drug stock solution (10 µM of drug in 500 µL final concentration for the incubation) and 
5 µL of Vivid regenerating system solution. After a period of pre-incubation of 5 minutes at 37 °C in 
an Eppendorf© thermomixer C water bath, 25 µL of NADPH solution is added to the so-composed 
system and the phase I reactions are let started. At different time points (0 minutes, 30 minutes, 60 
minutes, 120 minutes, 180 minutes, 24 hours, 48 hours) 100 µL of reaction mixture is withdrawn and 
100 µL of cold solution 2.5 µM of Reserpine in acetonitrile is added in order to stop any enzymatic 
activity. Then, the mixtures are centrifuged at 10000 rpm for 15 minutes at room temperature and the 
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supernatant is immediately recollected and saved in Eppendorfs, which they have been stored at -20 °C 
till further analysis. At each time point the compounds are analysed using LC-MS/MS. A rationalized 
identification of phase I metabolites is performed successfully. Neviripine is used as positive control. 
In human microsomes: Thawed human pooled liver microsomes (20 mg protein/ mL), a solution of 
NADPH (16.7mg in 1 mL of 100 mM phosphate buffer 7.4) regenerating system, NRS regenerating 
system and 5 mM stock solution of compounds 34 and 34e (100% DMSO) are prepared. To reach the 
final volume of 500 µL, for the drug incubation, the reaction mixture at the end contains 449 µL of 100 
mM phosphate buffer pH 7.4, 20 µL of male rat microsomes (0.8 mg protein/ mL final concentration), 
1 µL of 5 mM drug stock solution (10 µM of drug in 500 µL final concentration for the incubation) and 
5 µL of Vivid regenerating system solution. After a period of pre-incubation of 5 minutes at 37 °C in 
an Eppendorf© thermomixer C water bath, 25 µL of NADPH solution is added to the so-composed 
system and the phase I reactions are let started. At different time points (0 minutes, 30 minutes, 60 
minutes, 120 minutes, 180 minutes, 24 hours, 48 hours) 100 µL of reaction mixture is withdrawn and 
100 µL of cold solution 2.5 µM of Reserpine in acetonitrile is added in order to stop any enzymatic 
activity. Then, the mixtures are centrifuged at 10000 rpm for 15 minutes at room temperature and the 
supernatant is immediately recollected and saved in Eppendorfs, which they have been stored at -20 °C 
till further analysis. At each time point the compounds are analysed using LC-ESI(+)-MS/MS. A 
rationalized identification of Phase I metabolites is performed successfully. Neviripine is used as 
positive control. 
 
4.5.2. Determination of stability of compounds 34 and 34e in human plasma by LC-ESI-MS and 
HPLC/UV-Vis 
4.5.2.1. Materials 
Human plasma was acquired commercially. Phosphate buffer solution was prepared as in section 
IV.4.1.1. Procaine hydrochloride was acquired from Sigma-Aldrich (Germany). All drugs, chemical 
and solvents were acquired from commercial suppliers at highest purity available. 
4.5.2.2. Methods 
For the specifics of the LC-DAD see section 4.4.1.2. HPLC analyses were conducted on an Ultimate 
3000 Dionex system, consisting of an LPG-3400A quaternary gradient pump and a diode array 
spectrophotometric detector (Dionex Co., Sunnyvale, CA), and equipped with a Rheodyne model 8125 
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injector (Rheodyne, Rohnert Park, CA). HPLC analyses were performed with a Luna C18 (2) column 
(250 mm × 4.6 mm; 5 µm; Phenomenex, Torrance, CA), at a flow rate of 1 mL/min. A 30-min linear 
gradient from 5 to 95% acetonitrile in 0.1% aqueous formic acid, followed by a 2-min linear gradient 
to 100% acetonitrile and an 8-min isocratic elution with acetonitrile, was used in all instances. The UV 
absorbance was monitored at 269 nm. 
LC-MS/MS analysis: Thawed human plasma is firstly centrifuged at 2000 rpm for 5 minutes and then 
diluted 1:1 with a 100 mM phosphate buffer 7.4. 5 mM stock solution of the compounds (100% DMSO) 
and are prepared. Procaine is used as reference drug for these studies and its 4 mM stock solution (100% 
DMSO) is prepared. 975 µL of phosphate buffer is placed in 37 °C Eppendorf© thermomixer C shaking 
water bath for 10 minutes and after this period of time 25 µL of procaine stock solution and 25 µL of 
test drug stock solutions are added. At different time points (0 minutes, 30 minutes, 60 minutes, 120 
minutes, 180 minutes, 24 hours, 48 hours) 100 µL of reaction mixture is withdrawn and 300 µL of cold 
solution 2.5 µM of Reserpine in acetonitrile is added in order to stop any enzymatic activity. Then, the 
mixtures are centrifuged at 10000 rpm for 10 minutes at room temperature and the supernatant is 
immediately recollected and saved in Eppendorfs, which they have been stored at -20 °C till further 
analysis. At each time point the compounds are analysed using LC-MS/MS. A rationalized 
identification of phase I metabolites is performed successfully. 
HPLC/UV-Vis analysis: Thawed human plasma is firstly centrifuged at 2000 rpm for 5 minutes and 
then diluted 1:1 with a 100 mM phosphate buffer 7.4. 5 mM stock solution of the compounds (100% 
DMSO) and are prepared. Procaine is used as reference drug for these studies and its 4 mM stock 
solution (100% DMSO) is prepared. 975 µL of phosphate buffer is placed in 37 °C Eppendorf© 
thermomixer C shaking water bath for 10 minutes and after this period of time 25 µL of procaine stock 
solution and 25 µL of test drug stock solutions are added. At different time points (0 minutes, 30 
minutes, 60 minutes, 120 minutes, 180 minutes, 24 hours, 48 hours) 100 µL of reaction mixture is 
withdrawn and 300 µL of cold solution 10-1 mM of Reserpine in acetonitrile is added in order to stop 
any plasma enzymatic activity. Then, the mixtures are centrifuged at 10000 rpm for 10 minutes at room 
temperature and the supernatant is immediately recollected and saved in Eppendorfs, which they have 
been stored at -20 °C till further analysis. At each time point the compounds are analysed using 
HPLC/UV-Vis methodology. A rationalized identification of Phase I metabolites is performed 
successfully. 
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4.5.3. Determination of stability of compounds 34 and 34e in phosphate buffer solution by LC-
ESI-MS and HPLC/UV-Vis 
A solution 100 mM of phosphate buffer pH 7.4 is prepared and after a period of 10 minutes where 975 
µL of this buffer solution are placed in a 37 °C Eppendorf© thermomixer C shaking water bath, 25 µL 
of procaine stock solution and 25 µL of test drug stock solutions are added. At different time points (0 
minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes, 24 hours, 48 hours) 100 µL of reaction 
mixture above described is withdrawn and 300 µL of cold solution 10-1 mM of Reserpine in acetonitrile 
is added. The mixtures are centrifuged at 10000 rpm for 10 minutes at room temperature and the 
supernatant is immediately recollected and saved in Eppendorfs, which they have been stored at -20 °C 
till further analysis. At each time point the compounds are analysed using LC-MS/MS and HPLC/UV-
Vis methodologies respectively to analyse the stability at neutral pH of each test compound along the 
time. Procaine is used as reference drug for this study.  
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6.1. Experimental Procedure for the in-vitro screening of indolizinoindoles 50-56a and 50-56b 
Immunofluorescence and Live Imaging. Huh-7 cells, a human hepatoma cell line, were cultured in 
1640 RPMI medium supplemented with 10% v/v fetal calf serum (FCS), 1% v/v non-essential amino 
acids, 1% v/v penicillin/streptomycin, 1% v/v glutamine and 10 mM HEPES, pH 7, and maintained at 
37 ºC with 5% CO2. Inhibition of P. berghei liver stage infection was determined by measuring the 
luminescence of Huh-7 cell lysates 48 hours after infection with a firefly luciferase-expressing P. 
berghei line, PbGFP-Luccon, as previously described ( [87], [88]). Briefly, cells (10 × 103/well) were 
seeded in 96-well plates the day before drug treatment and infection. Tested compounds were prepared 
in the following way: 2.5 mM, 5 mM or 10 mM stock solutions were obtained by dissolving accurately 
weighed compounds in DMSO and dilutions subsequently made with medium to the desired 
concentration. Medium was replaced by fresh medium containing the appropriate concentration of each 
compound 1 hour prior to infection. Sporozoites (10,000 spz/well), freshly obtained through disruption 
of salivary glands of infected female Anopheles stephensi mosquitoes, were added to the wells 1 hour 
after compound addition. Sporozoite addition was followed by centrifugation at 1700 g for 5 min. 
Parasite load was determined 48 hours after infection by luminescence measurement using Biotium’s 
Firefly Luciferase Assay Kit. The effect of the compounds on the viability of Huh-7 cells was assessed 
by the Alamar Blue assay (Invitrogen, UK), using the manufacturer’s 40 protocol. Nonlinear regression 
analysis was employed to fit the normalized results of the dose-response curves, and EC50 values were 
determined using GraphPad software. 
